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Abstract 
Bacillus thuringiensis is a gram-positive spore forming soil bacterium and one of the 
most successful, environmentally friendly, intensively used and studied microbial 
insecticides. The major characteristic of Bt is the production of proteinaceous crystals 
containing toxins with specific activity against many insects including diptera, 
lepidoptera and coleoptera. Understanding the basis of specificity of Cry2A toxins of 
Bacillus thuringiensis is important for the risk assessment of novel insecticidal toxins 
from this bacterium to ensure that they are not detrimental to non-target organisms 
within the environment. Cry2A toxins are a group of three-domain proteins with highly 
similar sequences, and this project sought to understand the basis of the specificity of 
Cry2A toxins against the mosquito Aedes aegypti. This was investigated through finding 
out which domain(s) and /or amino acid motif(s) were crucial for activity. Cry2A toxins 
in our lab were characterised and expressed, after which bioassays were conducted 
against Aedes aegypti, and several hybrid toxins and mutants were created based on the 
bioassay results and were used to determine the relationship between amino acid 
sequence and toxicity through bioassay and bioinformatic analyses. Domain I was found 
to be responsible for the specificity of Cry2A toxins against Aedes aegypti, specifically 
the 49-amino acids comprising the N-terminal region, which folds back onto domain II. 
The specificity-determining region was further found to consist of four amino acids 
(E/RTD) within this N-terminal region. Finally, the mechanism of proteolytic activation 
of Cry2A by Aedes aegypti was studied in vitro, leading to a proposed model of 
proteolytic activation, which was contrary to previously published reports. 
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1. General introduction 
1.1 Bacillus thuringiensis 
Bacillus thuringiensis is a gram-positive spore forming bacterium, which is classified in 
to the Bacillus cereus group of Bacilli and produces insecticidal toxins in the form of 
parasporal crystal proteins during its sporulation phase. This unique feature 
differentiates it from other members in the group (Read et al., 2003, Rasko et al., 
2005).These are predominantly comprised of Cry and Cyt toxins, also referred to as δ-
endotoxins (Figure 1.1.1) and are the major virulence factors for this pathogen. 
Bacillus thuringiensis was originally discovered by a Japanese biologist named Shigetane 
Ishiwatari in 1902. He isolated it from a diseased silkworm, Bombyx mori.  It was then 
formally characterised by Ernst Berliner of Germany in 1915 following its   isolation  from 
diseased larvae of Ephestia kuhniella (flour moth caterpillars) in Thuringia province, and 
it was then associated with the cause of a disease named Schlaffsucht (Milner, 1994). 
Bacillus thuringiensis grows rapidly if the environmental  conditions such  as availability  
of nutrients and temperature appear to be favourable, whilst  it has been shown that 
spores formation is activated by both internal and external factors, which include  
signals  for  cell density, nutrient  starvation, and  cell  cycle  progression (Hilbert and 
Piggot, 2004). 
The toxins found in the crystals are classified into two major families referred to as Cry 
and Cyt toxins. The Cry (from crystal) toxins belong to a large  family, which is currently 
composed of about 300 different members (Crickmore, 2018).The Cyt (from cytolytic) 
toxins are generally known to possess cytolytic activity in vitro, a property used in their 
characterisation, although they are also known to display a primarily dipteran specific 
activity in vivo (Soberon et al., 2013). The third minor family of proteins are referred to 
as - the vegetative insecticidal proteins (Vips) because they are secreted from vegetative 
growing cells and not included in the crystals during sporulation, as such, they are not 
classified as crystal (de Maagd et al., 2001). 
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1.2 The Cry Toxins 
Cry toxins are officially defined as proteins that have remarkable sequence similarity to 
existing toxins within the Bt nomenclature or be a B. thuringiensis parasporal inclusion 
protein that shows pesticide activity, or some toxic effect to a particular organism that 
can be verified experimentally (Crickmore et al., 1998). 
Currently, there are around 75 primary subgroups of Cry toxins in the nomenclature 
having different primary ranks, such as (Cry1, Cry2, Cry3, etc.). Their lengths vary from, 
for instance,  369  in Cry34 to 1,344 amino acids found in  Cry43 (Adang, 2014). 
The naming of toxins is, solely, based on their amino acid sequence identity and does 
not consider their host specificity. Therefore, Cry toxins that showed activity against the 
same order of insect will not necessarily have similar names. The name of toxin consists 
of four different levels, e.g., Cry41Ab1, the first number is referred to as the primary 
level and toxins that share this number (41 in the above example) will share some 
significant sequence identity of at least 45%. The order of sequence identity will increase 
for toxins sharing secondary, tertiary and quaternary level respectively. 
Toxins that differ in the quaternary level descriptor only (e.g. Cry41Ab1 and Cry41Ab2) 
do show at least 95% sequence identity. All toxins that are newly characterised are given 
a different quaternary level descriptor, and thus some toxins that are identical to others 
in the nomenclature  were assigned different names (Adang, 2014). In their 1989 review, 
Hofte and Whiteley identified five conserved sequence blocks in many of the Cry toxins, 
shown in Figure 1.2.1. The 3D-Cry toxins described in figure 1.2.1 share the following 
characteristics: they encode insecticidal proteins, either of 130 to 140 kDa or of ca. 70 
kDa, which have a toxic fragment of 60+10 kDa. One exception is a member of the Cry4 
1.1.1 Transmission electron micrograph of a sporulating Bacillus thuringiensis (Bt) cell. PB stands for protein 
body while SP stands for the spore. Figure from de Maagd et al. (2001) 
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toxins (Cry4D) protein, which has a ca. 30-kDa active core component (Chilcott and Ellar, 
1988). For the 130- to140-kDa proteins, the toxic portion is localized in the N-terminal 
half of the protoxin. Whereas,  the C-terminal part of the ca. 130-kDa proteins (Cry1, 
Cry4A, and Cry4B), extending from the five conserved blocks, is not required for activity, 
but it appears to be the domain that is highly conserved in these crystal proteins (Hofte 
and Whiteley, 1989). It is worthy of note to state that within these conserved blocks, no 
(or relatively few) gaps were required for the alignment of identical or related amino 
acids. These blocks were divided by highly variable sequences of varying lengths for the 
different crystal proteins. This property does not apply to Cry proteins which share 
homology only within block 1 region as can be seen in Figure 1.2.1. Another common 
characteristic for most crystal proteins is the presence of a stretch of hydrophobic amino 
acids at a similar position within the 120 N-terminal amino acids. This stretch of amino 
acids displays the properties of a predicted transmembrane sequence. Remarkably, it is 
the hydrophobic character of the amino acids  and not their identity that is conserved 
in this, strongly supporting a functional significance (Hofte and Whiteley, 1989). It was 
proposed that the conserved hydrophobic region is required for interaction between 
the toxin and the membrane of mid gut epithelial cells (Schnepf et al., 1985), but there 
is no any direct experimental evidence for such interaction. 
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Most Cry toxins have three structural domains and share a high level of topological 
similarity.  Domain I is made up of a bundle of seven α-helices connected by loops. There 
is a central amphipathic α-helix in this α-helical bundle, which is well conserved among 
all the toxins.  Different mutations in domain I appear to affect toxicity but not its ability 
to bind to cellular receptors. It is not known if these mutations affect the overall 
conformation of the toxin molecule, thus compromising toxicity. Based on the 
observation that there are similarities between domain I of Bt and pore forming domains 
from other bacterial toxins, and the fact that most of the α-helices of domain I are long 
enough to span a hydrophobic cellular membrane, the involvement of domain I in 
membrane insertion and pore formation was hypothesized and later proven (Li et al., 
1991). Domain II is made up of three sets of antiparallel β-sheets, each of which 
Figure 1.2.1  Graphical representation of the diversity of Bt Cry toxins. The length of each toxin is drawn to scale 
and the five conserved blocks described by Hofte and Whiteley (1989) are shown as coloured inserts. Figure taken 
from Adang (2014). 
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terminates with a loop. The beta sheets are packed around a central hydrophobic core, 
thereby forming a structure called beta-prism. Domain III consists of a sandwich of two 
antiparallel β-sheets, which form a “jelly-roll” topology. Experimental results from site-
directed mutagenesis and truncation analysis provided strong evidence for the 
involvement of Domain II in receptor binding and oligomerisation (Liu and Dean, 2006), 
while domain III is also shown to be involved in receptor binding and toxicity (Ibrahim et 
al., 2010). 
1.3 Mechanism of action of Cry toxins 
There are many hypotheses in the literature, which seek to explain how Cry toxins exert 
their killing activity. These have now given rise to two current models, which describe 
the mechanisms of action of Cry toxins. The first one is the sequential binding model, 
which involves pore formation (PF), (Haider and Ellar, 1989, Grochulski et al., 1995, 
Schnepf et al., 1998, Bravo et al., 2004, Rausell et al., 2004, Knowles, 1987). This model, 
which is for three domain toxins with C-terminal extensions postulates that, on ingestion, 
a crystal toxin is solubilised by the alkaline environment of the insect’s mid gut leading 
to the release of protoxins initially processed by mid gut proteases. The C-terminal half 
and about 30 amino acid residues from the N-terminal of CryIA protoxin are removed as 
a result of the initial cleavage of a Cry1A protoxin by the gut proteases. This is followed 
by the release of the active toxin monomers, which bind to different receptors such as 
cadherin, Aminopeptidase N etc.  (Atsumi et al., 2008, Bel et al., 2009, Chen et al., 2009, 
Fabrick et al., 2009, Munoz-Garay et al., 2009, Obata et al., 2009, Pacheco et al., 2009, 
Arenas et al., 2010). It is proposed that the initial binding of the activated toxins to the 
receptors results in some conformational changes, which facilitate a second cleavage by 
a membrane bound protease leading to the removal of the N-terminal helix α-1. The 
removal of helix α-1 results in the formation of oligomers, which possess membrane 
insertion ability (Bravo et al., 2004). It was shown that the binding of Cry toxins to the 
cadherin-like receptors involved some specific interactions of the variable loop regions 
within domain II and III with cadherin epitopes (Soberon et al., 2013). 
The oligomerised activated toxin gets bound to the membrane receptors, and is inserted 
into the apical membrane of mid gut cells, thus causing osmotic shock, bursting of cells 
within the mid gut and ultimately ending in the death of the insect (Haider and Ellar, 
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1989, Grochulski et al., 1995, Schnepf et al., 1998, Bravo et al., 2004, Rausell et al., 2004, 
Knowles, 1987). The sequential binding model as proposed by Bravo et al. (2004) for 
Cry1A toxins is presented in Figure 1.3.1 below. 
 
 
The second model known as the signalling pathway model, proposed by Zhang et al. 
(2005), which is based on a single system, Cry1Ab, critiques the notion that ‘Cry toxins 
kill cells exclusively by osmotic lyses’. However, they proposed that the binding of 
Cry1Ab toxin monomer to the cadherin receptor BT-R1 activates a Mg2+-dependent 
signal-transduction pathway, which leads to cell death. It was shown in this model that 
Cry1Ab oligomers integrated into the cell membrane of living cells do not associate with 
cytotoxicity (Fig. 1.3.2).  They propose that the mechanism of action of Cry toxin is much 
more complex than the toxin-induced osmotic lysis earlier proposed. The action of Cry 
toxin is a complex and dynamic process involving the univalent binding of toxin to the 
highly conserved structural motif in the cadherin receptor BT-R1, which triggers a series 
of events leading to a programmed cell death known as oncosis.  
Molecular signal is induced by the binding of Cry1Ab toxin to the BT-R1 receptor, which 
stimulates heterotrimeric G protein and adenylyl cyclase leading to a marked increase 
in cAMP production (Zhang et al., 2005). The cAMP activates protein kinase A, resulting 
Figure 1.3.1 Bravo model of the mode of action of Cry1A toxins. 1 Solubilisation of the crystal toxin, 2 Initial 
cleavage by gut proteases, 3 Binding of toxin monomer to the receptors and its second cleavage by membrane 
bound protease, 4 Formation of membrane insertion-competent oligomer, 5 Binding of oligomers to receptors, 
6 Formation of Lytic pores. Taken from Bravo et al. (2004). 
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in several kinds of cellular alterations including cytoskeletal rearrangement and ion 
fluxing. The chemistry of the cell is altered by the acceleration of this second messenger 
pathway, which results in cell death. In addition, the killing process involves promotion 
of exocytotic translocation of BT-R1 from intracellular membrane  vesicles  to  the  cell  
membrane by the toxin (Zhang et al., 2005), movement  of  the receptor is brought about 
by the toxin-induced signal-transduction, the amplification of which signalling pathway 
is directly linked to the execution of cell death. 
 
 
 
Figure 1.3.2 The Zhang model for Cry toxin action. The univalent binding of Cry toxin monomer to BT-R initiates 
cell death by transmitting a death signal into the cell. A signal transduction pathway, involving G protein (Gα) 
adenylyl cyclase (AC) and protein kinase A (PKA) is activated. Activation of this signalling pathway brings about 
exocytosis of the BT-R receptor from intracellular vesicles to the cell membrane. The resulting enhanced display 
of BT-R on the cell surface facilitates recruitment of additional toxin molecules, which, in turn, amplifies the 
original signal in a cascade-like fashion. The signalling kinase PKA modifies downstream molecules that promote 
the biochemical activities that destroy the cell. Toxin oligomers incorporated into the plasma membrane of living 
cells do not form lytic pores and are not toxic (Ibrahim et al., 2010). 
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1.4 Mode of action of Cry toxins in Mosquitoes 
Bt subsp. israelensis (Bti) is reported to be highly toxic to different Aedes, Culex and 
Anopheles mosquito species, which are vectors that transmit human diseases (Margalith 
and Ben-Dov, 2000). This bacterium produces crystal inclusions comprising of four major 
toxins namely: Cry4Aa, Cry4Ba, Cry11Aa, Cyt1Aa, and to a minor extent two toxins 
namely Cry10Aa and Cyt2Ba (Berry et al., 2002). (Cry11Aa, Cry4Aa and Cry4Ba, which 
are mosquitocidal active toxins share structural similarities with the lepidopteran active 
Cry1Aa, suggesting a similar mode of action of these Cry proteins in mosquitoes as well, 
just that the receptors may differ. The various receptors of Cry toxins for mosquitoes 
are shown in Table 1.4-1 below. 
 
1.5 Aedes aegypti Mosquito 
Mosquitoes are major pests in human health because they transmit pathogens such as 
viruses and parasites through blood feeding, causing serious human diseases including 
but not limited to malaria, dengue fever, west Nile fever, zika fever, lymphatic filariasis, 
yellow fever, Japanese encephalitis other forms of encephalitis. These diseases 
Table 1.4-1 Cry protein receptors in mosquitoes. Table taken from Zhang et al. (2017). 
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outbreaks are very frequent in tropical and subtropical regions, where environmental 
conditions are ideal for mosquito breeding, and result in billions of disease cases and 
millions of deaths worldwide annually (WHO, 2006). 
Among mosquitoes, Aedes aegypti is a primary disease vector in urban areas 
transmitting viruses that cause chikungunya, yellow fever, dengue fever and zika fever 
(WHO, 2005a, Tomori, 2004, Ligon, 2006, Faucon et al., 2017). Yellow fever, for example, 
is a serious disease in Africa and South America: with 200,000 infections annually 
resulting in 30,000 deaths despite vaccine usage (WHO, 1998). Dengue fever is a serious 
arboviral disease of the Americas, Asia, and Africa and causes 1,000 million infections 
and 25,000 deaths worldwide annually (WHO, 1997). Moreover, there is no effective 
vaccine for dengue fever and the incidence of dengue fever is on the increase. Therefore, 
control of its vector, Aedes aegypti, is the only reasonable preventive option.  
For a long time, attempts to manage Aedes mosquitoes have used chemical, biological, 
and physical methods. Chemical insecticides such as DDT, Malathion, or pyrethroids 
have been used, the world over, since the 1940s. Physical methods were also attempted 
in many sites where breeding sites were eliminated or predators were added to remove 
larvae. This strategy, a combination of insecticide treatment and breeding site 
elimination, seemed to contribute to the successful control of Aedes aegypti (Gomez-
Dantes and Willoquet, 2009). Unfortunately, the widespread use of insecticide has 
resulted in outbreaks of insecticide-resistant Aedes mosquitoes in the Americas 
(Rodriguez et al., 2007, Harris et al., 2010).Insecticides often kill even non-target 
organisms and contribute to environmental pollution, while physical methods have 
limitations in their applications. Therefore, biological methods are now considered an 
alternative, including the introduction of parasites and predators, or use of pathogens 
to target mosquitoes. Among the pathogens used to control mosquito larvae are various 
bacterial strains, including Bacillus thuringiensis and Lysinibacillus sphaericus. B. 
thuringiensis has high insecticidal activity, low toxicity against non-target organisms, and 
is environmentally friendly. Thus, strains of this bacterium are used worldwide for the 
control of Aedes aegypti and other mosquito species (Alphey et al., 2013). 
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1.5.1 The Life Cycle of Aedes aegypti Mosquito. 
Aedes mosquitoes are container-inhabiting mosquitoes; they often breed in spare 
tyres, untreated swimming pools, unused flowerpots, and drainage ditches. They 
grow well in urban areas in close contact with people, which make them to be an 
exceptionally successful vector.  They are very common in areas that lack piped 
water systems and, which relied mainly on stored water. Both the adult male and 
female feed on the nectar of plants; however, females feed on blood-meal obtained 
mainly from humans to produce eggs, and are active during the daytime. Eggs could 
easily be spread to new locations because they possess the capacity to survive 
desiccation for long periods.  
 
Adults: Aedes aegypti is a holometabolous insect, which means that it undergoes a 
complete metamorphosis; starting from egg, larva, pupa, and to the adult stage. The life 
span of an adult mosquito can range from two weeks to a month base on the 
environmental conditions (CDC, 2019). Aedes aegypti occur in three polytypic forms: 
domestic, peridomestic and sylvan. The domestic form usually breeds in urban locations, 
often around or inside houses. The peridomestic form grows well in environmentally 
Figure 1.5.1 Life cycle of Aedes aegypti mosquito. The orange arrows point towards the direction of 
metamorphosis. 
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modified areas such as farms and coconut groves, whereas the sylvan form is a more 
rural form, which breeds in tree holes and  forests (Tabachnick et al., 1979).  
Eggs: The female Aedes aegypti mosquitoes produces an average of 100 to 200 eggs per 
batch after ingesting a blood-meal; however, this number is mainly dependent on the 
size of the blood meal ingested. During their life time, the females can produce up to 
five batches of eggs (Nelson, 1986). The eggs are usually laid on damp surfaces in areas 
that are likely to flood temporarily e.g.  tree holes and manufactured containers. The 
eggs are not laid in mass but rather singly. The laying of eggs can be spread out over 
hours or days depending on substrates availability, and they are not all laid at once 
(Clements, 1999). The eggs are, most often times, placed at varying distances above the 
water line, and the female do not  lay the entire clutch at a single site, but rather spread 
them out over two or more sites (Foster, 2002).  
Eggs of Aedes aegypti are approximately one millimetre long, smooth, and ovoid shaped. 
The eggs usually appear white when first laid but they turn to shiny black within few 
minutes. They can develop within two days in warm climates, such as the one obtained 
in the tropics, whereas their development can take up to a week in cooler temperate 
climates (Foster, 2002). Aedes aegypti eggs have the ability to withstand desiccation for 
months and can hatch once submerged in water, making the control of Aedes aegypti 
difficult (Nelson, 1986). 
Larvae: The mosquito larvae are usually referred to as "wrigglers" or "wigglers," because 
of their ability to wiggle intermittently in the water when disturbed. They use their 
posteriorly located siphon, which is usually held above the surface of the water, to 
breathe oxygen while the rest of the body hangs vertically. Most Aedes larvae are easily 
differentiated from the other genera through their short siphon even by the use of bare 
eyes (Nelson, 1986). Larvae feed on organic particulate matter such as algae and other 
microscopic organisms found in the water. 
The larvae are often found at homes in puddles, tyres, or within any object that holds 
water. The development of the larvae is temperature dependent. They pass through 
four instar stages, spending a short period in the first three, undergoing three moulting 
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processes, and spending up to three days in the fourth instar stage. The fourth instar 
larvae are approximately eight millimetres long. The development of the male Aedes 
mosquitoes occur faster compare to the females, so the males generally pupate earlier. 
At cooler temperatures, Aedes aegypti can remain in the larval stage for provided there 
is sufficient water supply (Foster, 2002).  
Pupae: This is the next stage of Aedes aegypti development after the fourth instar. The 
pupae of mosquitoes behave different from those of many holometabolous insects 
because they are mobile and can respond to stimuli. Pupae, are also known as 
“tumblers," they do not feed and develop in approximately two days. Adults emerge by 
ingesting air thus expanding the abdomen and splitting open the pupal case, and emerge 
head first.  
1.5.2 Current approaches to Aedes aegypti population control 
Vector-based control has been the global strategy for the control of mosquito-borne 
diseases for a very long period and the use of chemical insecticides such as DDT, 
Malathion, or pyrethroids have been the most important components in this effort. 
However, despite the initial promising results obtained through this method (Gomez-
Dantes and Willoquet, 2009), it is being halted by the emergence of insecticide 
resistance and cross-resistance (Buttler, 2011). Therefore, this has resulted in the re-
emergence of mosquito-borne diseases in many parts of the world. In addition, 
insecticides are usually toxic against non-target organisms and contribute to 
environmental pollution. Physical methods involving the elimination of mosquito-
breeding sites has some limitations in its applications such as: 
i. If the mosquito breeding sites in a particular location are large, they can 
hardly be covered.  
ii. Some important species in the ecosystem, which share a habitat with 
mosquitoes are being destroyed as well, which may lead to their extinction. 
iii.  Important medicinal plants are also burnt because of bush burning during 
the control of mosquito breeding sites.  
Therefore, biological methods including the introduction of parasites and predators, or 
use of pathogens to target mosquitoes are now an alternative. The current and most 
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promising of these methods for mosquito control has been the ‘Release of Insects with 
Dominant Lethality’ (RIDL) program (Alphey et al., 2013). Although effective in reducing 
populations by up to 90% (Carvalho et al., 2015), there are nonetheless some challenges 
associated with this method. For example, it can lead to the decline of species that rely 
primarily on mosquitoes/mosquito larvae as their source of food like the western 
mosquitofish, Gambussia affinis etc. There is also the possibility for development of 
resistance via assortative mating (Koyama et al., 2003) or overcoming the zygotic killing 
mechanism (Alphey et al., 2011). Although rare, resistance genes could appear and 
spread rapidly. They are manageable by developing new strains or stacking traits, but 
this program is expensive to maintain, most especially in developing countries 
bedevilled by diseases spread by Aedes aegypti mosquitoes. 
Therefore, the use of spray formulations developed from a crystal toxin produced by 
Bacillus thuringiensis, which are toxic to mosquitoes, very specific in their actions, 
environmentally friendly, and which have no reported cases of field resistance against 
Aedes aegypti, is considered the only alternative. 
1.5.3 Factors that affect the susceptibility of Aedes aegypti to Cry toxins 
The implementation of proper control programs against Aedes aegypti and other 
mosquito species requires that the susceptibility profiles of the target field populations 
to the intended control agent(s) be carried out. In some cases, laboratory colonies were 
employed as surrogates to establish susceptibility status. However, such colonies may 
still underestimate the presence of resistance alleles in the field due to founder and 
bottleneck effects in maintaining laboratory colonies (Robertson et al., 1995). Therefore, 
some factors, which may affect the susceptibility to Cry toxins (Bti based insecticides) of 
Aedes aegypti that are the current agents used for the control of mosquito population 
and to which there is no any case of field resistance reported yet are discussed here. 
Susceptibility is species-dependent and relates to the insecticidal proteins. The toxicity 
of Bti against mosquito larvae is linked to a crystal produced during sporulation, which 
contains mainly Cry11Aa, Cry4Aa, Cry4Ba and Cyt1Aa toxins. Therefore, for toxicity to 
occur there must be proper interaction between the Cry toxin and the mosquito larvae 
in question. As such, anything that could limit these interactions can affect toxicity. 
14 
 
 
Despite the efficacy of products based on B. thuringiensis israelensis, they still have 
some limitations as biopesticides leading to no/or reduced activity on the target 
organism. One of these is the fact that the crystals settle at the bottom of the water 
column away from the larval feeding range just within few days of application. This 
problem could be overcome by the development of live recombinant algae or bacteria 
that expresses toxin(s) and can remain within the feeding range of the mosquito larvae 
(Romero et al., 2001, Zhang et al., 2017). The disadvantage to this approach is the high 
risk of development of resistance by the target insects as resistance to individual Bti 
toxins has already been observed in laboratory colonies of Culex quinquefasciatus 
(Georghiou and Wirth, 1997). 
Elleuch et al. (2015) observed two mechanisms that affect the susceptibility of Aedes 
aegypti larvae to Bti toxins.  The first of which involves the change or removal of any of 
the Cry toxin genes, which form part of the Bti toxin by mutagenesis, or plasmid transfer 
between Bti and other closely related Bacillus isolates. This could lead to decreased 
crystal toxin production and loss or inactivation of such cry genes.  This, consequently, 
results in reduced toxin to interact with the Aedes larvae, resulting in decreased 
effectiveness. The second mechanism involves the stage of the toxin processing and 
stability. Elleuch et al. (2015) also observed early degradation of mutated Bti toxin by 
Aedes mid gut protease compared to the wild type, suggesting that the amino acid 
changes in the mutated Bti toxin might have caused alteration in the number and or the 
accessibility of the protease cleavage sites as a result of tertiary structure modifications. 
Hence, accessibility of the Aedes protease to the Cry toxin affects its activation step by 
not allowing proper interaction between them leading to decreased activity. For 
instance, mutagenesis of loop I and loop II of Cry4Ba has been shown to abolish its 
activity against Aedes aegypti and Anopheles larvae (Abdullah et al., 2003), which may 
suggest early degradation of the mutated Cry4Ba by the insect’s mid gut due to 
structural modifications caused by mutagenesis leading to early degradation and hence 
lack of activity due to decrease interaction between the toxin and the insect’s mid gut 
protease.  
Toxin sequestration is another factor that can affect the susceptibility of Aedes aegypti 
larvae to Cry toxin. This is because the toxin, after its processing, must remain stable in 
15 
 
 
the gut epithelium for it to exert its toxicity. But, the presence of some specific binding 
sites on the peritrophic membrane have been proposed to exert a trapping effect 
thereby reducing the ability of specific toxins to diffuse across the peritrophic 
membrane and interact with the gut epithelium (Hayakawa et al., 2004).  
The receptor binding stage in the mechanism of action of Cry toxin has been shown to 
be one of the important stages (Bravo et al., 2007). Cry toxins when activated bind to 
specific mid gut proteins, and a number of these have been identified in Aedes aegypti 
larvae (Table 1.4-1). In addition, mutagenesis of the putative loop α-8 residues of 
Cry11Aa confirmed that this region is important for its interaction with Aedes aegypti 
Brush Border Membrane Vesicles (BBMV) and toxicity (Fernandez et al., 2006). 
Therefore, this showed that binding of the Cry proteins to their receptors on the insect’s 
mid-gut is very essential for their interactions and hence susceptibility.  
Cry proteins are applied as insoluble proteins because mosquitoes are filter feeders as 
such able to absorb them in that form. Therefore, due to the fact that the proteins are 
in an insoluble form, some settled at the bottom of the water and not accessible to the 
larvae, and only little are absorbed by the larvae resulting in low mortality (McNeil and 
Dean, 2011). In addition, the age of the Aedes mosquito larvae has a role to play in their 
susceptibility because sensitivity to Cry toxin decreases with decrease larval age. 
Volume of the water to larval number also has a critical effect on larval stress and 
sensitivity to toxin; thus affecting susceptibility (McNeil and Dean, 2011). If the volume 
of the water is high, the larvae die of stress rather than sensitivity to the toxin. Thus, 4ml 
of water to a larvae is generally recommended (WHO, 2005b). 
1.6 Mechanism of Aedes resistance to insecticides 
Following the first report of resistance to chlorinated hydrocarbon insecticides by 
mosquitoes (Gjullen and Peters, 1952), there have been many researches aimed at 
understanding the mechanism underlying the development of resistance in mosquitoes. 
The ability of Aedes mosquitoes to resist chemical insecticides such as pyrethroid is a 
major threat against the control of major arbovirus diseases, the world over. It was 
discovered that there is increase in mosquito resistance to all classes of insecticides in 
more than sixty countries with respect to all the major vector species (WHO, 
2013).Therefore, until an alternative control strategies are widely introduced, the 
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monitoring of  resistance levels of insecticides and understanding  their  mechanisms of  
resistance by mosquito populations in the field is crucial for implementing appropriate 
management plan.  
Two basic mechanisms have now been widely accepted to be generally responsible for 
an insect’s resistance to insecticides: increased metabolic detoxification of insecticides 
and decreased sensitivity of the target proteins on which an insecticide acts, so-called 
target sites insensitivity (Ranson et al., 2011, Li and Liu, 2010, Wang et al., 2015). 
Target site insensitivity, arises from mutation of genes encoding proteins that interact 
with insecticides (Casida and Durkin, 2013). Insecticides such as 
dichlorodiphenyltrichloroethane (DDT) and pyrethroids appear to target sodium 
channels causing a repetitive discharge on the nervous system of the insect after binding 
to the sodium channels, resulting in depolarization of the  its nerve membranes and 
ultimately death (Narahashi, 1988). Acetylcholinesterase (AChE) is key enzyme in the 
nervous system, which hydrolyses acetylcholine neurotransmitters and terminating 
nerve impulses, it appears to be the target for organophosphates and carbamate 
insecticides. The γ-aminobutyric acid (GABA) receptors appear to be the target for 
cyclodiene and fipronil insecticides (Cole, 1993. , Ffrench-Constant et al., 2000). Two 
mutations in the active site of AChE1 of mosquitoes has been shown to result in their 
insensitivity or reduced sensitivity to organophosphate and carbamate insecticides. A 
G119S substitution has been reported in many mosquito species, including Anopheles 
albimanus, Culex pipiens, Anopheles gambiae, Culex vishnui, and Culex  quinquefasciatus 
(Alout and Weill, 2008).  
The GABA receptor is a type A receptor for γ-aminobutyric acid, a neurotransmitter, and 
is the target site for many cyclodiene insecticides such as dieldrin, and phenyl pyrazoles 
such as fipronil. It is made up of five subunits, and each contains an extracellular Cys 
loop as well as four transmembrane domains (M1–M4). The second transmembrane 
domain designated M2 represents the main portion of the ion channel. A296G 
substitution has been observed in Anopheles gambiae (Du et al., 2005), whereas a A296S 
substitution is linked to dieldrin resistance in Anopheles stephensi, Anopheles arabiensis, 
Anopheles funestus, and Aedes aegypti (Ffrench-Constant et al., 2000, Du et al., 2005). 
Two novel mutations within the sodium channel gene (F1552C and F1554C) were also 
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linked to pyrethroid and DTT resistance in Aedes aegypti populations from Thailand 
(Yanola et al., 2011). 
The second mechanism is via metabolic detoxification of insecticides. Three major 
detoxification gene families namely: cytochrome P450s (P450s), esterases, and 
glutathione S-transferases (GSTs) are mainly responsible for detoxification of 
insecticides in mosquitoes. One of the remarkable features of insect’s P450s and GSTs 
is their ability to upregulate transcription process, which results in increased enzymatic 
activities and consequent increase in protein production levels. This in turn increases 
the metabolic detoxification of insecticides resulting in the development of resistance 
to insecticides (Ponlawat et al., 2005). Esterase is a group of heterogeneous enzymes, 
which are present in many organisms. The overproduction of this enzyme has been 
studied extensively. It has been shown that the amplification and/or random 
overexpression of esterase genes increases the level of production of detoxification 
proteins and hence resistance (Pasteur and Raymond, 1996). 
The silencing of a GST gene in Aedes aegypti has been demonstrated to show its role in 
insecticide resistance (Lumjuan et al., 2011). In addition, some Cytochrome P450 genes: 
CYP6BB2, CYP6M11, CYP6N12, CYP9J9, CYP9J10 and CCE3 were implicated in conferring 
resistance to Aedes aegypti populations as they were found to be upregulated in the 
resistant populations, and hence their involvement in resistance is highly suggested 
(Dusfour et al., 2015). 
From the above it is obvious that there are many cases of insect resistance to chemical 
insecticides and hence the need to rely on biological insecticides for mosquito control. 
The biological insecticides mostly used for mosquito eradication are the Bti based 
larvicides. There is no established case of field resistance to Bti toxin. There is 
considerable difference between laboratory-selected resistance and field selected 
resistance as the former may have considerably lower genetic diversity. The most 
important one being considered mostly is the field resistance. 
Several studies carried out test for resistance in Aedes aegypti populations against Bti 
based insecticides from various parts of the world and discovered that this mosquito 
species is still highly susceptible to the Bti based larvicides (Marcombe et al., 2012, 
Araujo et al., 2013, Suter et al., 2017). Some researchers have reported cases of 
laboratory resistance to Cry toxins (Cadavid-Restrepo et al., 2012, Stalinski et al., 2014). 
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Cadavid-Restrepo et al. (2012) reported a case of resistance in Cry11Aa, which forms 
part of the Bti toxin, by Aedes aegypti. He observed the development of resistance to 
Cry11Aa toxin by the 54th generation of Aedes aegypti. Stalinski et al. (2014) used Cry4Aa, 
Cry4Ba and Cry11Aa toxins from a strain that consists of 80% of susceptible Bora-Bora 
strain 20% of LiTOX strain that are resistant to Bt for the selection of three strains of 
Aedes aegypti LR4A, LR4B and LR11 from the 22nd generations. A mixture of Bti Cry 
toxins in a similar amount to those found in Bti (12.5% Cry4Aa, 12.5% Cry4Ba, 75% 
Cry11Aa) with unformulated Bti, or not selected, to select this composite strain for up 
to 5 generations in order to generate the LR3Tox, LR3Bti and LR3NS strains. The degree 
of resistance of these strains to each of the three Cry toxins, Bti, and the mixture of the 
Cry toxins was determined using bioassay. They observed an increased in the level of 
resistance in each of the three strains of Aedes aegypti to their selected toxins, and a 
cross resistance between each pair of toxins. Nevertheless, no case of field resistance to 
Bti larvicide, as a whole, by this insect is reported yet. 
 
1.7 The Cry2A family of toxins 
The Cry2A proteins constitute one of the largest classes among the Cry family of toxins, 
with a group of 11 toxins with molecular weight ranging between 61-72kDa, present in 
cuboidal crystals produced by Bt (Donovan et al., 1988, Nicholls et al., 1989, Dankocsik 
et al., 1990). Cry2A proteins include some toxins, which exhibit dual activity spectra to 
both the lepidopteran and dipteran orders of insects that pose threats to agriculture 
and public health. For instance, the Cry2Aa toxin is toxic to both moths and mosquitoes, 
which makes it an attractive platform to combat diseases caused these insects (McNeil 
and Dean, 2011). 
The crystal structure has been solved for Cry2Aa at 2.2Ǻ resolution. It consists of a 633-
amino acid protoxin containing 49-amino acid peptides at the N-terminal region, which 
is speculated to be cleaved on activation, and three domains that form the  mature toxin 
(Morse et al., 2001). There is remarkable structural similarity between the three 
domains of Cry2Aa to those of the activated toxins of Cry3Aa (Li et al., 1991) and Cry1Aa 
(Grochulski et al., 1995) despite the fact that they have only little sequence identity to 
Cry2Aa; 20% in the case of Cry3Aa and 17% for Cry1Aa. 
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The structure of Cry2Aa toxin consists of domain 1 (residues 1–272), which is a pore-
forming seven-helical bundle (Schnepf et al., 1998). It is cleaved at around amino acid 
144th position for the active Cry2Aa toxin to be formed, leading to the loss of the N-
terminal region, which has 49 amino acid residues. The second domain comprises of 
(residues 273–473) and is a β prism with a three-fold symmetric arrangement of β sheets, 
each of which has a Greek key fold (Figure 1.7.1), this domain is known for receptor 
binding. The third domain comprises of (residues 474–633) is associated with both larval 
receptor binding (Lee et al., 1995, de Maagd et al., 1999) and pore function (Schwartz 
et al., 1997) and has a lectin-like β-sandwich (Fig 1.7.1). Morse et al. (2001) suggested 
based on modelling studies using Cry2Aa that proteolytic activation of the toxin might 
involve the cleavage of the 49 N-terminal amino acids which results in exposing a residue 
comprising a putative toxin-receptor binding surface. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7.1 The three-domain crystal structure of Cry2Aa.Domain I is highlighted in magenta colour, domain II 
highlighted in blue colour; domain III highlighted in cyan colour whereas the 49-N-terminus sequence is highlighted 
in red. The putative 800 Å2 binding epitope is bordered by dashed black line, and the β-strands have been numbered 
by their order in the sequence. Taken from Morse et al. (2001).   
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1.8 Determination of Cry toxins’ specificity to insects 
Specificity of a crystal protein is defined as the extent of species or taxa to which it is 
active on. In other words, it is referred to its activity spectrum. The corollary, however, 
referred to the susceptibility spectrum of a particular species tested with different toxins 
i.e. the range of toxins that are active against a particular species. 
There has been an extensive review by van Frankenhuyzen (2009), who looked at the 
specificities of toxins grouped at that time in to 55 Cry and 2 Cyt families by Crickmore 
et al. (1998). van Frankenhuyzen (2009) gathered the information on biological 
specificity, which have been generated for over 25 years, and carried out a 
comprehensive review on this information. The review seems quite complicated 
because the bioassay results were confused by many factors apart from the toxin type.  
van Frankenhuyzen (2009) made of the data base for toxin specificity limited to spore-
free preparations of protoxins or crystals obtained by the expression of cloned genes or 
purified from single-gene strains, which were individually bioassayed (with binary toxins 
being exempted). Genetically altered crystal proteins were not included in his review 
except a few that were changed through single amino acid substitutions e.g. (Lambert 
et al., 1996). 
Specificity within orders was examined by analysing the activity of the toxins at the 
species level (tertiary rank) depending on mortality using a binary response (active or 
not active). Activity was examined with no reference to the life stage of the organism 
under consideration, the method employed in the bioassay, or the nature of the toxin 
used (protoxin, crystal or activated toxin). Crystal proteins were considered ‘not active’ 
when they failed to cause mortality response at the highest concentration used and 
‘possibly active’ when there are conflicting reports.  
van Frankenhuyzen (2009) also assessed specificity across orders by rolling up 
qualitative data by secondary toxin rank and order of test organism and supplementing 
them with information that were published but failed to meet the requirements for 
inclusion in to the data base. A family of toxin is considered active against a given order 
if at least one toxin in the family has been reported to be active against at least a species 
belonging to that order. However, it is a toxin is considered not active when none of the 
toxins that caused a considerable mortality response in any of the tested species, and 
‘possibly active’ when there are conflicting reports. 
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There are some limitations associated with specificity determination as highlighted by 
van Frankenhuyzen (2009). First of which is that our current understanding on specificity 
is limited by the number of toxins tested to date and the range of species in those tests 
as presented in Figure 1.8.1. 
 
Figure 1.8.1 above, for specificity looks fragmentary as the majority of the toxins (91%) 
were tested against only small number of species (10 or less), 49 out of the 174 holotype 
toxins have not been tested at all (the box in Figure 1.8.1 above) and the species and 
toxin tested were not distributed equally across the families of protein and taxa. 
Secondly, the difference between toxins considered to be active and non-active is 
undoubtedly subjective, because some toxins that were reported as non-active might 
evoke mortality response when tested at higher concentrations. 
van Frankenhuyzen (2009) carried out the specificity determination of the Crystal 
proteins, as a qualitative assessment across, and within orders of insects as follows: 
 
1.8.1 Specificity determination across orders 
The specificity based on order was considered across toxin families at the secondary 
rank as depicted in Figure 1.8.2. It is obvious here, that the number of crystal proteins 
Figure 1.8.1 The number of holotype toxins (tertiary rank) that have been bioassayed as a function of the number 
of taxa (mostly species) tested. The toxins listed in the box have no any published bioassay data. Taken from  (van 
Frankenhuyzen, 2009). 
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that show activity across order has increased considerably after the first classification 
done by Hofte and Whiteley (1989), who  identified four major pathotypes based on 
order specificity. These are: Lepidoptera-specific (CryI, now Cry1), Coleoptera- specific 
(CryIII, now Cry3), Diptera-specific (CryIV, now Cry4, Cry10, Cry11; CytA, now Cyt1A), 
and lastly CryII (now Cry2), which was the only family that was known to possess dual 
specificity at that time (Lepidoptera and Diptera) specificity but has been found now to 
have additional cross activity against Hemiptera. This additional cross activity is because 
of Cry2Aa being active against this order of insects (Sims, 1997). Cross-order activity 
displayed by 15 of the 87 pesticidal crystal protein families as shown in Figure 1.8.2. 
 
 
Figure 1.8.2 Specificity of Cry and Cyt toxin families (secondary rank) across orders. Toxin families are indicated as 
being active    , not active      , possibly active     , or not tested      .Toxin families for which no bioassay data are 
available are not shown (Cry1L, 7C, 8H, 18B, 18C, 21B, 24A, 25A, 26A, 28A, 30D, 42A, 50A, 52A, 53A, 54A, Cyt1C). 
Cry toxins are displayed horizontally while the insect orders are displayed vertically. Taken from van Frankenhuyzen 
(2009). 
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1.8.2 Specificity determination within orders 
The specificity was also considered within orders for three major orders of insects 
namely: Lepidoptera, Diptera, and Coleoptera. Other insects were then grouped 
together. For the purpose of this thesis, which is concerned with the Cry2A group of 
toxins, I will consider only those orders to which Cry2A toxins appeared to be active. 
 
1. Lepidoptera 
Considering all the bioassays previously carried out on Lepidoptera where 59 holotype 
toxins have been tested against 71 species in 1,182 bioassays; van Frankenhuyzen (2009) 
presented a figure for susceptibility spectra of these species in the rows as depicted in 
Figure 1.8.3. Four members of Cry2A toxins (Cry2Aa, Cry2Ab, Cry2Ae and Cry2Af) were 
shown to have specificity towards this order of insects as indicated in Figure 1.8.3. P. 
xylostella appeared to be the most frequently tested species (9.8% of total bioassays), 
followed by Spodoptera exigua (8.7%), Heliothis virescens (6.4%), Manduca sexta (5.9%), 
Trichoplusia ni (5.3%), Ostrinia nubilalis (5.1%), Helicoverpa armigera (4.8%), Heliothis 
zea (4.0%) and Bombyx mori (3.9%)”(van Frankenhuyzen, 2009) as shown in Figure 1.8.4.  
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Figure 1.8.3 Activity spectrum of Cry and Cyt holotype toxins that were tested against species of Lepidoptera. Toxins 
are indicated as active indicated by black dots inside a square, not active indicated by plain dots inside a square or 
possibly active indicated by a question mark. Taken from van Frankenhuyzen (2009). 
The activity spectra of the 59 holotype toxins that were tested are represented by 
columns in Figure 1.8.3.  The 96.2% of total bioassays resulted from Cry1, Cry2 and Cry9 
toxin families, with Cry1 and specifically Cry1A toxins responsible for 80% and 36.6% 
respectively. The widest range of toxins was tested against Plutella xylostella (43 toxin 
types) and it was one of only 12 species that were tested with 15 or more toxins as 
shown in Figure 1.8.4 below. 
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Figure 1.8.4. Permissiveness of the most frequently tested species as indicated by the proportion of toxin types 
that displayed toxicity. Taken from van Frankenhuyzen (2009). 
 
 
 
The activity spectra of the holotype toxins that were tested against at least 15 species 
was presented as a proportion of the susceptible species (Figure 1.8.5). Cry2Aa and 
Cry2Ab, from the Cry2A group of toxins, were found to be among the active toxins in 
the activity spectrum of toxins presented as depicted in Figure 1.8.5.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8.5 Activity range of holotype toxins that were tested against at least 15 species as indicated by the 
proportion of species that were susceptible. Taken from van Frankenhuyzen (2009). 
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2. Diptera 
The dipteran species are very crucial here, as the species of insects investigated in 
this work fall within this order. van Frankenhuyzen (2009) presented the activity 
spectra of 53 toxins, which were tested against 23 dipteran species in 233 bioassays 
with their corresponding susceptibility spectra in rows and columns depicted in 
Figure 1.8.6. 
 
 
 
 
From the above (Figure 1.8.6), three of the toxins from the Cry2A group of toxins (Cry2Aa, 
Cry2Ab and Cry2Ac) were all tested against at least an insect in this order. Cry2Aa was 
found to be active against Aedes aegypti, Aedes triseriatus, Anopheles stephensi, Culex 
fatigans, Culex quinquefasciatus, and Anopheles quadrimaculatus, and non-active to 
Culex pipiens, Musca domestica, and Drosophila melanogaster. Cry2Ab was found to be 
active against Anopheles gambiae, and in terms of Aedes aegypti it is not very clear as 
there are conflicting reports hence it is indicated as being possibly active. Cry2Ac was 
reported in this review (van Frankenhuyzen, 2009) to be nontoxic to Aedes aegypti. 
Furthermore, it was shown that only four species were responsible for 77.7% of the total 
number of bioassays, with Aedes aegypti as the species that was tested most frequently 
Figure 1.8.6 Activity spectra of Cry and Cyt holotype toxins that were tested against species of   Diptera. 
Toxins, which are active, are indicated by black dots inside a square, not active indicated by plain dots 
inside a square or possibly active indicated by a question mark. Taken from van Frankenhuyzen (2009). 
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(37.2%), followed by Culex pipiens (15.8%), Anopheles stephensi (14.9%) and Culex 
quinquefasciatus (9.8%) as shown in Figure 1.8.7. The 84% of all the bioassays was 
against Culicidae alone, and it was the only family that was tested against more than 10  
toxins, and having 60% of the species–toxin combinations being positive (van 
Frankenhuyzen, 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Considering the number of species which were susceptible against toxins tested on five 
or more dipteran species, as reviewed by van Frankenhuysen (2009), it was only Cry2Aa 
among the Cry2A group of toxins, which fall in this category of toxins as depicted in 
Figure 1.8.8 below. 
 
 
Figure 1.8.7 Number of toxins that were tested for each family of diptera and the proportion of positive 
species–toxin combinations within those families. Taken from van Frankenhuyzen (2009). 
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1.9 Determination of regions/residues responsible for specificity in Cry2A 
toxins 
Specificity region of a Cry toxin refers to amino acid residues/motifs within a particular 
region(s) of the Cry toxin structure that is or /are responsible for its activity against one 
or more insects. One of the major characteristics of Bt is the production of 
proteinaceous crystal toxins that possess specific activity against many insect pests 
including dipteran, lepidopteran and coleopteran. Therefore, determination of the 
region/ residues responsible for specificity of Cry2A toxins against Aedes aegypti 
involves studying the different associations between the amino acid sequences of Cry2A 
toxins and their toxicities against this insect. Understanding the specificity region of 
Cry2A toxins of Bacillus thuringiensis is essential in the risk assessment of novel 
insecticidal toxins from this bacterium many of which are being considered for 
commercialisation to ensure that they are not detrimental to non-target organisms 
within the environment. It will also provide a platform for the design of Cry toxin with 
broader species spectra of activities since a member of this group of toxins, Cry2Aa, has 
a broad spectrum of activity against both dipteran and lepidopteran insects. 
Previous studies on Cry toxins specificity region determination focused on identifying 
the residues that define dipteran and lepidopteran specificities or either of these 
Figure 1.8.8 Proportion of susceptible species for toxins that were tested against five or more dipteran 
species. Taken from van Frankenhuyzen (2009). 
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through chimeric scanning mutagenesis (Widner and Whiteley, 1990, Liang and Dean, 
1994), or elucidating the structure of Cry toxin by multiple isomorphs replacement using 
six heavy atoms derivatives and refined to 2.2Ǻ resolution (Morse et al., 2001). 
Widner and Whiteley (1990) constructed 16 hybrids by the combinations of Cry2Aa and 
Cry2Ab as shown in Figure 1.9.1. 
 
Figure 1.9.1 Hybrids created between Cry2Aa and Cry2Ab. Cry2Aa (shaded bar), Cry2Ab (non-shaded bar), and 
hybrid gene products (combination of the two patterns) and their toxicities to A. aegypti and M. sexta. All of the 
toxicities are relative to that of Cry2Aa (value of 1); a fivefold difference in toxicity is considered significant, the 
bigger the number the lesser the toxicity of the hybrid. The bar at the top of the figure is a diagram depicting a 
FASTP alignment of the Cry2Aa and Cry2Ab polypeptides; vertical lines represent differences between the two and 
arrows above the bar denote the locations of non-conservative changes. Vertical broken lines show locations of the 
hybrid junctions determined by restriction mapping (hybrids 1, 9, 10, and 11) and DNA sequence analysis (hybrids 
2 to 4, 6, 8, 12 to 14, and 513). The dotted lines extend upwards to the alignment diagram to show where the 
junctions are located with regard to the amino acid differences that exist between the two polypeptides (Widner 
and Whiteley, 1990).       Sign represents hybrid junctions determined through DNA sequence analysis, and             sign 
represents hybrid junctions determined by restriction mapping. Taken from Widner and Whiteley (1990).  
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From  Figure 1.9.1 from Widner and Whiteley (1990), the amino-terminal end, hybrids 1 
to 7 (Cry2Ab-Cry2Aa hybrids) contain decreasing amounts of Cry2Aa sequences and 
increasing amounts of Cry2Ab sequences; the amounts of Cry2Aa sequences in hybrids 
8 to 15 (Cry2Aa-Cry2Ab hybrids)decrease from the carboxyl-terminal end. 
Widner and Whiteley (1990) tested the activity of these hybrids against A. aegypti larvae 
and Manduca sexta, but I will focus on the results for Aedes aegypti being the species 
considered in this thesis. Hybrid 1 exhibited the same toxicity as Cry2Aa, and inclusions 
from the Cry2Ab containing strain were nontoxic. Inclusions from hybrids 2 to 5, which 
contained more of Cry2Ab in the N-terminal region, were found to be substantially less 
toxic than the Cry2Aa control. Inclusions from hybrids 6 and 7, with a difference of 
Cry2Ab sequence from position 382 to around 580 replacing Cry2Aa in hybrid 7, and 
lacking Cry2Aa sequence in the region 307-382, were nontoxic to Aedes aegypti 
mosquito larvae, even when tested at high concentrations (250 ng/ml). 
When they tested the Cry2Aa-Cry2Ab inclusions (hybrids 8 to 15), for activity, they 
discovered that hybrids 12 and 13 were as toxic to Aedes aegypti larvae as was Cry2Aa. 
Hybrids 8 to 10 were progressively less toxic, and hybrid 11 as well as hybrids 14 and 15, 
were nontoxic. Except for the results they obtained with inclusions from hybrid 11, the 
absence of mosquitocidal activity in hybrids 6, 7, 14, and 15 suggests that the boundaries 
of hybrids 5 and 13 delineate the Cry2Aa sequences that are minimally required for 
toxicity to mosquito larvae. Therefore, to determine whether the short segment of 
Cry2Aa defined by these boundaries is, in fact, sufficient to influence specificity, they 
further constructed a Cry2Ab-Cry2Aa-Cry2Ab hybrid gene in vitro between hybrids 5 and 
13 to generate hybrid 513 (Figure 1.9.1). The resulting gene product was toxic to both 
test insects, indicating that residues 307 through 382 of the Cry2Aa polypeptide 
influence mosquitocidal activity. However, the toxicity of hybrid 513 inclusions to A. 
aegypti was reduced 20-fold relative to that of Cry2Aa, which is still somehow negligible 
considering the fact that only 5-fold reduction in activity was considered significant in 
their research. This may suggest that sequences outside this putative mosquitocidal 
region may also be important for specificity determination and therefore they have not 
clearly defined the region and/or amino acid motifs responsible for the specificity of 
Cry2A toxins to Aedes aegypti. 
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The results of Widner and Whiteley (1990), were further studied by Liang and Dean 
(1994) who also located the regions responsible for specificity of Cry2A toxins to both 
dipteran and lepidopteran insects by creating hybrids between Cry2Aa which possessed 
activity against mosquito larvae and gypsy moth larvae, with Cry2Ab, which possessed 
only lepidopteran activity. 
They located the specificity regions of Cry2Aa against lepidopteran and dipteran insects, 
by replacing the putative domain II of Cry2Aa by the putative domain II of Cry2Ab. They 
made used of the sequence alignment generated by Hodgman and Ellar (1990) for the 
different domains of Cry proteins. Domain II of Cry2Aa was aligned between amino acid 
278 and amino acid 487, which is encoded by the naturally existing NheI- NarI fragment 
of the Cry2Aa gene. The DNA fragment for domain II of Cry2Ab (also aligned between 
amino acids 278 and 487) was amplified and they use the PCR technique to introduce 
NheI and NarI sites into the fragment ends. With this approach, they created a 
recombinant gene DL105 as shown in Figure 1.9.2 below. 
 
They further introduced MIuI and XhoI sites in to both the wild-type Cry2Aa gene DL103, 
and the recombinant gene DL105, at positions that appear to divide the domain II of 
both genes in to three regions as shown in Figure 1.9.3. They designated these regions 
as region 1, region 2 and region 3, encoding polypeptide fragments from amino acid 278 
to amino acid 340, from 341 to 412 and from 413 to 487, respectively. Therefore, they 
Figure 1.9.2 Generation of Hybrid DL105 (BBB) containing Cry2Ab at domain II of wild type Cry2Aa (DL103) by 
recombination using the restriction enzymes NheI and NarI. The red colour denotes Cry2Aa and the green colour 
denotes Cry2Ab (Liang and Dean, 1994). 
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produced six chimeric genes (Table 1.9-1) by homologue-scanning mutagenesis by 
substituting one or two regions of domain II of Cry2Aa with the corresponding region of 
Cry2Ab. 
 
Table 1.9-1 below shows the various hybrids created from chimeric scanning 
mutagenesis involving changes among the three fragments created between the 
domain II of Cry2Aa and that of Cry2Ab, and their associated toxicities against both 
Aedes eagypti and Lymantria dispar. 
Protein Domain II origin LC 50 of Aedes aegypti (95% 
confidence interval) (ng/ml) 
ID 50 of Lymantria dispar 
(95% confidence interval) 
(ng) 
DL103 aaa 65.5 (41.1-100) 102(77-181) 
DL105                  bbb >105 304(226-418) 
DL111 abb ND ND 
DL112 baa 1.23 X 105 (2.82 X 104-8.33 x 105) 126(85.7-187) 
DL113 bab 1.50 X 105 (1.05 X 105-1.02 X 106) 88.7(58.0-129) 
DL114 aba ND ND 
DL115 bba >105 3200(1340-51900) 
DL116 aab 52.2 (25.7-107) 90.6(57.7-136) 
 
Table 1.9-1 Bioassays of homologue-scanning mutants against A. aegypti and L. dispar. Letters indicate the origin 
of each of the three regions in domain II of each mutant. a, stands for amino acids from Cry2Aa origin, b stands for 
amino acids from Cry2Ab origin. ND stands for not determined. 
 
They carried out the bioassay as shown in Table 1.9-1 above and discovered that the 
wild type Cry2Aa was toxic against Aedes aegypti and slightly toxic against Lymantria 
Figure 1.9.3 MIuI and XhoI sites introduced into DL103 and DL105. MluI and Xhol almost equally divide domain II 
into three regions, which have been named (from N-terminal to C-terminal) regions 1, 2, and 3, NheI and NarI are 
naturally occurring sites bordering domain II of Cry2Aa (Liang and Dean, 1994) 
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dispar larvae as well, but Cry2Ab was about three times less toxic than Cry2Aa to 
Lymantria dispar larvae. Dankocsik et al. (1990) who used spores/crystal mixes also got 
similar toxicity ratios for these two Cry2A toxins. When domain II of Cry2Aa was replaced 
by domain II of Cry2Ab (Hybrid D105), it was three times less toxic to L. dispar than wild-
type Cry2Aa and showed a similar toxicity to wild-type Cry2Ab. As with wild-type Cry2Ab, 
it did not show any mosquitocidal activity even at concentrations as high as 100µg/ml. 
Their results, therefore, demonstrated that the specificity regions of Cry2Aa against L. 
dispar larvae and A. aegypti larvae are both located in domain II. The mutants they 
created by substituting regions within domain II behaved differently. While DL116 
(containing Cry2Ab at amino acids position 413 to 487) was as active as wild-type Cry2Aa 
against both L. dispar and A. aegypti larvae, DL115 (containing Cry2Ab at amino acid 
position 278 to 412) lost its activity against both insects. Its activity against L. dispar 
larvae reduced by 10 and 30 times when compared to the wild type toxins DL103 and 
DL105, respectively, and had no activity against A. aegypti larvae. DL112 (containing 
Cry2Ab at amino acid positions 278 to 340) and DL113 (containing Cry2Ab at amino acid 
positions 278 to 340 and 413 to 487 respectively) appeared to show similar activities 
against both insects. While their activities against Lymantria dispar larvae was similar to 
that of wild-type Cry2Aa, their activities against Aedes aegypti larvae were both reduced 
by approximately 2000-fold. 
 
Therefore, from their findings it was clear that only when both region 1 and region 2 of 
the recombinant protein were of Cry2Aa origin (DL116) did the protein possessed 
mosquitocidal activity at an extent that could be comparable to wild-type Cry2Aa. This 
indicated that the specificity region against the mosquito larvae was located in regions 
1 and 2 (amino acids 278-412) and not region 3 (amino acids 413 to 487). When they 
further analysed this region using their bioassay data (table 1.9-1, it showed that region 
1 of Cry2Aa was required for activity against mosquitoes (DL112 and DL113). The 
findings that substituting region 1 of Cry2Ab with Cry2Aa had no effect on the stability 
of the protein, its ability to form crystals, or its activity against L. dispar (DL112 and 
DL113) but had dramatically affect its activity against A. aegypti indicated that the 
difference in region 1 (amino acids 278-340) between Cry2Aa and Cry2Ab is only 
associated with mosquitocidal activity. However, region 2 of Cry2Aa was also essential 
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for production of a functional toxin against mosquitoes but Liang and Dean (1994) were 
unable to exclude or demonstrate the role of region 2 in the toxicity due to the inability 
of their two hybrids (DL111 and DL114) to form crystals. 
 
Research by Morse et al. (2001) was based on understanding the structural 
determinants of Cry toxin specificity. Therefore, to achieve this, they elucidated the 
structure of Cry2Aa from Bacillus thuringiensis subspecies kurstaki by multiple 
isomorphic replacement using six heavy atoms derivatives and refined to 2.2Ǻ 
resolution. They chose Cry2Aa because it is among the unusual subset of Cry proteins 
possessing broad insect species specificity by exhibiting high specificity against both 
Dipteran and Lepidopteran insects (Yamamoto, 1981, Donovan et al., 1988). Therefore, 
it could serve as an important platform for the design of Cry toxin with broader species 
spectra of activities. 
Morse et al. (2001) were able to identify a putative candidate toxin receptor-binding 
surface, which appeared to be consistent with the available chimeric-scanning 
mutagenesis data (Widner and Whiteley, 1990, Liang and Dean, 1994). 
This defines a continuous 106 amino acid block (307-412), of specificity-distinguishing 
residues, within which there are 23 residues that differ between Cry2Aa and Cry2Ab 
(Morse et al., 2001).  
Liang and Dean (1994) demonstrated that substitution of residues 278-340 resulted in 
loss of Aedes activity in Cry2Aa, DL115 in figure 1.9.4, while Widner and Whiteley (1990) 
demonstrated that substitution of residues 307-382 of Cry2Aa to Cry2Ab conferred 
dipteran specific activity to Cry2Ab Hyb513. Thus, the sequence responsible for the lack 
of dipteran activity in Cry2Ab, which falls in its amino acid residues 307-382 is now 
tracked with Cry2Aa (Hyb 513). 
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The chimeric data above was reported by Morse et al. (2001) to have enabled the 
determination of a candidate toxin-receptor binding surface on Cry2Aa, after the 
structure of Cry2Aa was determined by multiple isomorphic studies replacement using 
heavy atoms and comparing the structure to those of Cry1Aa and Cry3Aa. In addition, 
the amino sequence of Cry2Aa and Cry2Ab were aligned around these regions defined 
by the chimeric mutagenesis studies to identify the specificity distinguishing residues. 
This binding surface is composed of an arrangement of hydrophobic residues Val365, 
Leu369 from the β5-β6 loop, β4-β5 and Leu402 – Leu404 from the β7-β8 loop), across 
the solvent-exposed surface of the β- prism and β -sandwich domains as earlier depicted 
in Figure 1.7.1. 
 
 
 
 
 
Figure 1.9.4 Schematic presentation of Chimeric-Scanning mutagenesis data. Figure adapted from Morse et al. 
(2001).The top band and all other red rectangles indicate Cry2Aa sequence. The bottom band and all other 
green rectangles indicate Cry2Ab sequence. DL112 and DL115 are data from Liang and Dean (1994). Hyb513 is 
a data from Widner and Whiteley (1990). Activity representations indicate an approximate log scale. For 
reference, (+) indicates an ID50 (infectious dose) of 126 (85.7-187) ng, and (+++) indicates an ID50 of 3,200 
(1,340-51,900) ng. (---) represents negligible toxicities. 
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Figure 1.9.5 The solvent accessible surface of domains II and III of Cry2Aa. The projection of residue hydrophobicity 
onto this surface is shown in colour. Portions of the hydrophobic surface contributed by residues 474, 476, and 477 
are shown in cyan, those contributed by residues 365–369 are shown in blue, those contributed by residues 402 and 
404 are shown in magenta, and the remainder of the surface contributed by hydrophobic residues is shown in 
yellow. The remaining surface that is identified as non-hydrophobic is coloured white. For orientation, the portion 
of the surface contributed by residue 357 of the β4-β5 loop is shown in red. Figure taken from Morse et al. (2001). 
 
Most of the amino acid differences between Cry2Aa and 2Ab spotted by Morse et al. 
(2001) are found within or about the domain II/III 800Ǻ2 hydrophobic patch depicted in 
figure 1.9.5 above and the surrounding residues from the β5- β6, β7- β8, and β4- β5 
loops shown in Figure 1.7.1 but not domain I. 
Proteolytic activation of the toxin was shown to involve the removal of the 49-N-
terminal amino acid (Audtho et al., 1999), through cleavage around amino acid at the 
144th position and this was reported by Morse et al. (2001) to expose the residues 
comprising the putative toxin-receptor binding surface shown in Figure 1.9.6 below. In 
addition, removal of the 49 N-terminal amino acids exposes these residues comprising 
the putative toxin-receptor binding surface. However, removal of the 49 amino terminal 
residues comprised of α0, α0a, and an N-terminal coil (Figure 1.9.6), they reported, 
would have no effect on the structure of the seven-helical membrane insertion domain, 
as examined through comparing the structures of the activated toxin from Cry1Aa and 
that of the protoxin from Cry2Aa. 
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The diagram showing the 49N-terminal residues of Cry2Aa, comprising α0, α0a, and the 
N-terminal coil. These components, based on the structure of Cry2Aa, may be suggested 
to sterically hinder access to the putative binding epitope, β5-β6 and β7-β8 loops, and 
the exposed parts of domain III closest to domain II as shown in the ribbon structure of 
Cry2Aa, depicted in Figure 1.9.7 below. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9.6 Diagram of Domain I of Cry2Aa showing the 49N-terminal amino acid residues coloured red. Labels 
with amino acid numbers indicate the visible N and C termini of the domain. Taken from Morse et al. (2001). 
 
Morse et al. (2001) showed that projection of hydrophobicity onto the solvent 
accessible surface of domains II and III reveals an 800A°2 hydrophobic patch (Figure 1.9.5) 
proximal to these loops. Nevertheless, they asserted that while the structure indicates 
that the 49 N-terminal residues (α0, α0a, and the N-terminal coil Figure 1.9.6 above) 
may sterically prevent access to the putative binding epitope, the biological logic for this 
function is unclear. That, it is very improbable that Bt has a receptor with affinity for the 
activated toxin. Hence, it does appear possible that the N-terminus acts to hinder 
premature activation of the toxin within Bt.  The explanation they gave was that the 
blockage of the hydrophobic patch of the putative binding epitope prevents nonspecific 
aggregation of the toxin with itself or other host proteins, and that the N-terminal amino 
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acids might play a role in the formation of an environmentally stable crystalline 
inclusions. 
1.9.1 Recent works toward finding the specificity determining regions (SDRs) in 
Cry2A toxins 
Work carried out by a previous project student, Jake Evans, involved the analysis of the 
amino acid sequences of four Cry2A toxins namely: Cry2Aa, Cry2Ab, Cry2Ac and Cry2Ag 
based on previous bioassay data from the literature, which is presented in table 1.9-2 
below. The bioassay data presented in table 1.9-2 below are unreliable because they are 
not comparable as different types of samples such as spore crystal mixes, purified 
proteins, single toxin producing strains and multi toxin producing strains were assayed, 
hence the need for me to carry out a comprehensive bioassay of all the available Cry2A 
toxins in our laboratory in order to produce a much more reliable bioassay data. 
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Bioassay data for Cry2A toxins       ●= toxic      o= nontoxic 
Genus Species Qualitative Quantitative (Toxicity 
Measure) 
Mortality 
recorded 
(time) 
Instar Origin of gene used (Subspecies, 
Strain, Plasmid or isolated gene) 
Reference 
 
Aedes 
 
Aegypti 
 
● 
 
LC50 = 0.5-1 μg/ml 
  
L1 
kurstaki HD-1 (not assayed) 
- WRW30 recombinant 
plasmid expressing Cry2Aa 
protein 
Widner and 
Whiteley (1989) 
   
● 
 
LD50 = 0.1-1.0 μg of 
cells, wet 
weight/ml 
 
72hrs 
 
L3 
& 
L4 
kurstaki – expressed in 
B.megaterium cells harboring 
the plasmid pEG204 (cry2Aa) 
 
Donovan et al., 
(1988) 
   
● 
 
LC50 = 6.25 μg/ml 
 
24hrs 
 
4 to 
6 day 
old 
kurstaki HD-1 (using strain 
information from the 
nomenclature database to 
identify 
which toxin is produced) 
 
Nicholls et al. 
(1989) 
   
● 
LD50 = 1-5 μg/ml of 
deionized 
water 
 
72hrs 
 
L4 
kurstaki HD-1 and HD-263 - not 
assayed - isolated gene 
Dankocsik et 
al. (1990) 
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● 
 
100% mortality 
Daily 
intervals up 
to 1 
week 
 
L3 
 
YBT-226 (whole crystal from 
this strain also toxic) 
 
Hodgman et al., 
(1993) 
   
● 
 
LC50 = 65.5ng/ml 
 
72hrs 
 
L3 
Plasmid pSB304.3 containing 
cry2Aa operon. Orf1 and orf2 
deleted leaving cry2Aa gene 
in 
vector pTZ18R forming pDL103 
 
Liang and Dean 
(1994) 
   
● 
 
LC50 = 37.06 ug/ml 
 
48hrs 
 
L3-4 
kurstaki - no assay with strain - 
purified cry2Aa protein 
 
Sims (1997) 
   
● 
 
20μg/m
l = ~38% 
50μg/m
l = ~95% 
100μg/ml = 100% 
mortality 
 
48hrs 
 
L3 
kenyae HD549 - shown to be toxic 
when bioassayed with all 6 
species 
in previous papers (Amonkar et 
al., 1979; 1985; Donovan et al., 
1988) 
 
Misra et al. 
(2002) 
   
o 
No toxicity observed 
at 
different doses:30 μl 
24 and 
48hrs 
 
L2 
kurstaki Brazilian S477 strain - 
recombinant viruses 
Lima et al. 
(2008) 
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   containing 30, 20, 15, 10, 5 
and 1 μg/ml, respectively 
  (vAcCry2Aa and vSynCry2Ab) were 
amplified in Trichoplusia 
ni (BTI-Tn5B1-4) cells and used to 
infect Spodoptera 
frugiperda larvae - crystals were 
purified and used in bioassays - 
S477 not assayed 
 
   
● 
 
LC50 >5000ng/ml - slightly 
toxic 
 
24hrs 
 
L3 
Plasmid pSB304.3 containing 
cry2Aa operon. Orf1 and orf2 
deleted leaving Cry2Aa gene in 
vector pTZ18R forming pDL103 
(Liang and Dean, 1994) 
 
McNeil and 
Dean (2011) 
   
o 
 
LC50 >100 μg/ml 
 
24hrs 
Early 
L4 
 
Rpp39 
Liang et al., 
(2011) 
 
Aedes 
 
triseriatus 
 
● 
 
LC50 = 2.84 μg/ml 
 
48hrs 
 
L3-4 
kurstaki - no assay with strain - 
purified cry2Aa protein 
 
Sims, (1997) 
 
Anopheles 
 
stephensi 
 
● 
Mortality measured at 20, 50 
and 100μg/ml 
= 90, 100 and 100% 
respectively 
 
48hrs 
 
L3 
 
kenyae HD549 - no assay with 
strain 
 
Misra et al., 
(2002) 
 
Anopheles 
 
gambiae 
 
● 
 
LC50 = 0.13μg/ml 
 
24hrs 
4 to 6 
day 
old 
 
kurstaki HD-1 - native crystal toxic 
 
Nicholls et 
al., (1989) 
   
● 
 
LC50 = 110 ng/ml 
 
24hrs 
 
L3 
Plasmid pSB304.3 containing 
cry2Aa operon. Orf1 and orf2 
deleted leaving Cry2Aa gene in 
vector pTZ18R forming pDL103 
(Liang and Dean, 1994) 
 
McNeil and 
Dean (2011) 
 
Anopheles 
 
quadrimaculatus 
 
● 
 
LC50 = 0.37 ug/ml 
 
24hrs 
 
L3-4 
kurstaki - no assay with strain - 
purified cry2Aa protein 
 
Sims (1997) 
   
● 
 
LC50 = 38ng/μl 
 
24hrs 
 
2 day 
Cry2Aa gene construct, pGEM103- 
9, made by subcloning cry2Aa 
Audtho 
(2001) 
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      gene from pDL103 (Liang and 
Dean., 1994) into pGEM-3Z(+) 
vector (promega) 
 
 
Culex 
 
pipiens 
 
o 
 
LC50 >200 μg/ml 
 
48hrs 
 
L2-4 
kurstaki - no assay - purified 
Cry2Aa protein 
 
Sims (1997) 
   
● 
LT50 at a concentration of 
100 μg/ml of the 
spore/crystal mixture = 
70hrs 
 
70hrs 
 
L2 
 
kurstaki - no assay with strain 
 
Zghal et 
al.(2006) 
   
● 
 
LC50 >5000 ng/ml (slightly 
toxic) 
 
24hrs 
 
L3 
Plasmid pSB304.3 containing 
cry2Aa operon. Orf1 and orf2 
deleted leaving Cry2Aa gene in 
vector pTZ18R forming pDL103 
 
McNeil and 
Dean (2011) 
 
Culex 
 
fatigans 
 
● 
mortality measured at 20, 50 
and 100μg/ml 
= 90, 100 and 100% 
respectively 
 
48hrs 
 
L3 
kenyae HD549 - shown to be toxic 
when bioassayed with all 6 species 
in previous papers - isolated 
protein assayed in this paper 
 
Misra et al., 
(2002) 
 
Culex 
 
quinquefasciatus 
 
● 
 
LC50 = 1.63 μg/ml 
 
48hrs 
 
L2 
 
Kurstaki NRD-12 isolate 
Moar et al. 
(1994) 
   
o 
 
No toxicity observed at 
different doses: 30 μl 
containing 30, 20, 15, 10, 5 
and 1 μg/ml, respectively 
 
24 and 
48hrs 
 
L2 
kurstaki Brazilian S477 strain - 
recombinant viruses 
(vAcCry2Aa and vSynCry2Ab) were 
amplified in Trichoplusia 
ni (BTI-Tn5B1-4) cells and used to 
infect Spodoptera 
frugiperda larvae - crystals were 
purified and used in bioassays - 
S477 not assayed 
 
Lima et al., 
(2008) 
   
● 
 
LC50 >200μg/ml 
 
48hrs 
 
L4 
Recombinant plasmid with cry2Aa 
(from pCL-92 into pDBF69 plasmid: 
(Ge et al., 1998)) - no assay of 
galleriae 
 
Bideshi et al., 
2013 
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 Bioassay data for Cry2Ab: ● = toxic, o = non-toxic 
Genus Species Qualitative Quantitative 
Measure) 
(Toxicity Mortality 
recorded 
(time) 
Instar 
Age 
Origin of gene used 
(Subspecies, Strain, Plasmid 
or isolated gene) 
Reference 
 
Aedes 
 
Aegypti 
 
o 
 
LC50 >50μg/ml 
  
L1 
kurstaki HD-1 - 
plasmid (Cry2Ab) 
WRW50 Widner and 
Whiteley (1989) 
   
o 
 
LD50 >20μg/ml 
 
72hrs 
 
L4 
EG7219 (pEG259 
Cry3A/2Ab fusion) 
Dankocsik et al., 
1990 
   
o 
 
LC50 >100μg/ml 
 
72hrs 
 
L3 
EG7219 (Dankocsik 
1990), 
et al, Liang and Dean 
(1994) 
  ● LC50 = 23.42μg/ml 24hrs early L4 Ywc5-4 Liang et al., 2011 
   
o 
 
LC50 >6000ng/ml ) 
 
24hrs 
 
L3 
 
kurstaki HD-1- isolated Cry2Aa 
(Morse et al., 2001) 
McNeil 
Dean (2011) 
and 
 
Anopheles 
 
gambiae 
 
● 
 
LC50 = 540ng/ml 
 
24hrs 
 
L3 
kurstaki HD-1- isolated Cry2Aa 
(Morse et al., 2001) 
McNeil 
Dean (2011) 
and 
 
Culex 
 
pipens 
 
o 
 
LC50 > 6000ng/ml 
 
24hrs 
 
L3 
kurstaki HD-1- isolated Cry2Aa 
(Morse et al., 2001) 
McNeil 
Dean (2011) 
and 
 
Bioassay data for Cry2Ac: ● = toxic, o = non-toxic 
Genus Species Qualitative Quantitative 
Measure) 
(Toxicity Mortality 
recorded 
(time) 
Instar 
Age 
Origin of gene used 
(Subspecies, Strain, Plasmid 
or isolated gene) 
Reference 
 
Aedes 
 
aegypti 
 
o 
 
LD50 >50 μg/ml 
  Bt S1 - inclusions 
mosquitocidal activity 
had  
Wu et al. (1991) 
 
Aedes 
 
albopictus 
 
● 
 
54·4% of 
mortality 
 
corrected 
 
72hrs 
 
L3 
Bt LLB6 strain containing 
Cry2Ac toxin - LLB6 (75·6% of 
corrected mortality) 
 
Zhang 
(2007) 
 
et 
 
al. 
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Bioassay data for Cry2Ag: ● = toxic, o = non-toxic 
Genus Species Qualitative Quantitative (Toxicity 
Measure) 
Mortality 
recorded 
(time) 
Instar 
Age 
Origin of gene used 
(Subspecies, Strain, Plasmid 
or isolated gene) 
Reference 
 
Aedes 
 
aegypti 
 
● 
LC50 =2.541 ug/ml  
24hrs 
 
L1 & L4 
 
JF19-2  
Zheng et al. 
(2010) 
Table 1.9-2 Bioassay data for some selected Cry2A toxins from the literature. Table taken from Evans (2014). 
 
 
 
 
 
45 
 
 
 
He used amino acid sequence alignments to compare proteins with different specificities. 
He expected that the specificity determining residues would be conserved amongst 
homologues with the same specificity, which as he determined, was not the case. This 
is because when the sequences of the three active toxins against Aedes aegypti (Cry2Aa, 
Cry2Ac and Cry2Ag) were compared there was no sequence conservation along the 
regions identified by Widner and Whiteley (1990), Liang and Dean (1994) to be the SDRs 
(amino acid positions 307-412) depicted in Figure 1.9.7.  
Figure 1.9.7 Cry2A amino acid alignments (in Espript format). Amino acid sequences are aligned in for Cry2Aa, 
Cry2Ac, Cry2Ag and Cry2Ab. Cry2Aa alignment position has been changed to be at the top of the alignment in order 
to allow the programme to use the Cry2Aa secondary structure, which is mapped on the top of the alignment. The 
blue arrow spans domain I, the green arrow spans domain II and the orange arrow spans domain III. The position in 
the alignments are in reference to the position of amino acids in Cry2Aa. The region containing amino acid residues 
which comprise the specificity determining residues is indicated by black vertical lines. Figure taken from Evans 
(2014). 
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He further used a method of grouping toxins by toxin specificity to genus A. aegypti 
where at a given amino acid position, no amino acid in the toxic group can be the same 
as the amino acid in the nontoxic group. With these, he identified some residues namely: 
Threonine 118, Methionine 464 and Serine 601 to be important for future mutagenesis 
studies in Cry2Ab. After further analysis of these identified amino acid using UCSF 
Chimera and Cry2Aa as a model structure, he discovered that Methionine 464 might be 
the most attractive target for future mutagenesis. His research work was complicated 
by the fact that the bioassay data in table 1.9-2 were having conflicting results as 
mentioned earlier. Therefore, he finally suggested that proper bioassay of all the Cry2A 
toxins be carried out, and at the same time, sequence analysis based on the results 
obtained be done in future research.  
Recent research carried out to identify Cry2A toxin genes in a collection of 300 strains 
of Bt identified a novel toxin named Cry2Aa17 which showed sequence similarity to 
Cry2Ab in domain 1 whilst the domains 2 and 3 resembled Cry2Aa (Figure 1.9.8). When 
the toxicity profile of this novel toxin against three different insect orders was 
determined, it matched those of Cry2Ab, and hybrid creation through domain I swap 
between Cry2Aa and Cry2Aab gave similar findings thus implicating domain I in toxicity 
region determination (Shu et al., 2017). This led to the current project work. 
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Figure 1.9.8 Domain configurations of the Cry2A toxins. Each toxin is split into the three domains identified from 
crystallographic studies of Cry2Aa each of which is represented by a rectangle (Morse et al., 2001). Cry proteins 
with two or more different colours in their domains represent natural hybrids whereas those rectangles with two 
names of Cry proteins assigned to them represent toxins that have similar amino acids composition in their 
respective domains. Figure taken from Shu et al. (2017). 
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1.10 Present work 
1.10.1 Prelude 
There is growing concern owing to the rapid increase in mosquito resistance to various 
chemical insecticides and their concomitant environmental pollution leading to the 
search for alternative means for mosquito control, such as the use of biological agents 
and insect growth regulators(Alphey et al., 2013). Therefore, Cry proteins from Bt strains 
having a wide toxicological spectrum and high specificity (Schnepf et al., 1998) became 
a common tool in mosquito control, Agriculture and Forestry and at the same time 
serving as a safer alternative to traditional pesticides. Importantly also, is the fact that it 
has been experimented and found that Cry2Aa toxin of Bt is toxic to mosquito vectors 
of human diseases including Zika fever, Chikungunya and yellow fever transmitted by 
Aedes aegypti making Cry2Aa an attractive mosquitocidal agent to control the spread of 
the disease (McNeil and Dean, 2011). Previous works were done to compare the activity 
of a closely related toxin, Cry2Ab that does not possess mosquitocidal activity against 
Aedes aegypti to Cry2Aa, which possessed mosquitocidal activity against Aedes aegypti 
(Hofte and Whiteley, 1989, Liang and Dean, 1994). However, with only two toxins it was 
difficult to find a good association between structure and function. That is why we want 
to use more Cry2A toxins- unfortunately; published data are confusing and often 
contradictory so we need to generate these here and use it to achieve the aim of this 
research, which is to understand the basis for the specificity of Cry2A toxins of Bacillus 
thuringiensis against the dipteran insect, Aedes aegypti. 
 
1.10.2 Aims and objectives of the research 
i. To carry out the characterisation, expression, harvesting and bioassay of the 
wild type Cry2A toxins against Aedes aegypti mosquito in order to generate 
a comprehensive and more reliable data for further work. 
ii. To identify the domain(s) and/ or amino acid motifs that encode toxin 
specificity to Aedes aegypti. 
iii. Last but not the least, to study the nature of the interactions between the 
mid gut juice of Aedes aegypti and Cry2A. This would be achieved by 
deciphering through in vitro studies if the cleaved fragments resulting from 
the activation of Cry2A toxins by protease within the Aedes mosquito mid gut 
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remain associated or dissociated from each other to exert their activity 
within the Aedes mid gut epithelium. 
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2. Materials and Methods 
2.1 Materials 
2.1.1 Bacterial strains and reagents 
The Crickmore Laboratory of the School of Life Sciences, University of Sussex, provides 
all bacterial strains and reagents used in this study.  
The Bacterial toxins used in this study comprise Cry2A toxins from Bacillus thuringiensis, 
which consist of the Bt toxin genes, and then two strains from E. coli, used for 
transformation and expression of the Bt gene. The various Cry2A used and their 
respective plasmids are shown in Table 2.1-1. 
Plasmid Toxin 
pGEM Cry2Aa2 
pEB Cry2Aa9 
pEB Cry2Aa17 
pEB Crym2Aa17 
pGEM Cry2Ab (4D6-4) 
pGEM Cry2Ab (916-2) 
pEB Cry2Ab4 
pEB Cry2Ab29 
pGEM Cry2Ac 
pGEM Cry2AcAa 
pGEM Cry2Ad 
pEB Cry 2Ah1 
pEB Cry 2Ax 
pGEM Cry2Ab (4D6-5 SP6) 
pGEM Cry2Ab (916-5 SP6) 
Table 2.1-1 The Bacillus thuringiensis toxins used in this study 
 
 
The E. coli strains used in this study are shown in Table 2.1-2 below. 
 
Strain  Application 
DH5α  Host for transformation 
   
BL21(DE3)pLysS  Host for Expression 
Table 2.1-2 The E. coli strains used in this study 
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2.1.2 Buffers 
10 x TBE buffer: 108 g of Tris base, 55 g of boric acid, 40 ml of0.5 M EDTA, 2 l of dH2O, 
pH 8.0. 
Resolving Gel Buffer (RGB): 18.18 g Tris-(Hydroxymethyl) amino methane, 0.4 g SDS, 
100 ml of dH2O, pH 8.8. 
Stacking Gel Buffer (SGB): 6.06 g Tris-(Hydroxymethyl) amino methane, 0.4 g SDS, 100 
ml of dH2O, pH 6.8.  
Resolving Gel Buffer (RGB) for native gel: 18.18 g Tris-(Hydroxymethyl) amino 
methane, 100 ml of dH2O, pH 8.8. 
Stacking Gel Buffer (SGB) for native gel: 6.06 g Tris-(Hydroxymethyl) amino methane, 
100 ml of dH2O, pH 6.8. 
10 ×SDS running buffer: 7.6g Tris-HCl, 36g glycine, 2.5g SDS, 250 ml of dH2O, pH 8.3 
10 x running buffer for native gel: 7.6g Tris-HCl, 36g Glycine, 250 ml of dH2O, pH 8.3 
2 × protein gel sample loading solution:2g SDS, 6 mg EDTA, 20 mg Bromophenol Blue, 5 
ml of RGB, 50 ml glycerol, 100 ml of dH2O. 
2 x native protein gel sample loading solution: 6 mg EDTA, 20 mg Bromophenol Blue, 5 
ml of RGB, 50 ml glycerol, 100 ml of dH2O. 
Coomassie blue stain: methanol, dH2O, acetic acid (10:9:1 v/v/v), Brilliant Blue R-250 
(0.25%, w/v). 
De-staining solution: methanol, dH2O, acetic acid (10:9:1, v/v/v).  
10 ×PBS: 80 g of NaCl, 2g of KCl, 14.4g of Na2HPO4, 2.4g of KH2PO4,1 l of dH2O, pH 7.4. 
50mM Na2C03 buffer (pH 10.5). 
 
2.1.3 Reagents and Enzymes 
Reagents obtained from Sigma-Aldrich: SDS, Tris-HCl, ammonium persulfate, 
Bromophenol Blue, β-mercaptoethanol, TEMED, acrylamide/bis-acrylamide 30%, 
sodium carbonate, Coomassie Brilliant Blue R-250, BSA, and IPTG. The following were 
purchased from AnalaR BDH: glucose, NaOH, EDTA, CaCl2, methanol, 1-butanol, and 
sodium acetate. Chemicals obtained from Thermo Fisher Scientific: Sucrose, glycine, KCl, 
NaCl, HCl, glycerol, mono-potassium phosphate, di-potassium phosphate, glacial acetic 
acid, sodium hydrogen carbonate, MgCl2. Pre-stained Protein Ladder, 1kb DNA ladder, 
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Gel red, DpnI, T4 DNA ligase, HaeIII and BSaAI restriction enzymes were obtained from 
New England Biolabs. The following reagents were obtained from Melford: Tris-base, 
ampicillin, LB Capsule (1kg), trypsin, and agarose. The protease inhibitor was obtained 
from Roche. 
 
2.2 Methods 
2.2.1 Expression and harvesting of protein from E. coli BL21 (DE3) pLysS 
Colonies of E. coli BL21 (DE3) pLysS cells harbouring the relevant Cry2A clone were 
scraped from agar plate using a sterile loop into 500 ml of L Broth, prepared by dissolving 
an LB capsule (1 kg) in 500 ml of deionised water, to which 500 μl of 100 mg/ml ampicillin 
was added. Cells were grown for approximately 3 hours in a 37oC shaking incubator 
checking the O.D at 30-minute intervals until an O.D of 0.4-0.6 was obtained. This was 
then followed by the addition of 250 μl of 1 molar IPTG. 
The E. coli BL21 (DE3) pLysS cells in L-broth was then left overnight (14hours) at 25oC in 
a shaking incubator. The cultures were then poured into a centrifuge bottle and 
centrifuged at 6,371 x g in JA 10 rotor for 10 minutes at 4oC to form a pellet, and the 
supernatant was discarded. The pellet was re-suspended in 30 ml of distilled water, 
transferred to a 50 ml Falcon tube and sonicated at an amplitude of 20 microns for a 
total of 4 minutes with intermittent 1-minute rest times between each 1-minute 
sonication. The sonicated cells were then transferred to a 50 ml Oakridge tube, and 
centrifuge for 30 minutes at 27,216 x g. The supernatant containing the cell debris was 
discarded and the pellet containing the protein was transferred to a 50 ml Oakridge tube, 
and sonicated again for the second time, then centrifuged again at 27,216 x g for 20 
minutes. It was then, finally, re-suspended in 1 ml of deionised water and viewed under 
the microscope to check for cell debris and protein inclusion. 5 μl of the re-suspended 
pellet was run on an SDS-PAGE gel. 
2.2.2 SDS- PAGE gel 
7.5% SDS-PAGE (Sodium Dodecyl Sulphate-Polyacrylamide Denaturing Gel 
Electrophoresis) gels were prepared for protein analysis. Glass plates were cleaned with 
ethanol and sealed with 200 μl of 1% SDS agarose, made up of 0.3g agarose in 30 ml 
1xSDS gel running buffer. Resolving gels were made up in a small glass bottle using the  
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protocol below. 
 
 
A 1 ml Gilson Pipette was used to introduce the resolving gel between the plates. 200 μl 
of water-saturated butanol was added to the top of the gel. When the gel was set after 
20-30 minutes the water-saturated butanol was removed, washed with water, and 
blotted to remove excess liquid from between the plates. The stacking gel solution was 
prepared using the protocol below. 
 
The gel was allowed to set for 15-20 minutes, after which the plates were then set up in 
the electrophoresis apparatus. 1xSDS gel running buffer was added to the reservoirs and 
wells were washed out as well.  
5 μl of the SDS-ME loading buffer, was added to 5 μl protein sample in a large Eppendorf 
tube. This was boiled for 4 minutes, and then centrifuged at 5,510 x g for 30 seconds. 
The total 10 μl sample was then loaded into the gel alongside a protein marker. An SDS-
PAGE gel was then run at 200V for 40 minutes. After the gel had run, it was then stained 
with Coomassie Brilliant Blue staining solution for 20 minutes on a shaker; this was 
followed by removal of the stain through the addition of different changes of de-staining 
solution for 20 minutes on a shaker until the bands became visible on the gels. 
Component Volume (µl) 
Distilled water 2000 
Resolving Gel Buffer (RGB) 
 
1000 
Acrylamide/bisacrylamide  1000 
Ammonium per sulphate (APS) 8 
TEMED 4 
Component Volume (µl) 
Distilled water 1170 
Stacking Gel Buffer (SGB) 
 
500 
Acrylamide/bisacrylamide  333 
Ammonium per sulphate (APS) 4 
TEMED 2 
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2.2.3 Native PAGE gel 
The native gel used in this study was prepared using the following protocol. Glass plates 
were clean with ethanol before assembly and the bottom of the plates were sealed with 
200 ul 1% agarose made up in 1 x running buffer (see Materials section).  The resolving 
gel solution was made following the protocol below. 
  
 Component 7.5% Gel  12% gel  
Water  2 ml  2 x 700 µl  
RGB  1 ml  1 ml  
Acrylamide  1 ml  2 x 800 µl  
400mg/ml APS  8 µl  8 µl  
TEMED  4 µl  4 µl  
  
 
The above components were carefully introduced between the plates using a 1 ml Gilson 
pipette. 200 ul of water or water-saturated butanol was carefully added to the top of 
the poured gel. After the gel has set, the top layer of water/butanol was removed, and 
washed with water and any traces of liquid remaining was blotted off. 
 The stacking gel solution was prepared using the protocol below. 
 
 
  
  
 
 
 
The stacking gel was carefully added on top of the freshly poured resolving gel, and the 
comb was immediately inserted. When set, the comb was removed and the gel was 
transferred to the electrophoresis apparatus.  
5 µl of the 2 x native protein gel sample loading buffer was added to 5 μl protein sample 
in a large Eppendorf tube then centrifuged at 5,510 x g for 30 seconds. 
The total 10 μl sample was then loaded into the gel alongside a protein marker. The 
native gel electrophoresis was then run at 200V for 40 minutes. After the gel had run, it 
was then stained with Coomassie Brilliant Blue staining solution for 20 minutes on a 
shaker; this was followed by removal of the stain through the addition of different 
Components  7.5% and 12% gel 
Water  2 x 585 µl  
SGB  500 µl  
Acrylamide  333 µl  
APS  4 µl  
TEMED  2 µl  
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changes of de-staining solution for 20 minutes on a shaker until the bands became 
visible on the gels. 
2.2.4 Determination of protein concentration  
Two methods were used to measure the protein concentration in this study. The first 
method was the Bradford method, which was used to measure the concentration of the 
Aedes mid gut juice protein and the densitometry method using Image J software to 
measure the Cry toxins concentration. 
Bradford method for determination of protein concentration 
Protein concentration was determined by the Bradford method (Bradford, 1976) using 
a Bio-Rad Protein Assay Kit (Bio-Rad) with BSA as the standard. All presented 
concentrations represent final concentrations used (unless stated otherwise). The 
mixture was incubated for 5 - 10 min at RT before measurement. Concentration of the 
unknown sample was determined by comparing its absorbance value against a plotted 
BSA standard curve. The standard curve showed near linear response (R2=0.9975) over 
0 - 1 mg/ml BSA concentration range, which is the range absorbance values from the 
least to the highest by which the standard curve obeys Beer-Lambert’s law. 
Determination of protein concentration using image J 
The concentrations of the toxins within the crude sample was determined using 
densitometric method by running the proteins along with three or four sets of BSA 
(Bovine Serum Albumin) standards at different concentrations. The gel obtained was 
then subjected to the Image J software, which quantified each toxin, as well as the BSA 
standards as area under the peak. The concentrations of the toxins were obtained by 
interpolation.  
Sucrose gradient protein purification 
Toxin inclusions were partially purified for bioassay by sucrose gradient purification. In 
a 1.5 ml Eppendorf tube, 100 µl of undiluted sample was layered on top of 1 ml of 50 % 
(w/v) sucrose solution, and then centrifuged for 10 minutes at 14,549 x g. The 
supernatant and any floating debris were discarded and 100 µl of deionised water was 
used to re-suspend the pellet. 
56 
 
 
 
2.2.5 PCR Amplification of the DNA 
PCR procedure was carried out in order to amplify the various domains which are to be 
ligated to form the various hybrids required using the wild type Cry toxins as the 
template strand. In addition, to be sure that the various domains amplified using PCR 
are free from interference by the template/parental DNA, each of the amplified 
products is further digested with DpnI. 
Primers were designed based on the specific amplification products desired at each 
stage of the study, and were ordered from the MWG Eurofins after making sure that 
they met the optimum conditions for PCR reaction. The primers were all adjusted to a 
concentration of 100 pmol/µl with deionised water and then each diluted 1:10 again 
with deionised water. 
The reaction mixture for the Cry2A toxins domains amplification is shown below. 
Master mix                                                           25 µl 
Primer DI or DII F                                                   1 µl   
Primer DI or DII R                                                   1 µl   
DNA template (pGEM Cry2A)                              1 µl  
Deionised water                                                   22 µl  
Total volume                                                         50 µl         
The PCR Program used for this procedure was PFU ULTRA 6KB. 
The reaction conditions for the reaction were as follows. 
1. Initial denaturation     950C    for 2minutes  
2. Denaturation               950C    for 20 seconds 
3. Annealing                     500C    for 20 seconds 
4. Elongation                    720C    for 1 minute and 20 seconds 
Reactions 2, 3 and 4 were repeated for 30 consecutive cycles then finally 
5. Final extension for 3 minutes 
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The product obtained above was run on a gel to see if the desired product had been 
amplified after which 45 µl of the PCR product was being mixed with 1 µl of DpnI enzyme, 
and incubated for 1 hour to digest the parental/ template strand. 
2.2.6 Agarose Gel Electrophoresis 
To prepare the gels, 0.3 g of agarose was mixed into 30 ml TBE (Tris/Borate/EDTA) inside 
a sterile 50 ml Erlenmeyer flask. The mixture was microwaved until visibly clear of 
agarose traces. Once cooled down, 1.5 µl of a 1:3 dilution of GelRed™ was introduced, 
and the liquid gel was poured into the receptacle of the electrophoresis device and a 
comb inserted. 5 µl of each amplified DNA sample was mixed with 1 µl of gel loading 
buffer prior to loading. 5 µl of 1 kb marker was loaded alongside for identification of the 
PCR products present in each sample. The gel was run at 120 V and imaged using a UV 
transilluminator. 
2.2.7 Purification of DNA from Agarose gels 
We used two different approaches to purify the DNA samples based on the observed 
purity of the DNA amplification products seen on the gel. These were: 
Liquid Purification 
Liquid purification was performed on DNA gel samples displaying a single band on an 
agarose gel following the QIAquick® PCR Purification Kit Protocol. 50 µl of the sample 
was placed inside a 1.5 ml Eppendorf tube and 250 µl of PB buffer was added to each 
tube. The samples were then placed in a spin column inside a collection tube, and 
centrifuged for 30 seconds at 8,609 x g. The flow-through was discarded. 750 µl of PE 
buffer was added to each spin column prior to two rounds of 30 seconds of centrifuging 
at 8,609 x g each time to get rid of residual buffer. The spin columns were then 
transferred to a 1.5 ml Eppendorf tubes prior to eluting by adding 30 µl EB buffer. Finally, 
the samples were given 1 minute to rest before being centrifuged for 1 minute at 14,549 
x g. The flow-through now contained the purified PCR products for visualising in later 
DNA gels. 
Gel Purification 
Excised gel samples were placed in a 1.5 ml Eppendorf tubes. The protocol from 
QIAquick® Gel Extraction Kit was used in this situation. 600µl of QG buffer was added to 
each tube prior to placing them on a pre-heated warming block at 50°C for 5 minutes to 
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dissolve the gel. The contents of each tube were then poured into individual spin 
columns and centrifuged for 1 minute at 14,549 x g. The flow through was discarded and 
500 µl of QG was added to the spin column. The samples were centrifuged again for 30 
seconds at 14,549 x g, the flow-through discarded, and 750 µl of PE buffer was added to 
each column and centrifuged for another 30 second at 14,549 x g and the flow-through 
discarded. At this point, the spin columns were transferred to 1.5 ml Eppendorf 
centrifuge tubes and 30 µl of EB buffer was added to each of them before leaving them 
to stand for 1 minute. This was then centrifuged for 1 minute at 14,549 x g. The flow 
through now contained the eluted and purified DNA samples. 
2.2.8  Ligation of the PCR products 
The ligation reaction was set up following the recommended ligation ratio of 1:3 to 1:5 
of vector to insert in the right estimated proportion based on the intensity of their 
respective bands on a gel, plus 1 µl of ligase buffer and 0.5 µl of DNA Ligase then adding 
deionised water to make a total of 10 µl mixture. This was left to stand overnight for 
ligation reaction to take place. A second ligation reaction that we later adopted in this 
work was the one using the Blunt/TA master mix reagent from New England BioLabs. 
1. The master mix was transferred to ice prior to reaction set up. The tube was 
mixed by finger flicking before use 
2. 20-100 ng of the Vector was combined with a 3- fold molar excess of insert and 
the volume was adjusted to 5 µl with deionised water. 
3. 5 µl of the Blunt/TA master mix was added to the above mixture by pipetting up 
and down 7-10 times or by finger flicking 
4. The above mixture was incubated at room temperature (250C) for 15 minutes 
and placed on ice 
The above ligation mixture was then used for transformation or stored at -200C for 
future use.  
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2.2.9 E. coli transformation 
We employed two methods (chemical and electroporation).  
Electroporation method 
E. coli strains were grown on 25 ml L-agar at 37oC overnight. The strains were then 
prepared for transformation by scraping a culture from the agar plate using a sterile 
toothpick into 100 ml L-broth and grown in a shaking incubator until it reached an OD 
of over 0.4-0.6. The cells were then harvested by centrifugation- the 100 ml of broth 
containing the E. coli was spun at 17,696 x g for ten minutes, the supernatant discarded 
and the pellet re-suspended in 100ml of deionised water at 4oC. The re-suspended cells 
were centrifuged again at 17,696 x g for a further ten minutes and the pellet re-
suspended in approximately 1ml of 4oC water, which was then transferred to a 1.5 ml 
Eppendorf. The Eppendorf was centrifuged at 14,549 x g for 1 min and the pellet re-
suspended in 200µl of 4oC sterile water. 
50 μl of the E. coli cell suspension was transferred to a small Eppendorf tube, and stored 
on ice- 1 µl of DNA was added and mixed before being transferred into a sterile 2 mm 
electroporation cuvette and tapped to ensure the cells settled at the bottom. The gene 
pulser was set to 1.8 kV, 200 Ohms and 25 µF, the electroporation cuvette placed in it 
and a short electrical pulse was applied to the cells. The cells and 0.5 ml of L-broth were 
mixed with a sterile Pasteur pipette, and transferred into small glass bottles. Then left 
to rest for one hour at room temperature. 
Heat shock method 
The protocol outlined below is the one specified by the New England BioLab for 
transformation using this method. The protocol is as follows: 
i. A tube containing 50 µl of NEB5-α competent E. coli cells was thawed on ice 
for 10 minutes 
ii. 2 µl of the ligation mixture was added to the 50 µl NEB5-α competent E. coli 
cells above and carefully flick the tube 4-5 times to mix the cells and DNA.  
iii. The mixture was placed on ice for 30 minutes without mixing 
iv. The above mixture was then heat shocked at exactly 420C for exactly 30 
seconds without mixing. 
v. It was then placed on ice for 5 minutes 
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vi. 950 µl of recovery media (SOC) maintained at room temperature was added 
to the mixture 
vii. It was then placed on a shaker maintained at 370C, 250 rpm and was allow 
to rotate for 1 hour 
viii. 500 µl of the above was poured on an ampicillin plate that was warmed at 
370C and the plate was placed in an incubator maintained at 370C and was 
allow to stay overnight for cell growth. 
  
2.2.10 PCR and restriction digest 
The cells obtained from the transformation procedure, which is expected to contain the 
hybrid comprising the two DNA fragments that were ligated together, needs to be 
checked for the presence of the insert (the DNA fragment that does not contain the 
vector), and to be sure that the insert is in the right orientation. This is because the insert 
could be ligated to the vector in two possible orientations; T7 (A) orientation, that is in 
the same direction with the promoter region and SP6 (B) orientation, meaning in 
opposite direction with the promoter region. In addition, the vector could self-ligate 
itself, and this could be picked by the NEB5-α competent E.coli cells during 
transformation process. Therefore, this confirmation was achieved using two 
approaches, each of which was employed at some points in this research work. The first 
approach involves the use of the plasmid DNA extracted from the colonies and then 
using enzyme digestion to confirm which of the colonies contain the insert whereas in 
the second approach the technique of colony PCR and HaeIII restriction enzyme 
digestion were used to confirm the presence of the insert (domain I in this case). The 
colony PCR procedure used in this research is outlined as follows: 
The colonies produced from the NEB5-α transformation were selected using a toothpick 
and were suspend on a tube containing the mixtures below. 
1. Master mix                               12.5 µl 
2. Forward primer                          0.5 µl 
3. Reverse primer                           0.5 µl 
4. D/water                                     12.5 µl 
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The above mixture in a tube was run on a PCR using the program RMMG with 
the following conditions: 
Heated lid 1050C 
Initial denaturation 2 minutes at 900C 
 
Seq 1 Denaturation for 30seconds at 950C 
Seq 2 Annealing for 30 seconds at 500C 
Seq 3 Elongation for 30 seconds at 720C 
The above three reactions are repeated for 25 cycles 
Then finally the final extension for 5 minutes at 720C 
The restriction enzyme digestion procedure is same for both the two approaches and it 
is as shown below: 
1. Deionised water                                    6.5 µl 
2. Plasmid DNA                                               2 µl      
3. Buffer                                                           1 µl  
4. Restriction enzyme                                0.5 µl 
Total                                                          10 µl 
This was incubated in a water bath for 20-30 minutes at 370C 
After which 2 µl of DNA loading buffer was added and run on a gel. The gel was scanned 
and the restriction fragments produced, which appeared as bands in the gel was 
compared to those predicted by NEB cutter for both A and B orientations. This then 
enabled us to know which of the colonies has the insert in the right orientation. 
2.2.11 Mosquito rearing. 
Insect population 
Aedes aegypti were obtained from Cardiff University, UK and subsequently cultured 
here. 
Feeding the mosquitoes 
The adult male mosquitoes were fed on 20% sucrose solution, which was prepared as 
soon as it is finishes and/or if any form of fungal or algal growth is noticed on the cotton. 
The sucrose solution was poured inside a bottle and a cotton wool was made in a thread-
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like fashion, and dipped inside it. The sucrose moves through the cotton via a capillary 
action. The adult males drink the sucrose through the soaked cotton wool. 
The female adult mosquitoes were fed on heparinised horse serum, freshly prepared 
after every two days when there was no high demand for eggs or on daily basis when 
there was high demand for eggs. The blood meal was prepared by pouring some blood 
in a bottle lid and the exterior of the lid was dried using tissue paper. After which, a para 
film was stretch and used to cover the lid containing the blood meal; the para film 
automatically sticks to the dry sides of the lid containing the blood meal. The extra para 
film extending from the lid was cut using scissors. Then the bottle lid containing the 
blood meal was carefully placed inside the cage in the position where a hole was already 
created in the cage, the parafilm facing the inside of the cage while the bottom of the 
bottle lid attached to the heating block maintained at 370C. 
The mosquito larvae were fed on ground tetramine fish food. This was ground to powder 
using pestle and mortar. Then a loop full of the feed was placed inside the water 
containing the larvae. This was repeated daily or after every two days depending on the 
demand for eggs. 
Changing the water containing the larvae or pupae 
The water containing the larvae and pupae was changed regularly, especially; any 
moment I noticed that it was cloudy or to have contained some fungal or algal growth. 
This was done by pouring clean water on the container containing the larvae or pupae 
and discarding it by pouring it away making sure the pupae or larvae were not poured 
along with the water. This was done continuously with many changes of the water until 
it becomes clear.   
Hatching of the eggs 
The eggs were hatched by putting the filter paper containing the eggs on a beaker that 
is 1/3 filled with a lukewarm water containing some feed and was allow staying at a 
temperature of 270C. Usually, the larvae began to appear after a period of 24 hours. This 
procedure was enhanced by placing the beaker containing the eggs inside an incubator 
maintained at 270C, this way the eggs began to hatch after 12 hours. The filter paper 
was removed after the eggs have hatched, but those still containing unhatched eggs 
were placed in a new beaker and returned in to the incubator until hatched. 
63 
 
 
 
Harvesting and transfer of the pupae 
Provided the larvae were fed regularly, they metamorphosed to pupae within a period 
of five days to a week. They were then transferred in to a cage to avoid their escape on 
metamorphosing to adult. Therefore, a pipette dropper was used to collect the pupae 
and transfer them to a new container, which was then placed inside the cage. The pupae 
metamorphosed to adults within a period of two to four days, hence the reason why 
they were quickly transferred in to the cage. 
2.2.12 Bioassay 
The standard bioassay method by WHO (2005c) was used in this study. This involved 
using 4 ml of deionised water per larvae. To 80 ml of deionised water containing five 
different concentrations of the toxins in a 100 ml beaker and the control containing only 
the deionised water with no toxin, 20 late 3rd instar larvae were carefully added using 
a pipette dropper.  They were then allowed to stay for a period of 24 to 72 hours at 270C 
and 18 light; 6-hour dark photoperiod. A little amount of larval food was added to each 
beaker since the exposure period is more than 24 hours. The number of dead larvae in 
each beaker was counted after a period of 24 hours, 48 hours and 72 hours. During 
counting of dead larvae, moribund larvae that are larvae incapable of rising to the 
surface of the water or not showing the characteristic diving reaction when the water is 
disturbed, were counted as dead. The result is expressed as percentage mortality, which 
was obtained by dividing the total number of dead larvae by the total number of larvae 
in each container for the number of replicates and multiplying the result by 100. During 
the bioassay experiment if more than 10% of the control larvae pupate or if more than 
20% mortality was recorded in the control, the test was discarded and repeated. For 
mortalities between 5% and 20% in the control group, the result of the treatment groups 
was treated using the Abbot’s formula designated as follows:             
Corrected percentage mortality= X-Y/X multiply by 100.  
Where X = Percentage survival in the untreated control, and Y= Percentage survival in 
the treatment group. 
2.2.13 Preparation of the Aedes mid gut protease 
The Aedes mid gut protease was prepared by extracting 50 mid guts from late third 
instar larvae of Aedes aegypti through dissection on ice cold. The motility of the larvae 
64 
 
 
 
was restricted by putting them on ice cold for five minutes before commencing the 
dissection. The 50 mid guts dissected were suspended in 100 µl of 1X PBS buffer and 
was homogenised by sonication for 8 minutes setting it at 20 sec on and off cycle or 
using a homogeniser. The above mixture, which contains both extracellular and intra 
cellular fluids as the mid gut of Aedes aegypti is too small and the mid gut juice 
comprising the intracellular fluid cannot be extracted alone, was centrifuged for 10 
minutes at 6,268 x g and 40C. The supernatant was decanted on a 1.5 ml Eppendorf tube 
as the Aedes mid gut juice (AMJ) and was stored at 40C for future use while the pellet 
was discarded. 
2.2.14 Protein solubilisation and activation 
Pellet containing Cry2Aa crystals was solubilized in 50 mM sodium carbonate (pH 10.5), 
in the presence of 5 mM dithiothreitol (DTT) and incubated at 37°C for 1 hour (1:1 w/v 
ratio of pellet to buffer). Sample was then spun down at 14,549 x g for 5 - 10 min and 
supernatant containing solubilized protein was treated with a protease. 10 mg/ml of 
chymotrypsin solution in the buffer was used for activation at the ratio of 1:5 (v/v) 
enzyme to supernatant at 37°C for 2hour whereas 1:3 ratio of the Aedes aegypti mid gut 
juice (AMJ) to the solubilised protein was used for activation using same temperature 
and time interval. After digestion, CompleteTM mini EDTA-free protease inhibitor was 
added to stop further proteolysis in a ratio of 1:6 of the inhibitor to the activated protein 
in both instances.  
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3. Characterisation, Expression, Harvesting and Bioassay of Wild 
type Cry2A toxins. 
3.1 Introduction 
This chapter involves the characterisation, expression, harvesting and bioassay of all the 
Cry2A toxins displayed in Table 2.1-1 of the Materials and Methods section of this 
project. The characterisation was achieved by sending the DNAs for sequencing and 
using the sequencing results to carry out sequence alignment, using blastn and Clustal 
Omega, with the sequences of already characterised Cry2A toxins from the Bt 
nomenclature data base (Crickmore et al., 1998). This is to enable us confirm their 
identity through the degree of their sequence similarity to those of the database. The 
Cry2A toxin genes were sequenced in both the T7, which is in the same direction with 
the promoter region, and SP6, which is in the opposite (reverse) direction with the 
promoter region. 
Further confirmation was done by running a protein gel and confirming the molecular 
weight of the toxin bands and comparing them to those found in the Bt nomenclature 
data base (Crickmore et al., 1998),and the ones predicted from a program in Expasy to 
be sure that there is actual agreement. This was done in order to have a much more 
comprehensive data for all the Cry2A toxins, as previous researches mostly concentrate 
on comparing the activity of a closely related toxin, Cry2Ab that does not possess 
mosquitocidal activity against Aedes aegypti to Cry2Aa that possessed mosquitocidal 
activity against Aedes aegypti (Widner and Whiteley, 1990, Liang and Dean, 1994). 
However, with only two toxins it was difficult to find a good association between 
structure and function. That is why we want to use more Cry2A toxins- unfortunately; 
published data are confusing and often contradictory (Table 1.9-2), so we need to 
generate these here. 
The host of expression for all the Cry2A proteins chosen in this research was E.coli. 
Therefore, we carried out an experiment to show that the proteins from E.coli are 
nontoxic to Aedes aegypti. This implies that any activity observed from the bioassay can 
thereafter, be attributed to the toxin alone but not the E.coli proteins, which may still 
be found in solution with the toxin.  
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Qualitative bioassay was also carried out to screen out those Cry2A that are toxic to 
Aedes aegypti larvae from those that are nontoxic to this insect. This was followed by 
quantitative bioassay for those Cry2A toxins that were toxic to Aedes aegypti larvae to 
be able to determine their LC 50 values.  
3.2 Results 
3.2.1 Confirmation of Cry2A toxin sequence 
The seven of the Cry2A toxins presented in table 2.1-1 (Cry2Aa9, Cry2Aa17, mCry2Aa17, 
Cry2Ab4, Cry2Ab29, Cry2Ah1, and Cry2Ax), were provided and sequenced by the 
institute of plant protection, Chinese Academy of Agricultural Sciences and were 
transformed into E.coli BL 21 strain by a previous student (Nicholas Stevens, 2015). A 
previous student (Phipps, 2015, BSc Dissertation) confirmed the sequence of Cry2Ac 
toxin. Cry2AcAa hybrid toxin, which encodes domain I of Cry2Ac, and domain II and III 
of Cry2Aa, was also designed by a previous student (Evans, 2014, BSc Dissertation). The 
two Cry2Ab protein, 4D6-5(SP6) and 916-5(SP6), which were designed to be in SP6 
(reverse orientation), that is in a direction that is opposite to the promoter region and 
as such could not be expressed, were also done by a previous project student (Evans, 
2014). Cry2Aa2 sequence was taken from the Bt nomenclature data base (Crickmore et 
al., 1998). Therefore, we sequenced Cry2Aa2 toxin available in our lab using a pGEM T7 
primer and compare it to the one in the Bt nomenclature database to confirm if it is truly 
Cry2Aa2, the result is shown in Figure 3.2.5.  
The two Cry2Ab proteins i.e. Cry2Ab (4D6-4) and (916-2) which contained Cry2Ab gene 
with the pGEM plasmid DNA were extracted and sent off to ‘MWG eurofins’ lab to be 
sequenced so we could confirm their sequence as they were yet to be determined. 
Therefore, in order to sequence the entire gene, three primers were designed as one or 
two primers cannot be sufficient to sequence the entire gene. These primers are: 
T7 with the sequence: 5’-TAATACGACTCACTATTAGGG-3’ 
Cry2F with the sequence: 5’-TATTACCTTTATTTGCACAGGCA-3’ 
SP6 with the sequence: 5’-ATTTAGGTGACACTATAG-3’ 
The sequencing results received were pieced together in each case to form the 
nucleotide sequence for the gene of the Cry2Ab being determined. The primer SP6, is a 
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reverse primer, therefore, the reverse complement of the sequence from this primer 
was obtained in order to carry out the analysis. Since there were areas of overlaps 
among the three sequences received from the sequencing results, we therefore, aligned 
them with the DNA sequence of Cry2Ab4 from the database as a template (Figure 3.2.1 
and 3.2.2). This is to enable us understand where to stop the sequence from one primer 
and start the sequence of the next primer to avoid repetition of the overlapping regions. 
Positions where there were differences between our sequence and that of the database 
were noted, and carefully studied to see if they are real differences, or just a case of 
ambiguity in the sequencing process but fortunately enough there were only few 
differences, which fall within the overlapping regions and were all resolved. The diagram 
illustrating the procedure for mapping the sequences of the two Cry2Ab (4D6-2 and 916-
2) received from the sequencing results to that of Cry2Ab4 from the database is shown 
in Figure 3.2.1 and 3.2.2 respectively. Thereafter, the DNA sequence generated was 
converted to protein using a program in EXpasy. 
 
 
 
 
Figure 3.2.2: The diagrammatic representation of gene mapping for Cry2Ab (4D6-4 gene). T7, F and SP6 denote 
the three results obtained from the sequencing results for the entire gene. Arrows shows the direction of 
sequencing. 
Figure 3.2.1 The diagrammatic representation of gene mapping for Cry2Ab (916-2). T7, F and SP6 denote the 
three results obtained from the sequencing results for the entire gene. Arrows shows the direction of 
sequencing.  
 
68 
 
 
 
The sequence of the two Cry2Ab (4D6-4 and 916-2) generated from the above analysis 
are shown in Figure 3.2.3 and 3.2.4 below. 
 
Figure 3.2.3 Sequence generated for Cry2Ab (4D6-4) after analysing the results obtained from sequencing the entire 
gene. 
 
 
GCTCCGGCCGCCATGGCGGCCGCGGGAATTCGATTAAGGAGGAATTTTATATGAATAATGTATTGAATAGCGGAAGAACTACTATTT
GTGATGCGTATAATGTAGCGGCTCATGATCCATTTAGTTTTCAACACAAATCATTAGATACCGTACAAAAGGAATGGACGGAGTGGA
AAAAAAATAATCATAGTTTATACCTAGATCCTATTGTTGGAACTGTGGCTAGTTTTCTGTTAAAGAAAGTGGGGAGTCTTGTTGGAAA
AAGGATACTAAGTGAGTTACGGAATTTAATATTTCCTAGTGGTAGTACAAATCTAATGCAAGATATTTTAAGAGAGACAGAAAAATT
CCTGAATCAAAGACTTAATACAGACACTCTTGCCCGTGTAAATGCGGAATTGACAGGGCTGCAAGCAAATGTAGAAGAGTTTAATCG
ACAAGTAGATAATTTTTTGAACCCTAACCGAAACGCTGTTCCTTTATCAATAACTTCTTCAGTTAATACAATGCAACAATTATTTCTAAA
TAGATTACCCCAGTTCCAGATGCAAGGATACCAACTGTTATTATTACCTTTATTTGCACAGGCAGCCAATTTACATCTTTCTTTTATTAG
AGATGTTATTCTAAATGCAGATGAATGGGGAATTTCAGCAGCATCATTACGTACGTATCGAGATTACTTGAAAAATTATACAAGAGA
TTACTCTAACTATTGTATAAATACGTATCAAAGTGCGTTTAAAGGTTTAAACACTCGTTTACACGATATGTTAGAATTTAGAACATATA
TGTTTTTAAATGGATTTGAGTATGTATCTATCTGGTCGTTGTTTAAATATCAAAGTCTTCTAGTATCTTCCGGTGCTAATTTATATGCAA
GTGGTAGTGGACCACAGCAGACCCAATCATTTACTTCACAAGACTGGCCATTTTTATATTCTCTTTTCCAAGTTAATTCAAATTATGTGT
TAAATGGATTTAGTGGTGCTAGGCTTTCTAATACCTTCCCTAATATAGTTGGTTTACCTGGTTCTACTACAACTCACGCATTGCTTGCTG
CAAGGGTTAATTACAGTGGAGGAATTTCGTCTGGTGATATAGGTGCATCTCCGTTTAATCAAAATTTTAATTGTAGCACATTTCTCCCC
CCATTGTTAACGCCATTTGTTAGGAGTTGGCTAGATTCAGGTTCAGATCGGGAGGGCGTTGCCACCGTTACAAATTGGCAAACAGAAT
CCTTTGAGACAACTTTAGGGTTAAGGAGTGGTGCTTTTACAGCTCGCGGTAATTCAAACTATTTCCCAGATTATTTTATTCGTAATATTT
CTGGAGTTCCTTTAGTTGTTAGAAATGAAGATTTAAGAAGACCGTTACACTATAATGAAATAAGAAATATAGCAAGTCCTTCAGGAA
CACCTGGTGGAGCACGAGCTTATATGGTATCTGTGCATAACAGAAAAAATAATATCCATGCTGTTCATGAAAATGGTTCTATGATTCA
TTTAGCGCCAAATGACTATACAGGATTTACTATTTCGCCGATACATGCAACTCAAGTGAATAATCAAACACGAACATTTATTTCTGAAA
AATTTGGAAATCAAGGTGATTCTTTAAGGTTTGAACAAAACAACACGACAGCTCGTTATACGCTTAGAGGGAATGGAAATAGTTACA
ATCTTTATTTAAGAGTTTCTTCAATAGGAAATTCCACTATTCGAGTTACTATAAACGGTAGGGTATATACTGCTACAAATGTTAATACT
ACTACAAATAACGATGGAGTTAATGATAATGGAGCTCGTTTTTCAGATATTAATATCGGTAATGTAGTAGCAAGTAGTAATTCTGATG
TACCATTAGATATAAATGTAACATTAAACTCCGGTACTCAATTTGATCTTATGAATATTATGCTTGTACCAACTAATATTTCACCACTTT
ATTAAGGTTTG 
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Figure 3.2.4 Sequence generated for Cry2Ab (916-2) after analysing the results obtained from sequencing the 
entire gene. 
 
 
 
 
 
 
 
 
 
 
 
 
 
TGCATGCTCCGGCCGCCATGGCGGCCGCGGGAATTCGATTAAGGAGGAATTTTATATGAATAATGTATTGAATAGCGGAAGAACTAC
TATTTGTGATGCGTATAATGTAGCGGCTCATGATCCATTTAGTTTTCAACACAAATCATTAGATACCGTACAAAAGGAATGGACGGAG
TGGAAAAAAAATAATCATAGTTTATACCTAGATCCTATTGTTGGAACTGTGGCTAGTTTTCTGTTAAAGAAAGTGGGGAGTCTTGTTG
GAAAAAGGATACTAAGTGAGTTACGGAATTTAATATTTCCTAGTGGTAGTACAAATCTAATGCAAGATATTTTAAGAGAGACAGAAA
AATTCCTGAATCAAAGACTTAATACAGACACTGTTGCCCGTGTAAATGCGGAATTGACAGGGCTGCAAGCAAATGTAGAAGAGTTTA
ATCGACAAGTAGATAATTTTTTGAACCCTAACCGAAACGCTGTTCCTTTATCAATAACTTCTTCAGTTAATACAATGCAACAATTATTTC
TAAATAGATTACCCCAGTTCCAGATGCAAGGATACCAACTGTTATTATTACCTTTATTTGCACAGGCAGCCAATTTACATCTTTCTTTTA
TTAGAGATGTTATTCTAAATGCAGATGAATGGGGAATTTCAGCAGCAACATTACGTACGTATCGAGATTACTTGAAAAATTATACAA
GAGATTACTCTAACTATTGTATAAATACGTATCAAAGTGCGTTTAAAGGTTTAAACACTCGTTTACACGATATGTTAGAATTTAGAACA
TATATGTTTTTAAATGTATTTGAATATGTATCTATCTGGTCGTTGTTTAAATATCAAAGTCTTCTAGTATCTTCCGGTGCTAATTTATATG
CAAGTGGTAGTGGACCACAGCAGACCCAATCATTTACTTCACAAGACTGGCCATTTTTATATTCTCTTTTCCAAGTTAATTCAAATTATG
TGTTAAATGGATTTAGTGGTGCTAGGCTTTCTAATACCTTCCCTAATATAGTTGGTTTACCTGGTTCTACTACAACTCACGCATTGCTTG
CTGCAAGGGTTAATTACAGTGGAGGAATTTCGTCTGGTGATATAGGTGCATCTCCGTTTAATCAAAATTTTAATTGTAGCACATTTCTC
CCCCCATTGTTAACGCCATTTGTTAGGAGTTGGCTAGATTCAGGTTCAGATCGGGAGGGCGTTGCCACCGTTACAAATTGGCAAACAG
AATCCTTTGAGACAACTTTAGGGTTAAGGAGTGGTGCTTTTACAGCTCGCGGTATTTCAAACTATTTCCCAGATTATTTTATTCGTAAT
ATTTCTGGAGTTCCTTTAGTTGTTAGAAATGAAGATTTAAGAAGACCGTTACACTATAATGAAATAAGAAATATAGCAAGTCCTTCAG
GAACACCTGGTGGAGCACGAGCTTATATGGTATCTGTGCATAACAGAAAAAATAATATCCATGCCGTTCATGAAAATGGTTCTATGAT
TCATTTAGCGCCAAATGACTATACAGGATTTACTATTTCGCCGATACATGCAACTCAAGTGAATAATCAAACACGAACATTTATTTCTG
AAAAATTTGGAAATCAAGGTGATTCCTTAAGGTTTGAACAAAATAACACGACAGCTCGTTATACGCTTAGAGGGAATGGAAATAGTT
ACAATCTTTATTTAAGAGTTTCTTCAATAGGAAATTCCACTATTCGAGTTACTATAAACGGTAGGGTATATACTGCTACAAATGTTAAT
ACTACTACAAATAACGATGGAGTTAATGATAACGGAGCTCGTTTTTCAGATATTAATATCGGTAATGTAGTAGCAAGTAGTAATTCTG
ATGTACCATTAGATATAAATGTAACATTAAACTCCGGTACTCAATTTGATCTTATGAATATTATGCTTGTACCAACTAATATTTCACCAC
TTTATTAAGGTT 
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The sequence alignment result for Cry2Aa2 obtained from sequencing result is shown in 
figure 3.2.5. 
 
Figure 3.2.5 Sequence alignment result for Cry2Aa2. 
 
The sequencing results showed that the sequence is for Cry2Aa2 toxins due to the 
complete homology between the sequence of our Cry2Aa2 (T7) and that of the database 
as shown above. 
Cry2Aa2-T7      TGCTCCGGCCGCCATGGCGGCCGCGGGAATTCGATTAAGGAGGAATTTTATATGAATAAT 60 
Cry2Aa2         ---------------------------------------------------ATGAATAAT 9 
                                                                   ********* 
 
Cry2Aa2-T7      GTATTGAATAGTGGAAGAACAACTATTTGTGATGCGTATAATGTAGTAGCCCATGATCCA 120 
Cry2Aa2         GTATTGAATAGTGGAAGAACAACTATTTGTGATGCGTATAATGTAGTAGCCCATGATCCA 69 
                ************************************************************ 
 
Cry2Aa2-T7      TTTAGTTTTGAACATAAATCATTAGATACCATCCAAAAAGAATGGATGGAGTGGAAAAGA 180 
Cry2Aa2         TTTAGTTTTGAACATAAATCATTAGATACCATCCAAAAAGAATGGATGGAGTGGAAAAGA 129 
                ************************************************************ 
 
Cry2Aa2-T7      ACAGATCATAGTTTATATGTAGCTCCTGTAGTCGGAACTGTGTCTAGTTTTTTGCTAAAG 240 
Cry2Aa2         ACAGATCATAGTTTATATGTAGCTCCTGTAGTCGGAACTGTGTCTAGTTTTTTGCTAAAG 189 
                ************************************************************ 
 
Cry2Aa2-T7      AAAGTGGGGAGTCTTATTGGAAAAAGGATATTGAGTGAATTATGGGGGATAATATTTCCT 300 
Cry2Aa2         AAAGTGGGGAGTCTTATTGGAAAAAGGATATTGAGTGAATTATGGGGGATAATATTTCCT 249 
                ************************************************************ 
 
Cry2Aa2-T7      AGTGGTAGTACAAATCTAATGCAAGATATTTTAAGGGAGACAGAACAATTCCTAAATCAA 360 
Cry2Aa2         AGTGGTAGTACAAATCTAATGCAAGATATTTTAAGGGAGACAGAACAATTCCTAAATCAA 309 
                ************************************************************ 
 
Cry2Aa2-T7      AGACTTAATACAGATACCCTTGCTCGTGTAAATGCAGAATTGATAGGGCTCCAAGCGAAT 420 
Cry2Aa2         AGACTTAATACAGATACCCTTGCTCGTGTAAATGCAGAATTGATAGGGCTCCAAGCGAAT 369 
                ************************************************************ 
 
Cry2Aa2-T7      ATAAGGGAGTTTAATCAACAAGTAGATAATTTTTTAAACCCTACTCAAAACCCTGTTCCT 480 
Cry2Aa2         ATAAGGGAGTTTAATCAACAAGTAGATAATTTTTTAAACCCTACTCAAAACCCTGTTCCT 429 
                ************************************************************ 
 
Cry2Aa2-T7      TTATCAATAACTTCTTCGGTTAATACAATGCAGCAATTATTTCTAAATAGATTACCCCAG 540 
Cry2Aa2         TTATCAATAACTTCTTCGGTTAATACAATGCAGCAATTATTTCTAAATAGATTACCCCAG 489 
                ************************************************************ 
 
Cry2Aa2-T7      TTCCAGATACAAGGATACCAGTTGTTATTATTACCTTTATTTGCACAGGCAGCCAATATG 600 
Cry2Aa2         TTCCAGATACAAGGATACCAGTTGTTATTATTACCTTTATTTGCACAGGCAGCCAATATG 549 
                ************************************************************ 
 
Cry2Aa2-T7      CATCTTTCTTTTATTAGAGATGTTATTCTTAATGCAGATGAATGGGGTATTTCAGCAGCA 660 
Cry2Aa2         CATCTTTCTTTTATTAGAGATGTTATTCTTAATGCAGATGAATGGGGTATTTCAGCAGCA 609 
                ************************************************************ 
 
Cry2Aa2-T7      ACATTACGTACGTATCGAGATTACCTGAGAAATTATACAAGAGATTATTCTAATTATTGT 720 
Cry2Aa2         ACATTACGTACGTATCGAGATTACCTGAGAAATTATACAAGAGATTATTCTAATTATTGT 669 
                ************************************************************ 
 
Cry2Aa2-T7      ATAAATACGTATCAAACTGCGTTTAGAGGGTTAAACACCCGTTTACACGATATGTTAGAA 780 
Cry2Aa2         ATAAATACGTATCAAACTGCGTTTAGAGGGTTAAACACCCGTTTACACGATATGTTAGAA 729 
                ************************************************************ 
 
Cry2Aa2-T7      TTTAGAACATATATGTTTTTAAATGTATTTGAATATGTATCCATTTGGTCATTGTTTAAA 840 
Cry2Aa2         TTTAGAACATATATGTTTTTAAATGTATTTGAATATGTATCCATTTGGTCATTGTTTAAA 789 
                ************************************************************ 
 
Cry2Aa2-T7      TATCAGAGTCTTATGGTATCTTCTGGCGCTAATTTATATGCTAGCGGTAGTGGACCACAG 900 
Cry2Aa2         TATCAGAGTCTTATGGTATCTTCTGGCGCTAATTTATATGCTAGCGGTAGTGGACCACAG 849 
                ************************************************************ 
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3.2.2 Expression and harvesting of toxins. 
The Cry2A toxins in this research were expressed using E. coli BL 21 (DE3) pLysS cells 
containing the T7 RNA polymerase gene under the control of the lac UV5 promoter in 
its chromosomal DNA by induction with IPTG.  
The expressed toxin was grown, harvested (figure 3.2.6) and its concentration measured 
by running the toxin on a gel along with BSA standards as depicted in Figure 3.2.7(a,b,c,d 
and e) below, by densitometry method using Image J software. 
  
 
 
 
 
 
 
 
Figure 3.2.6 Protein SDS-Page gel showing Cry2A toxins bands. The arrow denotes the position of the Cry2A 
toxin bands.  
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The bands observe at the position of the Cry2A toxins clearly show that these toxins 
were expressed and the concentration was measured. 
 
 
 
 
a b 
c d 
e 
Figure 3.2.7(a, b, c, d and e): Protein SDS-Page gel showing the various Cry2A toxins run along with BSA 
standards. The arrows on the right of the gel denote the position of the Cry2A toxin bands while those on the 
left denote the position of the bands for the BSA Standards.  
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Plasmid Protein Concentration(µg
/ml) 
Predicted molecular 
weight 
(KDa) 
pGEM Cry2Aa2 600 70.85 
pEB Cry2Aa9 600 70.85 
pEB Cry2Aa17 700 70.64 
pEB Crym2Aa17 300 70.71 
pGEM Cry2Ab(4D6-4) 200 70.75 
pGEM Cry2Ab(916-2) 600 70.71 
pEB Cry2Ab4 600 70.73 
pEB Cry2Ab29 300 70.82 
pGEM Cry2Ac 100 69.75 
pGEM Cry2AcAa 300 70.55 
pGEM Cry2Ad 60 70.63 
pEB Cry 2Ah1 100 70.78 
pEB Cry 2Ax 800 70.81 
Table 3.2-1 Concentrations of the available Cry2A toxins used in this research as measured using Image J.  
 
Table 3.2-1 above showed the plasmid, name of protein, predicted molecular weight 
and the concentrations of the proteins as measured using densitometry. The results of 
the concentrations clearly showed that even though the same methods and procedures 
were used for the harvesting of the toxins, the amount of protein obtained from each 
toxin differed significantly, with Cry2Ax toxin giving the highest amount of Cry protein 
and Cry2Ad giving the least amount of Cry protein. 
The next thing I did after measuring the concentrations of these toxins was to calculate 
the amount of each toxin that could give the required concentration for bioassay 
experiment in each case.  
 
 
 
 
 
74 
 
 
 
3.2.3 Control experiment to see if E.coli protein contributes to the activity of Cry2A 
grown using E.coli expression system. 
Therefore, before we can start any proper bioassay for these toxins, as stated in the 
introductory section of this chapter there is need for an experiment, which could clearly 
show if E. coli proteins which may still remain in solution with our toxins, even after 
purification, is actually nontoxic to this insect. This is necessary to be established 
because all the Cry2A toxins to be used in this experiment will be expressed using E. coli 
expression system. Therefore, we used the cells from pGEM 4D6-5 and pGEM 916-5, 
which were cloned in E.coli DH5-α strain by a previous project student Evans (2014). 
Therefore, the cells were miniprepped and a pure DNA obtained from them, which were 
run on an agarose gel for confirmation as shown in Figure 3.2.8. These were then cloned 
in E.coli BL21 strain for expression of their proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The idea behind using either of these two toxins in this experiment was that since they 
have their respective genes in the opposite direction to the promoter region, as such, 
the E.coli expression system, which expresses only if the gene is in the same direction to 
the promoter, cannot express them. Therefore, when grown on a shaker we will have 
only the E.coli protein but no Cry toxin protein, which will enable us to test the effect of 
the E.coli protein alone on Aedes aegypti mosquito to be sure that it has no interference 
with the bioassay results. 
Figure 3.2.8 DNA agarose gel showing the Plasmid DNAs for Cry2Ab toxins (4D6-5 and 916-5) which are 
to be used for the control experiment. The two plasmid DNAs above were cloned in E.coli DH5-α. 
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The cells obtained from the E.coli BL21 strain cloning were then grown on a shaker and 
the protein harvested. The protein SDS- PAGE gel is shown in Figure 3.2.9 below. 
 
 
 
 
 
 
 
 
 
 
From the above protein gel for the two Cry2Ab toxins (4D6-5 and 916-5) all expressed in 
the reverse orientation, and Cry2Aa, which is toxic to Aedes aegypti used as a positive 
control. It is very apparent that there is no Cry2A protein expressed for the two Cry toxin 
genes in the reverse direction; therefore, any protein resulting from these two after they 
are grown will just be only E.coli protein. The band indicated by an arrow is from Cry2Aa 
protein, which is the only one expressed. The concentration of the three proteins 
Cry2Aa, Cry2Ab(4D6-5) and Cry2Ab (916-5) were each measured as shown in table 3.2-
2 below. 
Plasmid Protein Concentration(µg/ml) Predicted m.weight 
(KDa) 
pGEM Cry2Aa2 600 70.85 
pGEM Cry2Ab (4D6-5 SP6) 3700 NA 
pGEM Cry2Ab (916-5 SP6) 1500 NA 
Table 3.2-2 Concentration of the E.coli proteins. NA stands for not-available. 
 
The concentrations of all the three proteins Cry2Ab (4D6-5), Cry2Ab (916-5), and 
Cry2Aa2 were measured using the Bradford method described in the materials and 
methods section of this thesis to ensure fair comparison among the three proteins. This 
is because the Cry toxin genes from the two Cry2Ab proteins (4D6-5 and 916-5) were 
Figure 3.2.9.SDS-PAGE gel for the two proteins harvested along with Cry2Aa2 as a positive control for expression. 
The arrow on the left indicates the position of the protein marker while the one on the right indicate the position 
of the Cry2A toxin band. 
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not expressed so they cannot be measured using the image J method as they do not 
form visible bands on the agarose gel rather just crude protein resulting from the E. coli. 
The above proteins were bioassayed qualitatively by estimating 2 mg/l from individual 
protein and testing it against Aedes aegypti mosquito, the graph of the bioassay results 
is depicted Figure 3.2.10. 
 
Figure 3.2.10. Graph showing the effect of E.coli inclusion protein on Aedes aegypti. The results are shown for the 
two proteins resulting from Cry2Ab (916-5 and 4D6-5) respectively, Cry2Aa as a positive control and deionised water 
as negative control. Mortality is presented as mean percentage of three replicate bioassay. Cry2A toxins with 
mortality below 10% are considered nontoxic while those with mortality above 10% are considered toxic. The toxins 
were all expressed, grown and harvested together at the same time. Error bar represents Standard error of mean 
(SEM). 
 
From the above graph, it is obvious that the E.coli protein has no effect on the Aedes 
aegypti larvae. This is because all the three Cry toxins were cloned in E.coli BL21 strain 
for expression, though only Cry2Aa2 was expressed, and were all grown together at the 
same time, but it appears, from the results that the two Cry toxins that were not 
expressed (916-5 and 4D6-5), did not show activity against Aedes aegypti. They have 0% 
mortality rate, whereas the Cry toxin that was expressed (Cry2Aa2) and known to 
possess activity against Aedes aegypti showed activity with 70% mortality rate against 
Aedes aegypti based on our bioassay results. 
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3.2.4 Bioassay results for all available Cry2A toxins 
The bioassay experiment was carried out for all the available Cry2A toxins following the 
method of WHO (2005c) described under materials and methods. Two bioassay 
experiments were done; first of which was a qualitative bioassay to screen out those 
Cry2A toxins that are toxic from the nontoxic ones whereas the second bioassay was the 
quantitative bioassay experiment which was carried out on only those Cry2A toxins that 
showed toxicity to Aedes aegypti. The second bioassay was carried out so that their 
respective LC50 values could be determined. 
The qualitative bioassay was carried out using a discriminatory dose of 0.2mg/l of each 
of the Cry2A toxin harvested to be able to know those toxins that are toxic from those 
that are nontoxic to Aedes aegypti. These data are presented graphically as shown in 
Figure 3.2.11 below. 
 
 
 
 
 
 
 
 
 
 
From the above graph it is obvious that Cry2Aa2, Cry2Aa9, Cry2Ac, Cry2AcAa, and 
Cry2Ax all induced mortalities of more than 10% against Aedes aegypti larvae whereas 
Cry2A17, mCry2Aa17, Cry2Ab (916-2), Cry2Ab (4D6-4), Cry2Ab4, Cry2Ab29, Cry2Ad and 
Cry2Ah each with mortality rate below 5% are nontoxic. 
Therefore, the above results showed that despite the 87.4% to 99.7% sequence 
identities, which is a measure of the empirical relationship between two or more 
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Figure 3.2.11 Activity of Cry2A toxins against Aedes aegypti. Cry toxins with mortality below 10% are considered 
nontoxic while those with mortality above 10% are considered toxic. The percentage mortality values on the graph 
represent a pool value for three replicates per toxin, and then presented as a mean of three-repeated experiments, 
each with a new batch of the same Cry2A toxins. Error bars represent standard error of mean (SEM). 
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sequences with a common objective of establishing the likelihood for sequence 
homology; the chance that sequences have evolved from a common ancestor, among 
the Cry2A toxins (Table 3.2-4). They still seem to differ in their spectrum of activities and 
hence specificities (Liang and Dean, 1994). None of the Cry2Ab toxins appear to show 
activity against Aedes aegypti larvae whereas the other toxins except for Cry2Aa17 and 
mCry2Aa17 whose domain 1 resembled those of Cry2Ab (Shu et al., 2017), showed 
activity against Aedes aegypti mosquitoes.  
The next aspect of the study was to carry out a quantitative bioassay for those Cry2A 
toxins, which were found to be toxic against Aedes aegypti namely: Cry2Aa2, Cry2Aa9, 
Cry2Ac, Cry2AcAa, and Cry2Ax respectively and use the results to determine their LC30 
values. The quantitative bioassay was done using a range of concentrations for each 
Cry2A toxins from 0.0125 mg/l to 0.2 mg/l. The result for the qualitative bioassay is 
shown in Figure 3.2.12 below. 
 
The graph above for the quantitative bioassay showed that among the Cry2A toxins that 
are toxic against Aedes aegypti mosquito, Cry2Ac showed the highest degree of toxicity 
(44%) at a concentration of 0.2 mg/l whereas Cry2Aa2 toxin, at this instance, showed 
the least degree of toxicity (15%) at the same concentration. The results indicated that 
0
5
10
15
20
25
30
35
40
45
50
0.
2
0.
1
0.
05
0.
02
5
0.
01
25 0 0.
2
0.
1
0.
05
0.
02
5
0.
01
25 0 0.
2
0.
1
0.
05
0.
02
5
0.
01
25 0 0.
2
0.
1
0.
05
0.
02
5
0.
01
25 0 0.
2
0.
1
0.
05
0.
02
5
0.
01
25 0
Cry2Ac Cry2AcAa Cry2Aa9 Cry2Ax Cry2Aa2
M
or
ta
lit
y a
t 7
2 
ho
ur
s (
%
)
Concentration (mg/l)
Dose-response relationship of active Cry2A toxins against Aedes 
aegypti mosquito larvae
Figure 3.2.12 Graph showing the dose-response relationship of Aedes aegypti larvae to all Cry2A toxins toxic 
against Aedes aegypti mosquito larvae at various concentrations of the toxins. The mortality rate on the y-axis is 
presented as percentage of the death larvae to those of the total number of larvae whereas the x-axis contained 
the various Cry2A toxins at varying concentrations. Error bars represent standard error of mean (SEM). 
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though all the toxins in (Figure 3.2.12) are toxic against Aedes aegypti some appeared 
to exert more activity than others as could be seen by the differences in the percentage 
mortality recorded even though the same concentration ranges of toxin were used. The 
values for the concentrations and percentage mortalities were used to calculate the 
LC30 as the LC50 of the toxins, which is used in calculating the diagnostic concentration 
of the toxins for effective formulation of an active biopesticides against Aedes aegypti 
mosquitoes and other insects, is not realisable using the current bioassay data. 
The LC30 values were calculated using Probit in analysis of variance by the SPSS software 
and is presented in the Table 3.2-3. 
Plasmid Toxin LC30 (mg/l) 95% Confidence 
limits (mg/l) 
pGEM Cry2Aa2 0.60 (0.30-4.00) 
pEB Cry2Aa9 0.20 (0.10-0.40) 
pGEM Cry 2Ac 0.10 (0.10-0.20) 
pGEM Cry2AcAa 0.10 (0.10-0.20) 
pEB Cry 2Ax 0.30 (0.20-0.80) 
Table 3.2-3 LC30 values of Cry2A toxins toxic against Aedes aegypti 
 
The table above represents the LC30 values of the Cry2A toxins that are toxic against 
Aedes aegypti mosquito larvae. The LC50 normally represents the value for 
concentration of the toxin that killed 50% of the mosquito larvae. Here, we obtained the 
LC30 values by extrapolation because the LC50 values could not be obtained from our 
current data due to not enough toxin being used in the assays. Therefore, the current 
data could be use only qualitatively as they are vague and not very reliable 
quantitatively. 
For better understanding of the relationship between toxicity and sequence identity 
amongst Cry2A toxins, I carried out a pairwise sequence alignment amongst all the 
Cry2A toxins using Clustal omega and presented the result as percentage identity. This 
will help us decipher if overall percentage sequence identity among Cry2A toxins infers 
how close their toxicity spectrum can be. This is presented in Table 3.2-4 below. 
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The results of the pairwise sequence identity above clearly showed that toxicity in Cry2A 
toxins is not dependent on the overall sequence identity signifying there may be some 
residues amongst the Cry2A toxins that may determine their specificity to Aedes aegypti 
but not the overall percentage sequence identity. For example, Cry2Aa2 has 98.4 
percentage sequence similarity to mCry2Aa17 (Table 3.2-4) but the latter being nontoxic 
while the former is toxic against Aedes aegypti. In the same vein, Cry2Aa2 and Cry2Ac 
have only 89.3 percentage sequence identity but all of them appear to be active against 
Aedes aegypti larvae further buttressing this point. 
3.3 Discussion 
This study seeks to understand the basis for the mosquitocidal specificity of Cry2A group 
of toxins against Aedes aegypti. The sequences of some of the  available Cry2A toxins 
used in this study which were not initially confirmed were done so by sequencing the 
gene and comparing the results of the gene sequencing obtained to those of the 
sequences of known Cry2A toxins from the Bt nomenclature database (Crickmore et al., 
1998). In addition, clustal Omega was used to determine the degree of sequence identity 
among the Cry2A toxins (Table 3.2-4). For those toxins whose sequence were not 
available in the database the sequence from the sequencing results were pieced 
together using a closely related Cry2A toxins as a template to take care of overlapping 
regions (Figure 3.2.1 and 3.2.2). These were used to determine the gene of these two 
Cry2Ab toxins (Cry4D6-5 and 916-5) in Figure 3.2.3 and 3.2.4 respectively. 
Table 3.2-4 Percentage sequence identities amongst Cry2A toxins. 
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Therefore, to further, confirm the identity of these toxins, they were grown, the 
respective proteins harvested, and the protein SDS-PAGE was ran comparing their 
molecular weights to those of standard protein marker and were checked using the 
predicted values obtained from Expasy (Table 3.2-1). 
The concentration of a toxin should be accounted for to carry out a standard bioassay 
procedure that enables proper comparison amongst different groups of toxins. 
Therefore, unlike previous research data published that use Bradford method, which 
measures all the crude proteins, in quantifying the protein (Wu et al., 1991, Wu and 
Aronson, 1992, Liang and Dean, 1994), we decided to use a different densitometry 
method (Image J) that measures the concentration of only the toxin band and leaving 
behind all other proteins. This, we believe will improve the quality of bioassay results 
(Figure 3.2.7 a to e). 
The control experiment which histogram was presented in Figure 3.2.10 clearly showed 
that there was no activity in Cry2Ab (both 916-5 and the 4D6-5) which contained only 
the E.coli proteins but no toxins because the Cry toxin genes were not expressed. This, 
therefore, means that proteins that may arise from the E.coli cannot interfere with our 
bioassay results. Several researchers have used E.coli expression systems to express 
their Cry toxin genes, but they did not report any case of toxicity arising from E. coli 
protein (Mandal et al., 2007, Audtho et al., 1999, Pang et al., 1992, Xu et al., 2016, Wu 
et al., 1991).Hence this experiment has explained why there are no such reports. The 
Cry2Aa toxin, which was used as positive control showed toxicity against Aedes aegypti. 
Different researchers have already shown this toxin to possess activity against Aedes 
aegypti (Widner and Whiteley, 1990, Liang and Dean, 1994, Morse et al., 2001, Shu et 
al., 2017). 
The bioassay results for all the available Cry2A toxins shown in table 3.2.11 indicated 
that some of the Cry2A toxins are toxic against Aedes aegypti while others are nontoxic 
despite having close percentage sequence identity to each other, as this does not 
determine the nature of their activity and /or specificity against Aedes aegypti. For 
example, Cry2Aa2 has 98.4 percent sequence identity to mCry2Aa17 (Table 3.2-4) but 
the latter appeared to be nontoxic while the former is toxic against Aedes aegypti. In 
contrast, Cry2Aa2 and Cry2Ac have only 89.3-percentage sequence identity, which is 
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slightly higher compare to the first example, but these two Cry toxins appear to be toxic 
against Aedes aegypti larvae. This therefore, clearly showed that though there is 87.4 to 
99.7% sequence identity amongst Cry2A toxins (Table 3.2-4), their toxicity is not 
dependent on the overall sequence identity. This signifies that, there may be some few 
residues amongst the Cry2A toxins that might determine their specificity to Aedes 
aegypti but not the overall percentage sequence identity, which makes Cry2A toxins an 
interesting group of Cry proteins. Interestingly, almost all the Cry2Aa toxins appeared to 
be toxic against Aedes aegypti mosquitoes while all the Cry2Ab toxins appear not to be 
toxic against this species of mosquitoes, a result that agreed with previous findings 
where these two toxins were compared (Widner and Whiteley, 1990, Liang and Dean, 
1994). Among the Cry2Aa toxins, it was only Cry2Aa17 and mCry2Aa17, whose domain 
1 resemble that of Cry2Ab that appear not to be toxic against Aedes aegypti. This is not 
surprising because the toxicity spectrum of Cry2Aa17 against three order of insects was 
reported to be like those of Cry2Ab toxins thus implicating domain 1 as a specificity-
determining region (Shu et al., 2017). 
The bioassay results for the five Cry2A toxins that are toxic against Aedes aegypti 
mosquitoes shown in (Figure 3.2.12), indicated the fact that though all of them have 
activity against this species of insects, some appear to exert more toxic effects than 
others did. This is apparent in the different values recorded for percentage mortality, 
which showed Cry2Ac, having the highest mortality rate (44%) and Cry2Aa2 having the 
least (15%) at this instance. These results, clearly, buttressed the fact that even among 
Cry toxins that are specific against an order of insect there are still differences in their 
level of specificities. This fact, which has already been stressed by a previous researcher 
(Liang and Dean, 1994), who stated that despite the high sequence identities among the 
Cry2A group of toxins (Table 3.2-4), they seem to differ in their spectrum of activities 
and hence toxicity, with some being more active than others while some were not active 
at all.  
Final bioassay results; are preferably presented as LC50 values but is presented as LC30 
in (Table 3.2-3). This is because the current bioassay data we have cannot give us up to 
the LC50 values, and remain within a good range of confidence limit. For instance, the 
95% confidence limits for some of the Cry toxins (Cry2Aa2 and Cry2Ah1) are wide and 
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so making the data for those toxins not very reliable (Table 3.2-3), hence the need for 
us to present these values as LC30.   
From available literatures, there are many differences in the LC50 values obtained for a 
given toxin even when tested on a given order of insects. For instance, different results 
for LC50 values were obtained for Cry2Aa toxin, which is toxic against Aedes aegypti, by 
different researchers (Widner and Whiteley, 1990, Liang and Dean, 1994, McNeil and 
Dean, 2011) but surprisingly Liang et al. (2011) reported this same Cry2Aa toxin to be 
nontoxic against Aedes aegypti. Similarly, Cry2Ac was reported by Wu et al. (1991) to be 
nontoxic against Aedes aegypti at an LC50 value greater than 50 µg/ml but, contrarily, 
the same Cry2Ac was reported to be toxic against Aedes aegypti with an LC50 value of 
70 ng/ml by Liang and Dean (1994). A result, which agrees with our current findings on 
Cry2Ac in terms of toxicity, even though we only obtained the LC30 value of 0.11 mg/l, 
instead of LC50, which would have made comparison of results much better.  
These variations in bioassay results, most especially in the case of Aedes aegypti 
mosquitoes could be attributed to the following factors. 
i. Differences in exposure periods, which affects the extent to which the larvae 
interact with toxin to bring about the desirable effects. 
ii. Difficulty in quantification; due to the fact that the toxin must be applied as 
crystals not as soluble proteins since mosquitoes are filter feeders and some 
of the toxins settled at the bottom of the water in the container and could 
not be accessible to the larvae(McNeil and Dean, 2011). 
iii. Age of the larvae; this is because sensitivity to Cry toxin decreases with 
decrease larval age, hence the need to use same instar stage of larvae for all 
bioassay in order to eliminate these discrepancies. 
iv. Volume of the water to larval number; which has a critical effect on larval 
stress and sensitivity to toxin (McNeil and Dean, 2011).  
These differences in results made comparison of bioassay results very difficult even 
within a given order of insect. This difficulty, can also arise due to complications on the 
bioassay methods used (McNeil and Dean, 2011), differences in the host of expression 
which affects toxicity (Lima, 2008), and lastly, the fact that intra species variation in toxin 
susceptibility may occur between test colonies obtained from different parts of the 
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world. A variation of 1-2 orders of magnitude has been observed, therefore, even insects 
from the same geographical region or colony may vary by 1 order of magnitude between 
cohorts or successive generations (van Frankenhuyzen, 2009). 
Therefore, to address the bioassay problems outlined above the method of WHO 
(2005c) described under Materials and Methods section of this report was adopted 
because it proffered solutions to most of the problems highlighted. This involves setting 
up a bioassay protocol involving the use of larvae at the same growth stage, same larvae 
to water ratio, same protocol for toxin preparation and the usage of the same unit of 
measurement for all bioassays. 
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4. Identification of the domain(s) and/ or amino acid motifs that 
encode toxin specificity to Aedes aegypti. 
4.1 Introduction 
This chapter seeks to use the results obtained from the bioassay of the available Cry2A 
toxins carried out previously, to find the domain/domains that is/are responsible for the 
activity of this group of toxins against Aedes aegypti. This was achieved by using the data 
obtained from the crystallographic studies of Cry2Aa by Morse et al. (2001),  and  by 
comparing the amino acid sequences of the Cry2A toxins through multiple sequence 
alignments using Clustal Omega software. These gave us information on the relative 
sequence identities of the three domains in all the Cry2A toxins, which enabled us to 
carry out domain analysis, and subsequently create some hybrids through making 
informed domain swaps. The creation of hybrids through informed domain swaps 
enabled us to determine which domain(s) is/are responsible for the activity of this group 
of toxins against Aedes aegypti.  The functional domain(s) discovered were used in 
determining the amino acid(s) of importance through mutagenesis of the conserved 
amino acids either within the group found to be active or inactive against this insect. 
Previous research had shown that comparisons of the amino acid sequences of Cry 
toxins and their structures have led to the identification of conserved regions, which are 
important in basic toxin function and insect specificities (Hofte and Whiteley, 1989). In 
addition, small sequence differences among Cry toxins can strongly affect specificity and 
therefore the role of sequence dissimilarities is important in specificity determination 
(Bravo et al., 2007, de Maagd et al., 2001). Therefore, our current research on Cry2A 
toxins have focused on identifying the region that defines Aedes specificity. Moreover, 
it has been established that one of the most common and well-studied means of altering 
the toxicity spectrum and hence improving insect susceptibility to Bt toxins is through 
hybrid creation. This is because some of the hybrids created have appeared to exert 
more toxic effects on insects, compared to the wild type when bioassay experiments 
were conducted (Hu et al., 2014, Liang and Dean, 1994, Mandal et al., 2007, Widner and 
Whiteley, 1990).  
Previous studies on Cry2A specificity region determination focused on identifying the 
regions that define dipteran and/or lepidopteran specificities through chimeric scanning 
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mutagenesis (Widner and Whiteley, 1990, Liang and Dean, 1994, Morse et al., 2001). 
They utilised the fact that Cry2Aa has both dipteran and lepidopteran activity whereas 
Cry2Ab is lepidopteran specific. Therefore, they created hybrids between these two 
toxins through random swapping then testing these hybrids for activity on these insect 
types (Liang and Dean, 1994, Widner and Whiteley, 1990). Therefore, with this approach 
all the authors cited were able to speculate on the amino acid regions that confer both 
dipteran and lepidopteran specificity in Cry2Aa, and lepidopteran specificity in Cry2Ab. 
We used a similar approach, after analysing the results of Cry2A toxins and knowing 
those that are toxic to Aedes and those that are not, we then created hybrid toxins 
through domain swaps between those that were toxic and those that were not.  
Recent research carried out to identify Cry2A toxin genes in a collection of 300 strains 
of Bt identified a novel toxin named Cry2Aa17 which showed sequence similarity to 
Cry2Ab in domain I, whilst domains II and III resembled Cry2Aa. When the toxicity profile 
of this novel toxin against Aedes aegypti was determined, it matched that of Cry2Ab 
more than Cry2Aa, thus implicating domain I as a toxicity determining region in Cry2A 
toxins (Shu et al., 2017).  
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4.2 Results 
4.2.1 Domain I implicated as the specificity-determining region of Cry2A toxins 
against Aedes aegypti. 
The results of the bioassay of the wild type Cry2A toxins depicted in Figure 3.2.11 was 
analysed. The domains of those Cry2A toxins that were toxic were compared to those 
that were non-toxic. This was achieved by carefully taking some representatives from 
the group of toxins that were toxic to Aedes (Cry2Aa, Cry2Aa9, Cry2Ac, Cry2AcAaAa, and 
Cry2Ax), and from those that were non-toxic (Cry2A17, mCry2Aa17, Cry2Ab (916-2), 
Cry2Ab (4D6-4), Cry2Ab4, Cry2Ab29, Cry2Ad and Cry2Ah) then examined the 
composition of their domains. We decided to use six representatives of Cry2A toxins for 
the domain analysis (Cry2Aa, Cry2Ac, Cry2AcAa, Cry2Aa17, Cry2Ab29, and Cry2Ab) 
respectively. This is because they represent all the possible domain combinations and 
activities required for comparison as Cry2Aa and Cry2Ac are active against Aedes 
aegypti, and Cry2AcAaAa was a hybrid between the two of them. In addition, Cry2Ab 
was nontoxic to Aedes aegypti and Cry2Ab29 and Cry2Aa17 are both natural hybrids 
containing both Cry2Ab and Cry2Aa in their domains and were non-active against Aedes 
aegypti. 
Cry2AcAaAa which was one of the most toxic ones based on our bioassay has the 
following domain composition; Domain I: (Cry2Ac), Domain II: (Cry2Aa) and Domain III: 
(Cry2Aa). 
Cry2Ab29, a native hybrid toxin that was non- toxic, has the following domain 
composition. Domain I: (Cry2Ab), Domain II (Cry2Ab), and Domain III (Cry2Aa).  
Cry2Aa17, which was also non-toxic has the following domain composition: Domain I 
(Cry2Ab), Domain II (Cry2Aa), and Domain III (Cry2Aa). 
 Also, from the bioassay results in Figure 3.2.11, the native Cry2Ac, which has all its three 
domains comprising Cry2Ac and native Cry2Aa2, which has all its three domains 
comprising Cry2Aa are all toxic against Aedes aegypti. These descriptions are presented 
diagrammatically in Figure 4.2.1 below: 
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From the analysis of the different domain compositions of the native Cry2A toxins and 
natural hybrids above, it is clear that all those that were toxic against Aedes aegypti 
mosquito, have their domains I from either Cry2Aa or Cry2Ac whose wild type are toxic 
against this insect. In contrast, all those that were nontoxic against this insect contain a 
Cry2Ab in domain I, whose wild type was nontoxic against Aedes aegypti. This, therefore, 
implicated domain I as a toxicity-determining region of Cry2A toxins against Aedes 
aegypti but this remained to be proven. With these findings, we therefore formulated a 
hypothesis that domain I influences the specificity of Cry2A toxins against Aedes aegypti 
mosquito. This implies that if we could swap the domain I of Cry2Ac or Cry2Aa2 into a 
native Cry2Ab toxin which was non-toxic, we could obtain a hybrid toxin that would be 
toxic against Aedes aegypti.  
We decided to start domain I hybrid creation by swapping the domain I of Cry2Ac and 
Cry2Aa into the Cry2Ab (4D6-4) and swap the domain I of Cry2Ab (4D6-4) into Cry2Ac 
and Cry2Aa following the plan designed in the diagram depicted in Figure 4.2.2 below.  
 
 
 
Figure 4.2.1.Domains matching of some representatives of Cry2A toxins that are toxic and some that are non-toxic 
against Aedes aegypti. The colours with letters represent each of the wild type Cry2A toxin and the hybrids; (red) 
stands for wild type Cry2Aa, b (green) stands for wild type Cry2Ab and c (blue) stands for wild type Cry2Ac. 
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Domain I was amplified using two primers named Cry2A domain I forward and Cry2A 
domain I reverse respectively as shown in Figure 4.2.2. The second part, which is 
pGEMCry2A without domain I contained the plasmid together with domain II and 
domain III but without domain I, and this portion was also amplified using two primers 
namely, Cry2ADIIF and pGEM reverse respectively as shown in Figure 4.2.2.  
Primer design for domain I swap among Cry2A toxins 
We checked Cry2A gene for possible restriction enzyme sites, which we could use for 
creating hybrids for the above design (Figure 4.2.2). Unfortunately, we could not get a 
clear restriction enzyme sites in Cry2A genes that could cut out the domain I region from 
the rest of the Cry2A gene. However, there was NcoI enzyme site upstream of the start 
codon of the Cry2A gene in both plasmids (pGEM and pEB) but additionally pEB plasmid 
Figure 4.2.2 Plasmid diagram showing the plan for Cry2A hybrids created through domain I swap. The part coloured 
blue denotes the domain I portion of the pGEM2A gene, whereas the part coloured yellow represents pGEM2A 
without domain I. 
Ligation 
pGEM2A domain I pGEM2A without domain I 
pGEM2A domain swap hybrid 
90 
 
 
 
also had NheI site upstream of the NcoI site. Moreover, both the two plasmids have NheI 
site at the boundary of domain II with domain III of the Cry2A gene as shown in Figure 
4.2.3, but we were concerned with excising domain I, hence these two restriction 
enzymes could not be used in this instance. 
 
 
Therefore, since we could not use the restriction enzyme sites for the amplification of 
domain I, we decided to design universal primers for the amplification of domain I of all 
the Cry2A toxins using Cry2Aa toxin sequence as a template. In addition, all necessary 
adjustments were made to make the sequences of other Cry2A toxins conform to those 
of Cry2Aa along the sequences that were used for the universal primer design. The area 
for the domain I forward primer designed for the Cry2A toxins is shown in Figure 4.2.4 
below. 
 
 
 
 
 
 
 
 
pGEMCry2A gene pEBCry2A gene 
Figure 4.2.3. Plasmid diagram showing the NcoI and NheI restriction enzyme sites in both pGEMCry2A gene on the 
left and pEBCry2A gene on the right respectively. Diagrams, which explained why these enzymes could not be used 
to amplify domain I of Cry2A gene in these plasmids. 
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The only difference spotted in the sequence alignment above is where T substitutes C in 
some of the Cry2A toxins. Therefore, this had to be resolved since it was around the 
3’end and as such, it can affect the binding of the primers to the template strand. This 
was resolved by making this primer degenerate. In this case, this primer was made 
degenerate through replacing this position by Y as it can now bind efficiently to either T 
or C in the nucleotide sequence of all the Cry2A toxins. Therefore, the final upper primer 
designed was as shown below. 
5’P -ATGAATAATGTATTGAATAAYGGAAG- 3’ 
 
The reverse primer for the amplification of domain I, and that of the forward primer for 
the amplification of pGEMCry2A without domain I were designed using the sequences 
in Figure 4.2.5 below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
M     N     V       L       N      N      G      R      N 
Cry2Ac        ATG AAT AAT GTA TTG AAT AAC GGA AGA--- 
Cry916-2      ATG AAT AAT GTA TTG AAT AGC GGA AGA--- 
Cry2Ab        ATG AAT AAT GTA TTG AAT AGC GGA AGA--- 
Cry2Ad        ATG AAT AAT GTA TTG AAT AGC GGA AGA--- 
Cry2Ab4       ATG AAT AGT GTA TTG AAT AGC GGA AGA--- 
Cry2Ah1       ATG AAT AAT GTA TTG AAT AGC GGA AGA--- 
Cry2Ab29      ATG AAT AGT GTA TTG AAT AGC GGA AGA--- 
Cry2Ax        ATG AAT AAT GCA TTG AAT AGT GGA AGA--- 
Cry2AcAa      ATG AAT AaT GTA TTG AAT AAC GGA AGA--- 
Cry2Aa17      ATG AAT AGT GTA TTG AAT AGC GGA AGA--- 
Cry2Aa9       ATG AAT AAT GTA TTG AAT AGT GGA AGA--- 
Cry2Aa2       ATG AAT AAT GTA TTG AAT AGT GGA AGA--- 
Figure 4.2.4 Sequence alignment for domain I forward universal primer designed. Areas shaded yellow represent 
those with sequence dissimilarities within this portion among the Cry2A toxin genes, ATG stands for the start codon. 
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The reverse primer for domain I amplification was as shown below. 
 
5’P- TTTAAATAACGACCAGATRGAKACATA- 3’ 
 
The areas replaced by R and K in the domain I reverse primer are areas where there 
were differences based on the sequence alignment, as such changing them to R and K 
enables the primer to bind to each of these nucleotides if found in any of the Cry2A toxin 
genes. The primers for domain I amplification were both phosphorylated at 5’ position 
to allow ligation to the pGEMCry2A and/or pEBCry2A plasmid without domain I, as 
depicted in Figure 4.2.2. 
The two vectors harbouring our Cry2A genes are pEB and pGEM, therefore we designed 
primers that can amplify both domain II and the rest of the plasmid in each case. The 
forward primer designed for amplification of pGEMCry2A without domain I or pEBCry2A 
without domain I of Cry2A toxins, which is taken from Figure 4.2.5 is shown below. 
5’- TATCAAAGCCTTCTAGTATCTTCYG-3’ 
  
The sequence represented by “Y” in the primer for pGEMCry2A without domain I or 
pEBCry2A without domain I above represent the area where there is sequence 
difference in some of the Cry2A toxins sequence, which coloured red in Figure 4.2.5. 
Figure 4.2.5 Sequence alignment for domain I reverse and domain II forward universal primer designed. The 
sequences coloured red represent those with sequence dissimilarities within these portions among the Cry2A toxin 
genes. The vertical line represents the boundary between domain I and domain II of Cry2A toxin sequences. 
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The reverse primer for pEBCry2A without domain I and/or pGEMCry2A without domain 
I amplification, which were designed upstream of domain I, at the beginning of the 
sequence from both plasmids respectively are shown below. 
Reverse primer for pEBCry2A without domain I amplification is shown below. 
 
5’ -CTCCCGGGATATCGCCATG- 3’ 
 
 
The reverse primer for pGEMCry2A without domain I amplification is shown below. 
 
5’ -ATAAAATTCCTCCTTAATCGAATTC -3’ 
 
         
5’Phosphate group was not added to the 5’ end in designing these primers in order to 
prevent self-ligation.  
The two components of the Cry2A domain I hybrid designed as depicted in Figure 4.2.2, 
were therefore ligated by the process of blunt end ligation using DNA ligase enzyme, 
since it is clear that restriction enzyme method could not be employed in this instance 
as demonstrated in Figure 4.2.3. The product of the ligation reaction is a hybrid 
containing domain I from one of the Cry2A toxin and domain II and III with the pGEM 
plasmid from the other Cry2A toxin. The ligation product, which is the hybrid, was 
transformed in to E.coli DH5-α strain, and the right colony selected and further 
transformed using E. coli BL21 (DE3) pLysS strain in order to express the protein as 
described in the material and methods section. 
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Hybrid toxins created among Cry2A toxins through domain I swap 
The domain I swap hybrids based on our hypothesis were created using two wild type 
Cry2A toxins (Cry2Aa and Cry2Ac) as representatives of the active Cry2A toxins against 
Aedes aegypti whereas Cry2Ab(4D6-4) was used as a representative of the nontoxic 
ones. Therefore, giving rise to three native Cry2A toxins used for the creation of four 
hybrids through domain I swap among Cry2A toxins as shown diagrammatically in Figure 
4.2.6. 
 
 
PCR amplification, purification, and ligation of the respective domains from different Cry2A toxins 
were swapped. 
The primers designed above were ordered from the MWG after making sure that they 
met the optimum conditions for PCR reaction. The primers were diluted 1:10 with 
deionised water to give a final concentration of 10 pmol/µl. PCR reaction was set up 
following the conditions outlined in the Materials and Methods chapter section in 
chapter two. 
The product obtained was run on a gel to see if the desired product has been amplified, 
after which 45 µl of the PCR product was mixed with 1 µl of DpnI enzyme and incubated 
Figure 4.2.6 Native Cry2A toxins and the domain I swap hybrids created from them. The colours represent each 
of the wild type Cry2A toxin and the hybrids: Red colour stands for wild type Cry2Aa, green colour stands for 
wild type Cry2Ab and blue colour stands for wild type Cry2Ac respectively. Each of the three rectangles in the 
figure that combined to form a Cry toxin represents a domain, I, II, and III moving from left to right. Each of the 
wild type toxins and the hybrids presented above was expressed, grown, and the protein harvested and tested 
against Aedes aegypti larvae. 
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for 1 hour to digest the parental/template strand. This was run on a DNA agarose gel 
following the procedure outlined in the materials and methods section in chapter two. 
  
The resulting gels (Figure 4.2.7) showed that all the desired domains for amplification 
were successfully amplified as can be seen by the presence and the positions of the 
respective DNA bands on the gel. 
The ligation reactions to obtain the four hybrids outlined in figure 4.2.7 were set up 
following the recommended ligation ratio of 1:3 to 1:5 of vector to insert in an 
approximate proportion based on the intensity of their respective bands on the gel. 
Figure 4.2.7: DNA Agarose gels showing the purified PCR amplification products for the various domains from 
Cry2A toxins. The arrows indicate the positions of the DNA 3Kb and 1Kb Markers.  
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The products of the ligation reaction were introduced in to E.coli DH5-α strains following 
the procedures described in the Materials and Methods in chapter two. 
The successfully transformed E.coli cells were identified by colonies from the L-agar 
plate, in that it was a blunt ligation, only the cells that contained the ampicillin resistant 
gene from the plasmid will grow on an ampicillin containing L. agar plate used in this 
transformation protocol. In addition, not all the colonies (transformants) contained the 
desired hybrid as others may pick only the plasmid, or the plasmid containing the 
domain in the wrong orientation, as such further screening was also performed to 
confirm the orientation of the domain. Colonies were selected, eight of which were then 
scraped up with a sterile toothpick and streaked on an ampicillin impregnated 
(100μg/ml) L-agar plate. 
Testing/confirming the transformants for domain orientation. 
Two approaches for testing and confirming the transformants for gene orientation 
described in the Materials and Methods section of this project were both employed at 
some points in this research work. The first approach involved the use of the plasmid 
DNA extracted from the colonies and then followed by enzyme digestion to confirm the 
colonies that contained the insert; this method was employed for the two of the hybrids, 
Cry2AcAbAb and Cry2AaAbAb. The second approach involved the use of colony PCR to 
confirm the presence of the insert (domain I in this case) then followed by HaeIII 
restriction enzyme digestion. This method was employed for the remaining two hybrids 
created namely Cry2AbAcAc and Cry2AbAaAa.The HaeIII digest fragments from the gel 
was compared to those generated by the NEB cutter to see if they were correct, if they 
were, then the next thing done was to confirm the orientation of the gene in those 
colonies selected. 
The plasmid DNA from the selected colony (ies) was tested for its orientation, since DNA 
can be ligated into the plasmid in two possible directions. 
The restriction digestion reaction was done using HaeIII as mentioned above, as this 
confirmed the presence of the insert, after which BsaAI restriction enzyme was 
employed to know the orientation of the insert because there was no HaeIII site in 
domain I. 
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HaeIII enzyme digest of Cry2A domain I swap hybrids appeared to give the same 
fragments for both the A and B orientations (Table 4.2-1 a), the only exception is 
pGEM2AbAaAa which produces a slightly different HaeIII digest fragments as shown in 
table 4.2-1b. As such, another enzyme must be employed in addition to HaeIII, to be 
able to confirm the orientation of the insert. For hybrids creation involving domain I 
swap among different Cry2A toxins, BsaAI enzyme appeared to solve this problem as it 
has a restriction site within the domain I with different restriction enzyme fragments for 
A and B orientations, which enabled us to confirm if the insert was in the right 
orientation. 
This was achieved by running the BsaAI digested DNA sample on a gel. The gel was 
scanned and the restriction fragments produced which appeared as bands on the gel 
(shown in Figure 4.2.8a to c), was compared to those predicted by NEB cutter for both 
A and B orientations (shown in Table 4.2-1a and b). This then enabled us to know which 
of the colonies had their respective inserts in the right orientation. 
The gels for the HaeIII restriction digest of domain I swap hybrids are displayed in Figure 
4.2.8 below. 
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Figure 4.2.8(a-c): DNA Agarose gels showing HaeIII digest fragments for the domain I swap hybrid toxins created. 
The arrows showed the positions of those bands on the marker, which enabled the detection of the positions and 
hence the length in kilo base of the unknown fragments on the gel; this applies to all the gels above. Asterisks 
indicate the colonies with correct HaeIII restriction fragments. 
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The restriction digest fragments in Figure 4.2.8 above were compared to those 
fragments generated by the NEB cutter, which is shown Table 4.2-1 below 
The above restriction digest fragments in Table 4.2-1a, was generated for all the Cry2A 
hybrid toxins that were created above using NEB cutter to confirm the right colony (ies) 
in that they all gave similar fragments to the one shown above. The only exception from 
all the other Cry2A hybrids created was pGEM2AbAaAa, which has a slightly different 
HaeIII restriction digest fragments as shown on the gel in Figure 4.2.8c, and the 
restriction fragments generated from the NEB cutter shown in Table 4.2-1b. 
The results obtained through comparing the bands from the HaeIII restriction enzyme 
digest (Figure 4.2.8 a to c), and the fragments generated from the NEB cutter predictions 
(Table 4.2-1 a and b), showed that colonies 5 and 7 for pGEM2AbAaAa in Figure 4.2.8a, 
colony 1 for pGEM2AcAbAb in Figure 4.2.8b, colonies 15 for pGEM2AbAaAa, and 
colonies 4 and 8 for pGEM2AcAbAb in Figure 4.2.8c, all contained the right HaeIII 
enzyme digest fragments. Asterisks indicate these colonies.  Nevertheless, we could not 
know if the inserts are in A or B orientation unless the colonies with the right fragments 
are digested with BsaAI enzyme. The DNA agarose gels for the BsaAI digest of the 
colonies selected from the HaeIII digest fragments in order to be screened for gene 
orientation are shown in Figure 4.2.9a to c. 
 
Table 4.2-1(a and b). HaeIII restriction enzyme digest fragments generated from NEB cutter prediction for 
PGEM 2AaAbAb and 2AbAaAa respectively. The fragments were generated using the DNA sequence of the 
constructs of the domain I hybrids created. 
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Figure 4.2.9(a-c). DNA agarose gels containing the BSaAI digest of the colonies selected from HaeIII digests. Colonies 
selected from HaeIII digest, which appeared to contain the insert, are digested with BsaAI enzyme to confirm the 
orientation of the inserts. All the colonies in the gels displayed in this figure contained the inserts in the right 
orientation with the exception of colony 8 from figure 4.2.9c whose insert is not in the right orientation. 
 
BsaAI restriction digest fragments were generated from the constructs of the above 
hybrids to check if they are the same as they appeared on the gel and if they are truly in 
the right orientations.  The BsaAI restriction digest fragments generated from the NEB 
cutter for both A and B orientations are shown in Table 4.2-2 below. 
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a. pGEM2AaAbAb (A) digested with BsaAI                  b. pGEM2AaAbAb (B) digested with BsaAI  
 
The colonies with the right restriction fragments when compared to the ones generated 
from the NEB cutter in the case of both HaeIII and BsaAI restriction fragments, they 
looked similar to the bands on the gel.  In addition, when all the hybrids created were 
checked using NEB cutter they gave very similar fragments to those in Table 4.2-2. 
Hence, the two tables above (Table 4.2-2a and b) are representative of the NEB cutter 
predictions for the entire Cry2A domain I swap hybrids created.  
Therefore, when the digestion fragments in (Figure 4.2.9a to c) were compared to the 
ones generated using NEB cutter, (Table 4.2-2 a and b).  It was discovered that they do 
not really match the sizes in Figure 4.2-2; this is because we used an old BsaAI enzyme 
thus resulting in partial digest. Therefore, we only considered 1103 and 599 bands 
during confirmation. With this, we confirmed that both colonies 5 and 7 for 
pGEM2AaAbAb from Figure 4.2.9a, C1 for pGEM2AcAbAb from 4.9b, colony 15 for 
pGEM2AaAbAb, and Colony 4 for pGEM2AbAcAc, from Figure 4.2.9c, have the BsaAI 
fragments that matched those predicted by the NEB cutter. Colony 8 for pGEM2AbAcAc 
from Figure 4.2.9c was in the wrong orientation. 
 The DNAs from the various colonies identified to be in the right orientation, were sent 
for sequencing. The sequences received from the sequencing results were compared to 
the sequence of the construct we created through sequence alignment using either 
BLASTN or CLUSTAL omega, after which the ones confirmed to be correct were 
introduced in to E. coli BL21 (DE3) pLysS strain for the expression of the hybrid protein. 
 
Table 4.2-2(a and b): BSaAI digest of PGEM 2AaAbAb fragments generated using NEB cutter predictions. The first 
one (a) is in the right(A) orientation whereas the second one (b) is when the gene is in the wrong(B) orientation, as 
can also be seen in colony 8 (C8) of the gel in figure 4.11c. For the B orientation, in order to generate the fragments 
from the NEB cutter, the reverse compliment of the DNA sequence of the construct was used. 
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Confirmation of sequencing results for domain I swap hybrids created. 
The sequence received from the sequencing results were confirmed by aligning them to 
the sequence of the wild type toxins whose domains were swapped together to form 
the hybrid. The idea was to check the alignment results along the boundary where they 
two wild type toxins were joined to form the hybrids. Before this boundary the wild type 
Cry toxin, whose domain I was used in the hybrid creation aligned with the hybrid 
sequence received from the sequencing results.  Whereas, after the boundary it will be 
the sequence from the other wild type Cry toxin, whose domains II and III was used to 
form the other parts of the hybrids that aligned perfectly with the hybrid sequence. This 
procedure for hybrid confirmation was used along with the other procedure, which 
involved aligning the sequence received from the sequencing results with the constructs 
generated from the hybrid sequence. These two procedures were employed due to the 
high level of sequence similarity among the Cry2A group of toxins in order to be able to 
make sure that hybrids have been successfully formed between the two wild-type Cry2A 
toxins in question. 
The various sequences for the confirmation of the domain I hybrids created are shown 
in Figure 4.2.10 below. 
 
Figure 4.2.10 Alignment results for the confirmation of the hybrid toxin PGEM2AaAbAb. The area shaded yellow 
indicate the sequences around the boundary where the two wild type Cry2A toxins forming the hybrid joined, the 
boundary between domain I of Cry2Aa and domain II and III of Cry2Ab is indicated by the vertical line. Sequences 
with red colour before the boundary indicates where there is difference between the hybrid sequence (Cry2aAbAb-
C7-T7) and Cry2Ab within domain I whereas sequences shaded red after the junction indicates sequence differences 
between Cry2Aa and the hybrid toxin (Cry2aAbAb-C7-T7). 
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From the above, it is apparent that there was successful hybrid formation between the 
two wild type Cry toxins (Cry2Aa comprising domain I and Cry2Ab comprising domain II 
and III of the hybrid toxin). This showed that the hybrid PGEM2AaAbAb was successfully 
formed by swapping the domain I of Cry2Aa to that of Cry2Ab. 
The next hybrid formed is PGEM2AbAaAa, and the sequence alignment for its 
confirmation is shown in Figure 4.2.11 below. 
 
 
 
 
 
 
 
 
 
Figure 4.2.11 Alignment results for the confirmation of the hybrid toxin PGEM2AbAaAa. The area shaded yellow 
shows the sequences around the boundary where the two wild type Cry2A toxins forming the hybrid joined, the 
boundary is indicated by the vertical line. Sequence with red colour before the boundary indicates where there is 
difference between the hybrid toxin sequence (Cry2AbAaAa-C15) and Cry2Aa within domain I, whereas sequences 
shaded red after the junction indicates sequence differences between Cry2Ab and the hybrid toxin (Cry2AbAaAa-
C15). 
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From the above, it is apparent that there was successful hybrid formation between the 
two wild-type Cry2A toxins (Cry2Ab comprising the domain I and Cry2Aa comprising the 
domain II and III of the hybrid toxin). This showed the hybrid PGEM2AbAaAa was 
successfully formed by swapping the domain I of Cry2Ab to that of Cry2Aa. 
The third domain I swap hybrid formed was PGEM2AcAbAb, and the sequence 
alignment for its confirmation is shown in Figure 4.2.12 below. 
 
 
 
 
 
 
 
 
 
Figure 4.2.12 Alignment results for the confirmation of the hybrid toxin PGEM2AcAbAb. The area shaded yellow 
indicates sequences around the boundary where the two wild type Cry2A toxins forming the hybrid joined, the 
junction is indicated by the vertical line. Sequence with red colour before the junction indicates where there is 
difference between the hybrid (Cry2AcAbAb-C1) sequence and Cry2Ab within domain I (DI), whereas sequences 
shaded red after the junction indicate sequence differences between Cry2Ac and the hybrid toxin (Cry2AcAbAb-C1) 
starting from domain II (DII). 
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The last domain I swap hybrid formed was pGEM 2AbAcAc, which has Cry2Ab comprising 
its domain I and Cry2Ac comprising its domain II and III. The sequence alignment for its 
confirmation is shown in Figure 4.2.13. 
 
Expression and harvesting of hybrid Cry2A toxin proteins from domain I swap. 
The colonies from the hybrids that were confirmed to harbour the gene of interest in 
the right orientation were further introduced in to E. coli BL21 (DE3) pLysS strain 
following the protocol outlined in materials and methods. After the transformation, 
colonies from the E. coli BL21 (DE3) pLysS cells harbouring each plasmid were expressed 
and subsequently harvested, following the procedure described in the materials and 
methods in chapter two. They were run on an SDS-PAGE gel (7.5%), to confirm if they 
were successfully expressed, or not. The gel showing the Cry2A hybrid toxins is depicted 
in Figure 4.2.14. 
 
 
Figure 4.2.13 Alignment results for the confirmation of the hybrid toxin PGEM2AbAcAc. The area shaded yellow 
showed the sequences around the boundary where the two wild type Cry2A toxins forming the hybrid joined, the 
junction is indicated by the vertical line. Sequence with red colour before the junction indicates where there is 
difference between the hybrid (Cry2AbAcAc-C4-T7) sequence and Cry2Ac within domain I, whereas sequences with 
red colour after the junction indicates sequence differences between Cry2Ab and the hybrid(Cry2AbAcAc-C4-T7) 
toxin starting from domain II. 
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The toxins, were successfully expressed as shown on the gel in Figure 4.2.14 above, they 
were then run along with BSA standards on a gel and their concentrations was measured 
using Image J. The gel used to measure the concentration of the Cry toxins is shown in 
Figure 4.2.15 below. 
  
Figure 4.2.14 Protein SDS-PAGE gel showing domain I swap hybrid Cry2A toxin proteins expressed. The arrow 
pointing towards the right showed the molecular weight protein marker used to estimate the weight of the Cry 
toxins, while the one pointing towards the left shows the position of the hybrid toxin bands on the gel. 
 
Figure 4.2.15 Gel to measure the concentration of the hybrid proteins. Densitometry method using Image J was 
used to measure the concentration of each of the Cry toxins represented by the bands above and those of the BSA. 
Since the concentrations of the BSA standards are known already, they were used to determine the concentrations 
of the various hybrid Cry2A toxins using excel. 
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The concentrations of the above hybrid toxins as measured using image J software is 
shown in Table 4.2-3.  
 
 
 
 
 
 
Qualitative bioassay was carried out for the above hybrids at a concentration of 2mg/l 
to be able to find out which ones among them were active against Aedes aegypti. The 
results of the bioassay are shown in Figure 4.2.16 below. 
 
Figure 4.2.16 Activity of Cry2A domain I hybrid toxins against Aedes aegypti mosquitoes. The percentage mortality 
values on the graph represent a pool value for three replicates per toxin, and then presented as a mean of three-
repeated experiments, each with a new batch toxins. The wild type Cry2Aa and Cry2Ac were used as positive 
controls, whereas Cry2Ab and deionised water were used as the negative controls for the experiment. Error bars 
represent Standard error of mean (SEM). 
 
The results of the bioassay in Figure 4.2.16 clearly showed that domain I of Cry2A toxins 
might be responsible for their specificity and hence toxicity to Aedes aegypti. This is 
because all the hybrids toxins created from domain swaps involving domain I of toxic 
Cry2A proteins (Cry2Ac and Cry2Aa), with domain II and III from the non-toxic Cry2A 
protein Cry2Ab (4D6-4), namely Cry2AcAbAb and Cry2Aa2AbAb, showed toxicity against 
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Table 4.2-3 Concentrations of the Cry2A domain I swap hybrid toxins created as measured using Image J. 
The hybrids toxins were all expressed, and their relative molecular weight predicted using a program in 
Expasy. 
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Aedes aegypti mosquito larvae. Whereas those hybrids created by domain swaps 
involving domain I from a non-toxic Cry2A toxin Cry2Ab (4D6-4) with domain II and III 
from a toxic Cry2A toxins (Cry2Ac and Cry2Aa), namely Cry2AbAcAc and Cry2AbAaAa to 
showed no activity against this insect. Cry2Aa toxin appears to have higher mortality in 
the present bioassay compared to Cry2Ac and Cry2Aa that was earlier  shown in Figure 
3.2.11, this could be as a result of problems which may arise from the bioassay 
procedure that have been discussed earlier in chapter 3. These results upheld our earlier 
hypothesis that domain I of Cry2A group of toxins might be responsible for their 
specificity. 
4.2.2 N-terminal region of Cry2A family of toxins as a determinant of specificity in 
Aedes aegypti. 
Previous reports implicated domain II as responsible for specificity among Cry2A toxins 
(Liang and Dean, 1994, Morse et al., 2001, Widner and Whiteley, 1990). Therefore, we 
thought that there might be a link between these two domains, which could be 
responsible for specificity. We proposed a hypothesis that since the N-terminal folds 
back from domain I onto domain II as shown in the structure elucidated by Morse et al. 
(2001), depicted in Figure 1.9.6. It may, therefore, be the N-terminal loop folding back 
onto domain II that maybe responsible for the specificity determinant role previously 
apportioned to domain II by previous researchers (Liang and Dean, 1994, Morse et al., 
2001, Widner and Whiteley, 1990). Our hypothesis was that it is this N-terminal region 
comprising the first 49 amino acids, depicted in Figure 4.2.17, that folds back and 
becomes a functional part of domain II and thus influencing toxin binding and specificity. 
 
 
 
 
 
 
 
109 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on this hypothesis, we then decided to create the hybrids represented in Figure 
4.2.18 below, this time swapping the N-terminal sequence of toxic Cry2A toxins (Cry2Ac 
and 2Aa) in to that of a representative of a nontoxic Cry2A toxin (Cry2Ab) and vice versa. 
This was to see the effect of the N-terminal 49 amino acids on the specificity/ toxicity of 
the Cry2A toxins. 
  
 
  
 
 
 
Figure 4.2.17 Cry2Aa binding epitope formed by the N-Terminus loop (shaded yellow) which folds back onto the 
second domain influencing binding. 
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The amino acids as well as the nucleotide sequence showing the boundary between the 
N-terminus and the remaining portion of the Cry2Aa toxin is depicted in Figure 4.2.19 
below. 
 
The N-terminal swap in the case of Cry2Ab to toxic Cry2A toxins i.e. Cry2Aa or Cry2Ac 
was done only for Cry2Ab N-terminus swapped into Cry2Ac domain as we presumed 
that it can provide the same information required even for hybrid that might be created 
using Cry2Ab N-terminus swapped into Cry2Aa. 
Figure 4.2.18 N-terminal domain swaps hybrid created from Cry2A toxins. The colours represent each of the wild 
type Cry2A toxin and the hybrids; Red stands for wild type Cry2Aa, green stands for wild type Cry2Ab and blue 
stands for wild type Cry2Ac respectively. 
Figure 4.2.19 Amino acids with their nucleotide sequence showing the boundary between the N-terminus and the 
remaining part of Cry2Aa toxin. The vertical line represents the junction between the two, while the sequence 
shaded yellow were those used for the design the Cry2AaNT reverse primer. ATG (M) at the beginning of the 
sequence represents the start codon. 
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To create the hybrids outlined in Figure 4.2.18, primers were designed for amplifying 
the N-terminus region and the pGEMCry2A without the N-terminus region for all the 
Cry2A toxins, which were used to create these hybrids. The general plan followed for 
the creation of the N-terminal swap hybrids is shown in Figure 4.2.20 below.  
 
 
 
 
 
 
 
 
 
 
 
 
From the above diagram showing the plan for hybrids creation involving N-terminus 
swapping, the N-terminus region of the Cry2A toxin was amplified using two primers 
named Cry2ANT-F and Cry2ANT-R respectively as shown in Figure 4.2.20. The second 
part, which is pGEMCry2A without the N-terminal region contained the plasmid 
together with all the domains but lacking the N-terminal region and this portion was 
amplified using two primers namely, Cry2A W/O NT-F and Cry2A W/O NT-R respectively 
as shown in Figure 4.2.20 above. These two portions were ligated using DNA ligase 
Figure 4.2.20 Plasmid diagram showing the plan for pGEM2A hybrids created through N-terminus region swap. The 
part coloured blue denotes the N-terminus region of the pGEM2A gene, whereas the part coloured yellow 
represents the pGEM2A gene without the N-terminus region. The combination of the two regions through ligation 
gave rise to the pGEM2A N-terminus swap hybrid represented above. 
 
Ligation 
pGEM2A N-terminus pGEM2A without N-terminus 
pGEM2A N-terminus swap hybrid 
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enzyme, the product of which is a hybrid containing an N-terminal region from one of 
the Cry2A toxin and the remaining portion including the pGEM plasmid from the other 
Cry2A toxin. The ligation product was introduced in to E.coli DH5-α strain, and the right 
colony was selected. This was transformed using E.coli BL21 strain for the expression of 
the protein as described in the Material and Methods section. The various primers 
designed are shown in Table 4.2-4 below.  
 
 
 
 
 
 
 
 
 
 
Table 4.2-4 Primers used for the amplification of the fragments used for N-terminus swap hybrids of Cry2A toxins. 
Those primers indicated by ‘Yes’ on the column for share, are those primers that were used for all Cry2A toxins used 
in the creation of the hybrids. 
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The PCR amplification products of the various fragments, which were used for creating 
the N-Terminal swaps hybrids, are shown in Figure 4.2.21(a-b) below. 
 
Figure 4.2.21(a-b). PCR products for the components of Cry2A N-terminal swap hybrids created. The arrows pointing 
towards the right indicate the positions of the DNA Markers, which were used to understand if the amplified PCR 
products resolved on the gel, were of the required base pairs.   
 
The ligation reaction for the creation of the Cry2A N-terminal swap hybrids was set up 
by ligating 2AcNT+2Ab plasmid, 2AbNT+2Ac plasmid and 2AaNT+2Ab plasmid following 
the procedure for Blunt TA master mixed ligation described in the materials and 
methods section. Then the ligation products were introduced in to NEB-5α competent 
E. coli cells as outlined in the materials and methods. HaeIII enzyme restriction digests 
was used to confirm successful transformants. The HaeIII restriction enzyme digest for 
the three Cry2A N-terminal swap hybrids mentioned above are shown in Figure 4.2.22 
below. 
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From the gels depicted in Figure 4.2.22, colony 4 and 6 for 2AaNT+2Ab, colony 4 for 
2AcNT+2Ab, colony 6 and 7 for 2AbNT+2Ac, were picked and sent for sequencing.  This 
was because the N-terminal sequence of Cry2A toxins, unlike domain I, did not contain 
any restriction site that could be used to confirm the orientation of the inserts. 
Therefore, this confirmation was done using the DNA sequencing results received after 
HaeIII digest by aligning them to the sequence of the construct generated from the 
hybrids created.  
Confirmation of sequencing results for the N-terminal swap hybrids created. 
The sequencing results for the N-terminal swap hybrids created were confirmed 
following the same procedure done for the domain I swap hybrids. The sequences for 
the hybrid toxins received from the DNA sequencing results was aligned with the DNA 
sequences of the two wild type toxins, in which the N-terminal sequence of one was 
joined with the sequence of the other toxin excluding its N-terminal sequence portion, 
Figure 4.2.22 (a-b).  HaeIII digest for the colonies obtained from N-terminal swaps hybrids of Cry2A toxins. The 
arrows showed the positions of those bands on the marker to enable the detection of the positions, and hence the 
length in kilo base of the unknown fragments on the gel; this applies to the two gels above. Asterisks indicate 
colonies with the correct HaeIII restriction fragments. 
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through swapping. The various hybrids created and confirmed through alignment using 
Clustal Omega are shown in Figure 4.2.23 below. 
The sequence alignment for the confirmation of the N-terminal swap hybrid, 
Cry2AaNT/AbAb formed by swapping the N-terminal sequence of Cry2Aa to the 
sequence of the rest of Cry2Ab without the N-terminal sequence portion is shown in 
Figure 4.2.23 below. 
 
The sequence confirmation for Cry2AcNT/AbAb formed by swapping the N-terminal 
sequence of Cry2Ac to the sequence of the rest of Cry2Ab without the N-terminal 
sequence portion is shown in Figure 4.2.24 below. 
 
 
 
 
 
 
Figure 4.2.23 Alignment results for the confirmation of the hybrid toxin PGEM2AaNT/AbAb. The area shaded 
yellow is the boundary where the two wild type Cry2A toxins forming the hybrid joined. The vertical line indicates 
the junction between them. Sequence with red colour before the boundary indicates where there is difference 
between the hybrid sequence and Cry2Ab within the N-terminal sequence whereas sequences shaded red after the 
junction indicates sequence differences between Cry2Aa and the hybrid toxin starting from the end of the N-
terminal sequence. NT stands for N-terminal sequence. 
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The sequence alignment for the confirmation of the N-terminal swap hybrid, 
Cry2AbNT/AcAc formed by swapping the N-terminal sequence of Cry2Ab to the 
sequence of the rest of Cry2Ac without the N-terminal sequence portion is shown in 
Figure 4.2.25 below. 
 
 
 
 
 
 
 
Figure 4.2.24 Alignment results for the confirmation of the hybrid toxin PGEM2AcNT/AbAb. The area 
shaded yellow is the boundary where the two wild type Cry2A toxins forming the hybrid joined. The vertical 
line indicates the junction between them. Sequence with red colour before the junction indicates where 
there is difference between the hybrid sequence and Cry2Ab within the N-terminal sequence whereas 
sequences shaded red after the junction indicates sequence differences between Cry2Ac and the hybrid 
toxin starting from the end of the N-terminal sequence. NT stands for N-terminal sequence. 
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The N-terminal sequence of the hybrid 2AbNT+2Ac, obtained from the sequencing 
results had aligned properly to Cry2Ab, which formed the N-terminal region for the 
hybrid as shown in the Figure 4.2.25 above. More also, the remaining sequence after 
the boundary aligned perfectly to Cry2Ac, which formed the other part of the two wild 
type Cry toxins that were ligated together to form the hybrid. This was found to be true 
from the alignment results in the entire N-terminal swap hybrids created, thus 
confirming that all the N-terminal swap hybrids were correct. 
The SDS-PAGE gel showing all the N-terminal swap hybrid proteins created, expressed, 
grown and harvested were run on as SDS-PAGE gel along with their domain I swap 
counterparts as shown in Figure 4.2.26. 
Figure 4.2.25: Alignment results for the confirmation of the hybrid toxin PGEM2AbNT/AcAc. The area shaded 
yellow is the boundary where the two wild type Cry2A toxins forming the hybrid joined. The vertical line indicates 
the junction between the two. Sequence with red colour before the boundary indicates where there is difference 
between the hybrid sequence and Cry2Ac within the N-terminal sequence whereas sequences shaded red after the 
junction indicates sequence differences between Cry2Ab and the hybrid toxin starting from the end of the N-
terminal sequence. NT stands for N-terminal sequence. 
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The N-terminal swap hybrid proteins that were expressed were run along with BSA 
standards and their concentration measured by densitometry using image J software. 
The gel is shown Figure 4.2.27 below. 
 
 
 
Figure 4.2.26 Protein SDS-PAGE gel showing the N-terminal swap hybrid Cry2A toxin proteins expressed. The 
arrow pointing towards the right showed the molecular weight protein marker used to estimate the weight of 
the Cry toxins, while the one pointing towards the left shows the position of the hybrid toxin bands on the gel. 
 
Figure 4.2.27 Gel used to measure the concentration of the N-terminal swap hybrid proteins. The arrow pointing 
towards the right showed the Bovine Serum Albumin (BSA) standard, while the one pointing towards the left shows 
the position of the hybrid toxin bands on the gel. 
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The table showing the concentration of the above hybrid toxins as measured from image 
J is shown in Table 4.2-5 below.  
 
 
 
 
 
A qualitative bioassay was performed using the above hybrid toxins, each at a 
concentration of 2mg/l following the procedures outlined by(WHO, 2005c). This was to 
know which among them was active against Aedes aegypti. The result of the bioassay is 
summarised in Figure 4.2.28 below. 
 
 
Figure 4.2.28 Activity of Cry2A N-terminal swap hybrid toxins against Aedes aegypti mosquito. Cry2A toxins with 
mortality below 10% are considered nontoxic while those with mortality above 10% are considered toxic. The 
percentage mortality values on the graph represent a pool value for three replicates per toxin, and then presented 
as a mean of three-repeated experiments, each with a new batch of the toxins. The wild type Cry2Aa and Cry2Ac 
were used as positive controls, whereas Cry2Ab and deionised water were used as the negative controls for the 
experiment. Error bars represent Standard error of mean (SEM).  
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Table 4.2-5 Concentrations of the Cry2A N-terminal swap hybrid toxins created as measured using Image J. The 
hybrids toxins were all expressed, and their relative molecular weight predicted using a program in Expasy. 
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From Figure 4.2.28, we could establish that the N-terminal sequence of Cry2A plays a 
role in their specificity against Aedes aegypti mosquito. This could be seen in that; 
Cry2Ab wild type toxin was not active against Aedes aegypti while the wild type Cry2Aa 
and Cry2Ac toxins were active against this insect. The swapping of the N-terminal 
sequence of Cry2Aa to Cry2Ab and that of Cry2Ac to Cry2Ab to form the hybrid toxins 
Cry2AaNT/AbAb and Cry2AcNT/AbAb respectively brought activity to the non-active 
Cry2Ab wild type toxin. Contrarily, the swapping of the N-terminal sequence of Cry2Ab 
to Cry2Ac to form the hybrid Cry2AbNT/AcAc abolished the activity seen in the active 
wild type Cry2Ac. These suggest that the basis for the activity/specificity of the Cry2A 
toxins resides in the N-terminal amino acid sequence. Hence, these findings supported 
our hypothesis that it is the N-terminal loop folding back onto domain II (Figure 4.2.20), 
which may be responsible for the specificity determinant role of this family of toxins 
against Aedes aegypti. 
 
4.2.3 Deletion of 45 amino acids from the N-terminus of Cry2A toxins abolished 
activity against Aedes aegypti. 
The previous results for the creation of hybrids through N-terminal swaps between the 
sequence of toxic Cry2A toxins (Cry2Ac and 2Aa) in to that of a representative of a 
nontoxic Cry2A toxin (Cry2Ab) and vice versa suggested that the N-terminal is 
responsible for the activity of Cry2A toxins against Aedes aegypti. Therefore, I decided 
to further confirm this by deleting the first 45 amino acids within the N-terminus of 
Cry2Aa2, to see if that will abolish the activity of Cry2A against Aedes aegypti. Two 
primers were designed for the creation of the truncated Cry2Aa toxin with 45- amino 
acid deleted from the N-terminus sequence, which we referred to as D45. Therefore, 
the forward primer starts from the 46th amino acid position whereas the reverse primer 
starts from the start codon ATG coding for methionine to allow the initiation of 
transcription after the deletion. The template strand used for this deletion mutant is 
Cry2Aa2 toxin. 
The primers designed are as follows: 
Forward primer 
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F- 5’P- CATAGTTTATATGTAGCTCCTGTAG-3’ (25) 
Reverse primer 
R-5’- CATATAAAATTCCTCCTTAATCG (23) 
The PCR conditions for the amplification of these products are as outlined in the 
material and methods section. 
The amplified product was run on a DNA agarose gel to see if it had been amplified 
successfully. The gel is as shown in Figure 4.2.59 below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The purified D-45 PCR product in Figure 4.2.29 above was ligated using T4 DNA ligase 
and introduced in to E.coli DH5-α competent cells following the procedure described in 
the materials and methods section of this thesis. Colonies obtained after transformation 
were picked using toothpick and streaked in an ampicillin plate and was placed in an 
incubator maintained at 370C and left to stay overnight. DNA miniprep was carried out 
using the cells harvested, and the purified DNA sample obtained from each of the 
Figure 4.2.29 Mutagenic PCR product for D-45 mutant from Cry2Aa N-terminus sequence. 
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mutants was digested using HaeIII restriction enzyme. The gel of which is displayed in 
Figure 4.2.30 below. 
 
 
 
 
 
 
 
 
 
 
 
The HaeIII restriction digest fragments for Cry2Aa-D45 mutant in Figure 4.2.30 above 
was compared to the fragments generated from the NEB-Cutter using the sequence of 
the construct designed from the mutant, depicted in Table 4.2-13 below. 
 
 
 
 
 
 
 
 
Figure 4.2.30 DNA Agarose gel of the HaeIII restriction digest of colonies selected from Cry2Aa-D45 mutant. 
Table 4.2-6 HaeIII restriction digest fragments of Cry2Aa-D45 mutant generated from NEB-Cutter. 
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Therefore, all the three colonies from Figure 4.2.30 above for Cry2Aa-D45 mutant 
appear to have same fragments to the one predicted from the NEB-cutter, hence all 
three colonies could contain the right transformant. Colony 1 and 2 were then sent for 
sequencing, and after the sequence from the sequencing results, were aligned with the 
two primers using CLUSTAL Omega they aligned perfectly well as shown in Figure 4.2.31  
below. Hence, all the two colonies contained the right mutation. 
 
Colony 1 from Cry2Aa-D45 mutant was expressed in E.coli BL21 strain and the protein 
grown and harvested. The proteins were run on an SDS-PAGE along with a BSA standard 
and their concentrations measured using densitometry. The protein gel used to measure 
the concentrations of these toxins is shown in Figure 4.2.32 below. 
 
 
 
 
 
 
 
 
 
Figure 4.2.31 Sequence alignment to confirm the creation of Cry2Aa-D45 mutant. Sequences shaded yellow showed 
the position of the forward primer and those shaded light green showed the position of the reverse primer. 
 
Figure 4.2.32 Protein SDS-Page gel for measuring the concentrations of Cry2Aa-D45 mutant. The arrow pointing 
towards right indicate the protein marker while the one pointing towards the left indicate the mutant Cry2A toxins. 
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A qualitative bioassay was performed for the mutant Cry2Aa-D45 in Figure 4.2.32 above 
using Cry2Aa as a positive control; each at a concentration of 2mg/l following the 
procedure outlined by WHO (2005c). Deionised water was used as a negative control. 
The graph is shown in Figure 4.2.33 below. 
 
 
Figure 4.2.33 Activity of mutant Cry2Aa-D45 toxin against Aedes aegypti. Cry2A toxins with mortality rate below 
10% are considered non-active while those with mortality rate above 10% are considered active. The percentage 
mortality values on the graph represent the mean value of three-repeated experiments. The wild type Cry2Aa was 
used as positive control, whereas deionised water was used as the negative control for the experiment. Error bars 
represent Standard error of mean (SEM).
 
From the results of bioassay depicted in the above graph (Figure 4.2.33), it was obvious 
that deletion of the first 45 amino acids from the N-terminus of Cry2Aa toxin abolished 
its activity against Aedes aegypti mosquito larvae. This is because the wild type Cry2Aa 
toxin from the bioassay was active against Aedes aegypti giving a percentage mortality 
of 65% whereas both the mutant Cry2Aa-D45 toxin and the control (deionised water) 
gave a percentage mortality of 5% each, less than the percentage mortality required 
(10%) to designate them as being active.   
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4.2.4 Finding the amino acid(s) residue responsible for specificity within the N-
terminus region of Cry2A toxins. 
Since we have established that the N-terminus region of Cry2A class of toxins is likely to 
be their specificity determinant region against Aedes aegypti. The next hurdle was to try 
to find the amino acid(s) residue, within the 49-amino acid N-terminal region, which 
is/are responsible for this activity among the Cry2A toxins. To achieve this, we aligned 
the 49 amino acids sequence comprising the N-terminus, for the toxic and nontoxic 
Cry2A toxins tested in this work, and at the same time of all the Cry2A available in the 
database using Clustal Omega. 
 MView v1.61 (Brown, 1998) was also used to render a multiple sequence alignment 
(MSA) of the N-termini of toxins used so far, alongside non-redundant N-terminus 
sequences of toxins, which we had in the lab and presented them in a colour format. A 
careful comparison between the sequences of the toxic ones and the non-toxic ones 
(Figure 4.2.34) was done to be able to see those amino acids that are conserved among 
the active ones and those conserved among the non-active ones. 
 
Figure 4.2.34 Graphical representation of a multiple sequence alignment of the N-termini of selected Cry2A toxins 
using MView (http://www.ebi.ac.uk/Tools/msa/mview/). Percentages indicate the amount of sequence identity 
of each 49-mer sequence relative to the first sequence (Cry2Aa). Amino acids are coloured by their properties first, 
while uncoloured amino acids indicate that a residue is not identical in that position to the residue in the first 
sequence. Arrows above the encapsulating black boxes highlight putative specificity-determining residues. Order 
represents toxicity profiles with sequences found to be toxic at the top (Cry2Aa, Cry2Ac, and Cry2Ax) and sequences 
of toxins found to be inactive against Aedes at the bottom (Cry2Aa17, Cry2Ab, Cry2Ad, and Cry2Ah) respectively. 
 
A pattern emerged from the Multiple Sequence Alignment (MSA) results in Figure 
4.2.34, which matched the toxicity profiles. Cry toxins found to be active against A. 
aegypti larvae (Cry2Aa, Cry2Ac and Cry2Ax), contained Glutamic acid (E) 27, and the 
triad of Arginine (R) 43, Threonine (T) 44, and Aspartic acid (D) 45, which I will refer to 
as RTD. In contrast, Cry toxins found to be inactive against A. aegypti larvae (Cry2Aa17, 
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Cry2Ab, Cry2Ad and Cry2Ah contained Glutamine (Q) 27 as well as the triad of Lysine (K) 
43, Asparagine (N) 44, and Asparagine (N) 45, which I will refer to as KNN. Other 
differences did not correlate with activity. 
To ensure this pattern was consistent, I carried out a far more intensive MSA of all 
currently known Cry2A toxins using a list created by another project student. In that 
work, the student had retrieved all sequences with >75% identity to Cry2Aa1 by running 
its sequence through Blastp, and removing all synthetic, hypothetical, misidentified or 
partial toxin sequences from the final list. The student found 99 sequences in this way, 
to which I have added new data for Cry2Aa18, Cry2Ac12, and Cry2Ax and removed data 
for U17(2Ab) since it displays a truncated N-terminus which bears no resemblance to all 
other Cry2A toxin N-termini (see appendix). This alignment showed that E / RTD and Q 
/ KNN, are always associated as pairs and are both highly conserved among Cry2A toxins 
(See appendix). 
However, we were yet to establish, which amino acid(s) among the four identified in 
Figure 4.2.34 is/are responsible for the specificity of this class of toxins. Therefore, we 
used mutagenesis to see which ones were important. The sequence representing the 
main areas of importance between the toxic and non-toxic Cry2A toxins is depicted in 
Figure 4.2.35 below. 
 
Figure 4.2.35 A figure representing amino acids of importance for mutagenesis between the N-terminal sequence 
of toxic and Non-toxic Cry2A toxins against Aedes aegypti. 
 
I carried out site-directed-mutagenesis by PCR on Cry2Ab and Cry2Aa in an attempt to 
reverse their toxicity profiles. Single mutants for E/Q and RTD/KNN were constructed 
and bioassays performed to investigate whether either of the amino acid E/Q or the 
triad RTD/KNN was enough on its own to influence specificity, or if both are needed to 
be co-expressed in order to achieve specificity towards A. aegypti larvae.  
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I created three mutants from Cry2Ab. Firstly, I created a mutant 2Ab that possessed the 
amino acid E, at position 27 instead of Q i.e. Cry2Ab-E; secondly, I created another 
mutant that possessed the amino acids RTD instead of KNN at positions 43, 44 and 45 
respectively i.e. Cry2Ab-RTD. Then lastly, I created a mutant that possessed all the amino 
acids substitutions mentioned for the two hybrids above (Q to E) at position 27 and (KNN 
to RTD) at positions (43, 44 and 45 respectively) i.e. Cry2Ab-ERTD. 
Mutagenic primers for the creation of Cry2Ab mutants 
Mutagenic primers for the above-mentioned amino acid substitutions were created 
following two important properties: 
I. The least substitution(s) that could give rise to the desired amino acid(s) 
II. E. coli codon bias was also taken in to consideration, as some of the codons might 
not be preferable for expression by E. coli bacterium. 
The general plan followed for the creation of the Cry2Ab-E and Cry2Ab-RTD mutants 
using Cry2Ab as the template strand and showing all the amino acids changes done on 
Cry2Ab are indicated in Figure 4.2.36a and b below. 
 
Figure 4.2.36 Primers for the creation of Cry2Ab-E and Cry2Ab-RTD mutants showing the areas where amino acids 
changes were done on Cry2Ab toxin sequence, these are indicated by red colour. 
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The mutagenic primers designed are shown in the Table 4.2-7 below. 
 
The PCR reaction was set following the procedure described in the material and methods 
section. 
PCR mutagenesis products for Cry2Ab mutants 
The mutagenesis products obtained from the PCR reaction above were confirmed by 
running 5 µl of the DNA on a gel and the remaining 45µl were digested with 1µl of DpnI 
enzyme for 60 minutes to get rid of the parental DNA. This was then run on a gel, excised, 
and purified using the procedure outlined in the methods section for DNA gel 
purification. The gels for the PCR mutagenesis products are shown in Figure 4.2.37(a-b) 
below. 
  
             
 
 
 
 
 
 
 
 
 
Table 4.2-7 Mutagenic primers for the creation of Cry2Ab mutant toxins 
 
Figure 4.2.37(a-b): Mutagenic PCR products for Cry2Ab mutant toxins. 
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The mutagenic products above were ligated using blunt TA DNA ligase master mix after 
which they were introduced in to NEB-5α E. coli competent cells, and few colonies were 
selected. The selected colonies were digested with HaeIII restriction enzyme (Figure 
4.2.38a and b), and the bands were compared to the fragments generated from NEB 
cutter (Table 4.2-1a); the correct colonies were selected, and sent for sequencing for 
further confirmation. 
 
 
 
 
 
 
 
 
 
The sequence received from the sequencing results for the creation of Cry2Ab-E by 
mutating glutamine (Q) at position 27 to Glutamic acid (E) was confirmed by aligning the 
sequence of the mutants received from the sequencing results (Cry2Ab-E-C4 and 
Cry2Ab-E-C5) with that of wild type Cry2Ab and checking at that position to see if the 
mutation has taken place. This is shown Figure 4.2.39 below. 
 
Figure 4.2.39 Alignment results for the confirmation of Cry2Ab-E mutant. The alignment results is for mutating 
glutamine (Q) at position 27 of Cry2Ab to glutamic acid (E) which were underlined. The mutated nucleotides along 
with the corresponding amino acid are indicated by a blue colour; whereas an asterisk indicates the amino acid 
that was changed from Cry2Ab, whereas the non-mutated nucleotides in Cry2Ab are indicated by red colour. 
Figure 4.2.38(a-b): DNA Agarose gel of the HaeIII restriction digest of colonies selected from Cry2Ab mutants 
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The mutant Cry2Ab-RTD made by mutating lysine, asparagine and asparagine (K, N, N) 
at positions 43, 44 and 45, to arginine, threonine, and aspartic acid (R, T, D) respectively, 
was confirmed by aligning the sequences of the mutants (Cry2Ab-RTD-C1 and Cry2Ab-
RTD-C2) received from the sequencing results with that of wild type Cry2Ab as shown in 
Figure 4.2.40 below. 
 
 
The mutant Cry2Ab-ERTD was created by mutating glutamine, lysine, asparagine and 
asparagine (E, K, N, N) at positions 27,43, 44 and 45, to glutamic acid, arginine, 
threonine, and aspartic acid (E, R, T, D) respectively. This mutant was confirmed by 
aligning the sequences of the mutants (Cry2Ab-ERTD-C1 and Cry2Ab-ERTD-C4) received 
from the sequencing results with that of the wild type Cry2Ab as shown in Figure 4.2.41 
below. 
 
 
 
 
 
 
 
Figure 4.2.40 Alignment results for the confirmation of Cry2Ab-RTD mutant. The alignment results is for mutating 
lysine, asparagine, asparagine (KNN) at position 43, 44 and 45 of Cry2Ab to arginine, threonine and aspartic acid 
(RTD) which are underlined. The mutated nucleotides along with the corresponding amino acids are indicated by 
a blue colour; whereas an asterisk indicates the amino acids that were changed from Cry2Ab, whereas the non-
mutated nucleotides in Cry2Ab are indicated by red colour. 
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From each of the three mutants represented in Figures 4.2.39, 4.2.40 and 4.2.41, a 
colony confirmed to have the right mutation was picked. Then introduced in to E. coli BL 
21 strain for the expression of the mutant proteins. The gel for the expressed mutant 
Cry2Ab proteins is shown in Figure 4.2.42 below. 
Figure 4.2.41 Alignment results for the confirmation of Cry2Ab-ERTD mutant. The alignment results is for mutating 
glutamine, lysine, asparagine, asparagine (QKNN) at position27, 43,44 and 45 of Cry2Ab to glutamic acid, arginine, 
threonine and aspartic acid (ERTD) which are underlined. The mutated nucleotides along with the corresponding 
amino acids are indicated by a blue colour; whereas an asterisk indicates the amino acids that were changed from 
Cry2Ab, whereas the non-mutated nucleotides in Cry2Ab are indicated by red colour. 
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The concentration of the above expressed mutant proteins were measured by 
densitometry using Image J as described earlier in the Material and Methods section. 
The gel used in measuring the concentration of the above protein is shown in Figure 
4.2.43 below. 
 
 
 
 
Figure 4.2.42 Protein SDS PAGE showing the expression of the mutant Cry2Ab toxins. The arrow by the left side is 
pointing towards the protein marker, whereas the arrow towards the right is pointing towards the mutant Cry2Ab 
protein expressed. 
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The concentrations of the above mutant toxins are depicted in Table 4.2-8 below. 
 
A qualitative bioassay which discriminates between a toxic and non-toxic Cry2A proteins 
was performed using the above Cry2Ab mutants, each at a concentration of 2mg/l 
following the procedures outlined by (WHO, 2005b). This was done to enable us know 
which among the proteins was active against Aedes aegypti. The result of the bioassay 
is presented in Figure 4.2.44 below. 
Figure 4.2.43 Protein SDS PAGE for measuring the concentration of the mutant Cry2Ab toxins. The arrow pointing 
towards right indicate the BSA standard while the one pointing towards the left indicate the Cry2Ab mutant toxins. 
 
Table 4.2-8 Concentrations of the Cry2Ab mutant toxins created as measured using Image J. The hybrids toxins 
were all expressed, and their relative molecular weight predicted using a program in Expasy. 
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Figure 4.2.44 Activity of Cry2Ab mutant toxins against Aedes aegypti mosquito. Cry2A toxins with mortality rate 
below 10% are considered non-active while those with mortality rate above 10% are considered active. The 
percentage mortality values on the graph represent the mean value of three-repeated experiments, each with a 
new batch of the toxins. The wild type Cry2Aa was used as positive control, whereas deionised water was used as 
the negative control for the experiment. Error bars represent standard error of mean (SEM). 
 
The graph in Figure 4.2.44 above showed that Cry2Ab-E and Cry2Ab-RTD mutants had 
no activity against Aedes aegypti larvae whereas Cry2Ab-ERTD was active against Aedes. 
These results showed that creation of single mutations, Q27E or KNN-43, 44, 45-RTD 
each in Cry2Ab (Cry2Ab-E and Cry2Ab-RTD) had no any effect on the activity of this 
inactive Cry toxin against Aedes aegypti. However, the combinatorial effect of the two 
mutations forming QKNN-27, 43, 44, 45- ERTD in Cry2Ab (Cry2Ab-ERTD) converted the 
non-active wild type Cry2Ab in to an active mutant toxin against Aedes aegypti. 
Creation of Cry2Aa mutant toxins 
The effect of creating the same kinds of mutants as created in Cry2Ab toxin was also 
investigated in Cry2Aa toxin. This was to enable us to further understand if the two 
positions identified in Cry2A toxins i.e. Q27E and the triad KNN-43, 44, 45-RTD are 
important in specificity. To achieve this, we created two mutants Cry2Aa-Q and Cry2Aa-
KNN to see if any of these two mutants can abolish the activity of Cry2Aa against Aedes 
aegypti mosquito hence asserting their roles in specificity determination. 
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The plan outlined in Figure 4.2.45a and b, showing the nucleotides used as primers as 
well as their corresponding amino acid sequences, was followed for the creation of the 
two mutants from Cry2Aa namely Cry2Aa-Q and Cry2Aa-KNN.  
 
 
Mutagenic primers for the creation of Cry2Aa mutants 
The primers used in amplifying the components involved in creating Cry2Aa-Q and 
Cry2Aa-KNN mutant proteins are displayed in Table 4.2-9 below. 
 
Table 4.2-9 Mutagenic primers for the creation of Cry2Aa mutant toxins. 
 
Cry2Aa toxin was used as the template strand for the PCR mutagenesis reaction for the 
mutants; Cry2Aa-Q and Cry2Aa-KNN. The PCR reaction was set following the procedure 
described in the material and methods section. 
Figure 4.2.45 (a-b). Plan for the primers designed for creation of Cry2Aa-Q and Cry2Aa-KNN mutants showing the 
areas where nucleotides as well as amino acids changes were done on Cry2Aa toxin sequence indicated by red 
colour. 
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PCR mutagenesis products for Cry2Aa mutants 
The PCR mutagenesis products for the two Cry2Aa mutants above were run on a gel to 
confirm if they have been amplified or not, this is shown in figure 4.2.46 below. 
 
 
 
 
 
 
 
 
 
 
 
 
The above gel showed the purified PCR products for the mutant toxins Cry2Aa-Q and 
Cry2Aa-KNN respectively. The DNA samples were then ligated, and introduced in to 
E.coli DH5-α strain. Successfully transformed colonies were picked using toothpick and 
further streaked on an ampicillin plate and was allowed to stay overnight in an incubator 
maintained at 370C and mini prepped to obtain a pure DNA sample. The DNA obtained, 
which is circular was then digested using HaeIII restriction enzyme in order to get the 
colony containing the correct transformant. The SDS-page gel showing the HaeIII digest 
is depicted in Figure 4.2.47 below. 
Figure 4.2.46 Purified mutagenic PCR products for Cry2Aa mutant toxins. The arrow is pointing towards the 
1Kb DNA marker used in estimating the size of the PCR products obtained on the agarose gel. 
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From the above gel. Colonies C1, C2 and C3 from the mutant Cry2Aa-Q all seemed to 
contain the correct HaeIII digest fragments when compared to those predicted by NEB-
Cutter. Colonies C5 and C6 of the mutant Cry2Aa-KNN but not C1 also contained the 
right fragments from the HaeIII restriction digest. 
The above colonies from each mutant were sent for sequencing after which colony 2(C2) 
from Cry2Aa-Q and colony 5(C5) from Cry2Aa-KNN were found to contain the desired 
mutation. The confirmation was done by aligning the sequence of the mutant toxin 
(Cry2Aa-Q-C2) received from the sequencing results to that of the wild type to see if the 
required mutations have been obtained, see Figure 4.2.48 below for the sequence 
alignment. 
 
Figure 4.2.47 DNA Agarose gel of the HaeIII restriction digest of colonies selected from Cry2Aa mutants. 
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The alignment results for the confirmation of the Cry2Aa-KNN mutant is shown in 
Figure 4.2.49 below. 
 
 
The two colonies confirmed above for Cry2Aa-Q and Cry2Aa-KNN were introduced in to 
E.coli BL 21 for the expression of the protein and the protein was grown and harvested. 
The gel for which is displayed in Figure 4.2.50 below. 
 
Figure 4.2.48 Alignment results for the confirmation of Cry2Aa-Q mutant. The alignment results is for mutating 
glutamic acid (E) at position 27 of Cry2Ab to glutamine (Q) which is underlined. The mutated nucleotides along 
with the corresponding amino acid are indicated by a blue colour; whereas an asterisk indicates the amino acid 
that was changed from Cry2Aa, whereas the non-mutated nucleotides in Cry2Aa are indicated by the red colour. 
 
Figure 4.2.49 Alignment results for the confirmation of Cry2Aa-KNN mutant. The alignment results is for mutating 
arginine, threonine and aspartic acid (RTD) at position 43, 44 and 45 of Cry2Aa to lysine, asparagine, and 
asparagine (KNN), which are underlined. The mutated nucleotides along with their corresponding amino acids are 
indicated by a blue colour; whereas red colour indicates the amino acids that were changed from Cry2Aa and the 
non-mutated nucleotides.  
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Figure 4.2.50 Protein SDS PAGE showing the expression of the mutant Cry2Ab toxins. The arrow pointing towards 
right indicate the protein marker while the one pointing towards the left indicate the Cry toxins. 
 
The concentration of the above mutants was measured by densitometry using Image J 
after running the SDS-gel along with BSA standards as shown in the gel in Figure 4.2.51 
below. 
 
 
Figure 4.2.51 SDS-Page gel for measuring the concentration of Cry2Aa-KNN mutant toxins. The arrow indicates 
the position of the Cry2A toxin bands. 
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The concentration of the above toxins (Figure 4.2.51) as measured from image J is 
shown in Table 4.2-10 below. 
 
 
  
 
 
 
A qualitative bioassay which discriminates between a toxic and non-toxic Cry2A proteins 
was performed using the above Cry2Aa mutants each at a concentration of 2mg/l 
following the procedures outlined by WHO (2005b). This was to enable us know which 
amongst the Cry2Aa mutants created is active against Aedes aegypti. The result of the 
bioassay is summarised in the Figure 4.2.52 below. 
 
 
Figure 4.2.52 Activity of Cry2Aa mutant toxins against Aedes aegypti mosquito. Cry2A toxins with mortality below 
10% are considered non-active while those with mortality above 10% are considered active. The percentage 
mortality values on the graph represent a pool value for three replicates per toxin, and then presented as a mean 
of three-repeated experiments. The wild type Cry2Aa was used as positive control, whereas deionised water was 
used as the negative control for the experiment. Error bars represent Standard error of mean (SEM).  
 
 
 
Table 4.2-10 Concentrations of the Cry2Aa mutant toxins created as measured using Image J. The hybrids toxins 
were all expressed, and their relative molecular weight predicted using a program in Expasy. 
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The graph above (Figure 4.2.52) showed that both the two mutants Cry2Aa-Q and 
Cry2Aa-KNN have no activity against Aedes aegypti since they all possessed a percentage 
mortality of less than 10, which is non-significant. This, therefore, signified that all the 
four amino acids E/RTD found within the N-terminus of Cry2Aa or a few possible 
combinations from these four could be very significant for activity against Aedes aegypti 
mosquito larvae. 
Effect of single point mutagenesis of Cry2Ab-E/ KNN 
The effect of creating a single point mutation within the triad KNN was investigated in 
order to see if single point mutation of any of this triad along with glutamic acid (E) on 
Cry2Ab i.e. the mutant Cry2Ab-E could lead to activity in Cry2Ab or all the four amino 
acids E/RTD must be present for activity in Cry2A toxins. Therefore, to achieve this we 
designed primers for the creation of the following three mutants:  
Mutant Cry2Ab-ERNN 
Mutant Cry2Ab-EKTN 
Mutant Cry2Ab-EKND 
The primers are as shown in Table 4.2-11 below. 
Cry2Ab-E toxin was used as the template strand for the PCR mutagenesis reaction in the 
creation of the mutants in Table 4.2-11 above. The PCR reaction was set following the 
procedure described in the material and methods section. The amplified products were 
run on a DNA agarose gel to see if they have been amplified successfully. These are 
shown in Figure 4.2.53 below. 
Table 4.2-11 Mutagenic primers for the creation of single point mutants within the triad ‘KNN’. 
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Figure 4.2.53 Mutagenic PCR products for single point mutants within Cry2Ab-E ‘KNN’ triad. 
 
The above mutants (Figure 4.2.53) were ligated using T4 DNA ligase and introduced in 
to E.coli DH5-α competent cell, following the procedure described in the materials and 
methods sections. Transformed colonies were picked using toothpick, streaked in an 
ampicillin plate, placed in an incubator maintained at 370C and was left to stay overnight. 
DNA miniprep was carried out using the cells harvested, and the pure DNA sample 
obtained from each of the mutants was digested using HaeIII restriction enzyme. The 
gels of which is shown in Figure 4.2.54 below. 
 
 
 
 
 
 
 
Figure 4.2.54 DNA Agarose gel of the HaeIII restriction digest of colonies selected from the single point 
mutants created within Cry2Ab-E ‘KNN’ triad. 
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From the gel in Figure 4.2.54 above, after comparison was made with the fragments 
generated from the NEB- cutter depicted in table 4.2-1a it showed that colony 1,2 and 
3 from Cry2Ab-EKTN, colony C2 of Cry2Ab-EKND, and both colony 2 and 3 from Cry2Ab-
ERNN may have the right transformants since they gave similar fragments to those 
generated by the NEB-cutter. Therefore, colony 1 and 2 of Cry2Ab-EKTN, Colony 2 from 
Cry2Ab-EKND and colony 2 and 3 from Cry2Ab-ERNN were sent for sequencing to 
confirm if they all contained the right mutations. This confirmation was done by aligning 
the sequence received from the sequencing results for each of these colonies from the 
mutants to that of Cry2Ab around the area where the mutation was expected to see if 
the right mutation has been successfully created. This is depicted in Figure 4.2.55. 
 
Figure 4.2.55 Sequence alignment to confirm the creation of single point mutants within Cry2Ab-E ‘KNN’ triad. 
 
Therefore, from the sequence alignment in Figure 4.2.55 above, it was apparent that 
colony 2 from Cry2Ab-EKND, colony 1 and 2 from Cry2Ab-EKTN and colony 2 and 3 from 
Cry2Ab-ERNN all have the desired mutations created successfully. Furthermore, colony 
2 from Cry2Ab-EKND, colony 1 from Cry2Ab-EKTN, and colony 2 from Cry2Ab-ERNN 
were selected and all put in E. coli BL21 strain for the expression of their respective 
proteins. The cells recovered after transforming each of these colonies with E. coli BL21 
were grown and the proteins harvested and run on an SDS-Page gel. This is depicted in 
Figure 4.2.56. 
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The concentration of the mutants Cry2Ab-E toxins created within the ‘KNN’ triad were 
measured by densitometry using image J from the gel depicted in Figure 4.2.57 below. 
 
Figure 4.2.57 Protein SDS-Page gel for measuring the concentrations of the single point mutants created within 
Cry2Ab-E ‘KNN’ triad. The arrow pointing towards right indicate the BSA standard while the one pointing towards 
the left indicate the mutant Cry2A toxins. 
 
 
 
 
 
Figure 4.2.56 protein SDS-Page gel for single point mutants created within Cry2Ab-E ‘KNN’ triad. The arrow 
pointing towards right indicate the protein marker while the one pointing towards the left indicate the mutant 
Cry2A toxins. 
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The concentration of the above toxins (Figure 4.2.57) as measured from image J is shown 
in Table 4.2-12 below. 
Table 4.2-12 Concentrations of the single point mutants created within Cry2Ab-E toxin ‘KNN’ triad as measured 
using Image J. The hybrids toxins were all expressed, and their relative molecular weight predicted using a program 
in Expasy. 
 
A qualitative bioassay was performed using the three mutants in Table 4.2-12 above 
along with Cry2Aa as a positive control; each at a concentration of 2 mg/l following the 
procedure outlined by WHO (2005c). Deionised water was used as a negative control. 
This was to determine which amongst the three mutants is active against Aedes aegypti. 
The result of the bioassay is summarised in Figure 4.2.58 below. 
 
Figure 4.2.58 Effect of the single point mutants created within the triad ‘KNN’ of Cry2Ab-E against Aedes aegypti. 
Cry2A toxins with mortality below 10% are considered non-active while those with mortality above 10% are 
considered active. The percentage mortality values on the graph represent a pool value for three replicates per 
toxin, and then presented as a mean of three-repeated experiments. The wild type Cry2Aa was used as positive 
control, whereas deionised water was used as the negative control for the experiment. Error bars represent 
Standard error of mean (SEM).  
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The graph above showed clearly that none of the triad ‘RTD’ along with ‘E27’ was solely 
responsible for the activity of Cry2A toxins against Aedes aegypti since all the three 
mutants: Cry2Ab-EKTN, Cry2Ab-EKND and Cry2Ab-ERNN possessed a percentage 
mortality of less than 10, which is non-significant compared to the positive control 
(Cry2Aa) having a mortality rate of 65%. This, therefore, signified that no single amino 
acid in the triad (RTD) in combination with E could give activity. 
Effect of double point mutagenesis of Cry2Ab-E/KNN 
Since it was obvious that none of the single point mutations on the triad KNN confers 
activity against Aedes aegypti mosquito larvae, I decided to create double mutants from 
the triad KNN to see the effect of double mutation on this position in Cry2A toxins. We 
used Cry2Ab-E mutant as the template strand; the three double mutants created are as 
follows:  
Cry2Ab-ERTN 
Cry2Ab-ERND 
 Cry2Ab-EKTD  
The primers used to create the three double mutants above are depicted in Table 4.2-
13 below. 
 
 
 
 
Table 4.2-13 Mutagenic primers for the creation of double mutants in Cry2Ab-E within the triad ‘KNN’ 
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The PCR reaction was set following the procedure described in the Material and 
Methods section. The amplified products were run on a DNA agarose gel to see if they 
have been amplified successfully. These are shown in Figure 4.2.59 below. 
 
 
 
 
 
 
 
The mutants in Figure 4.2.59 were ligated using T4 DNA ligase and introduced in to E.coli 
DH5-α competent cells following the procedure described in the Materials and Methods 
section of this thesis. Colonies present after the transformation were picked using 
toothpick and streaked in an ampicillin plate and was placed in an incubator maintained 
at 370C and was left to stay overnight. DNA miniprep was carried out using the cells 
harvested, and the purified DNA sample obtained from each of the mutants was 
digested using HaeIII restriction enzyme. The gels of which is shown in Figure 4.2.60 
below. 
Figure 4.2.59 Mutagenic PCR products for double point mutants within Cry2Ab-E ‘KNN’ triad. 
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From the above gel (Figure 4.2.60), colony 1 and 2 from Cry2Ab-ERTN, colony 1, 2, 3, 
and 4 from Cry2Ab-ERND, and colony 4 and 5 from Cry2Ab-EKTD appeared to have the 
right transformants when the bands from the HaeIII digestion were compared to the 
fragments generated from the NEB- cutter (Table 4.2-1a). Therefore, colony 1 and 2 
from Cry2Ab-ERTN, colony 2 and 3 from Cry2Ab-ERND and colony 3 and 4 from Cry2Ab-
EKTD were sent for sequencing, the results of which was aligned to the sequences of the 
constructs created in each case using Clustal omega. The result showed that all the 
colonies contained the desired mutations. This confirmation was done by aligning the 
sequence received from the sequencing results for each of these colonies from the 
mutants to that of Cry2Ab around the area where the mutation was expected, to see if 
the right mutation has been successfully created. This is depicted in Figure 4.2.61. 
 
 
 
 
 
Figure 4.2.60 DNA Agarose gel of the HaeIII restriction digest of colonies selected from the double point mutants 
created within Cry2Ab-E ‘KNN’ triad. 
 
149 
 
 
 
 
 
 
 
 
 
Therefore, colony 1 from Cry2Ab-ERND, colony 2 from Cry2Ab-ERTN and colony 3 from 
Cry2Ab-EKTD were expressed in E.coli BL21 strain and the protein grown and harvested. 
The proteins were run on an SDS-PAGE along with a BSA standard and their 
concentrations measured using densitometry. The protein gel used to measure the 
concentrations of these toxins is shown in Figure 4.2.62 below. 
 
 
 
Figure 4.2.61 Sequence alignment to confirm the creation of double point mutants within Cry2Ab-E ‘KNN’ 
triad. 
Figure 4.2.62 Protein SDS-Page gel for measuring the concentrations of the double point mutants created within 
Cry2Ab-E ‘KNN’ triad. The arrow pointing towards right indicate the BSA standard while the one pointing towards 
the left indicate the mutant Cry2A toxins. 
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The concentration of the above toxins (Figure 4.2.62) as measured from image J is shown 
in Table 4.2-14 below. 
 
 
 
 
A qualitative bioassay was performed using the three mutants in Table 4.2-14 above and 
Cry2Aa as a positive control; each at a concentration of 2 mg/l following the procedure 
outlined by WHO (2005c). Deionised water was used as a negative control. This was to 
determine if any of the three double point mutants created within Cry2Ab-E ‘KNN’ triad 
mutants is active against Aedes aegypti. The result of the bioassay is summarised in 
Figure 4.2.63 below. 
 
Figure 4.2.63 Activity of the double point mutants created within the triad ‘KNN’ of Cry2Ab-E against Aedes aegypti. 
Cry2A toxins with mortality rate below 10% are considered non-active while those with mortality rate above 10% 
are considered active. The percentage mortality values on the graph represent a pool value for three replicates per 
toxin, and then presented as a mean of three repeated experiments. The wild type Cry2Aa was used as positive 
control, whereas deionised water was used as the negative control for the experiment. Error bars represent 
Standard error of mean (SEM).  
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The above graph (Figure 4.2.63), showed that none of the double point mutants created 
within the triad ‘KNN’ of Cry2Ab-E has activity against Aedes aegypti since all the three 
mutants: Cry2Ab-EKTN, Cry2Ab-EKND and Cry2Ab-ERNN possessed a percentage 
mortality of less than 10, which is non-significant compared to the positive control 
(Cry2Aa) having a mortality rate of 65%. This, therefore, signified that no any 
combination of three among the four amino acids ‘E/RTD’ found within the N-terminus 
of Cry2A toxins influences their specificity against Aedes aegypti.  
Quantitative bioassay results for all Cry2A toxins active against Aedes aegypti mosquitoes. 
This was to confirm the qualitative bioassay results for all the hybrid/mutant toxins 
created in the various stages of this study for more clarity and to carry out a quantitative 
bioassay for all the mutant/hybrid Cry2A toxins that were toxic against Aedes aegypti. 
For all the Cry2A hybrids created via domain I swapping between the wild type Cry2A 
toxins (Cry2Aa2, Cry2Ac) which were toxic against Aedes aegypti and the non-toxic 
Cry2A (Cry2Ab), the following hybrids were found to be active against Aedes aegypti: 
Cry2AaAbAb, Cry2AcAbAb whereas Cry2AbAaAa and Cry2AbAcAc were non-toxic 
(Figure 4.2.16). For those hybrids involving N-terminus swap of Cry2Aa and Cry2Ac and 
Cry2Ab, the following results were obtained: Cry2AaNT+2Ab and Cry2AcNT+2Ab were 
toxic whereas Cry2AbNT+2Ac was non-toxic (Figure 4.2.28). In addition, mutant created 
by the deletion of the first 45 amino acids within the N-terminus of Cry2Aa toxin was 
non-toxic against Aedes (Figure 4.2.33). The results for mutants created within the 49-
amino acids comprising the N-terminal sequence of Cry2Ab toxin the following results 
were obtained: Mutants Cry2Ab-E and Cry2Ab-RTD were non-toxic whereas Mutant 
Cy2Ab-ERTD was toxic (Figure 4.2.44). The results for mutants created within the 49-
amino acids comprising the N-terminal sequence of Cry2Aa toxin yielded the following: 
Mutants Cry2Aa-Q and Cry2Aa-KNN, which were each non-toxic to Aedes (Figure 
4.2.52). Mutant toxins involving single point and double points mutagenesis of Cry2Ab 
within the ‘KNN’ triad were all non-active against Aedes aegypti mosquito larvae (Figure 
4.2.58 and 4.2.63) respectively.  Therefore, the quantitative bioassay results for those 
Cry2A wild type and hybrid/mutant toxins found to be active against Aedes aegypti 
mosquito (Cry2Ac, Cry2Aa, Cry2AaAbAb, Cry2AcAbAb, Cry2AaNT+2Ab, Cry2AcNT+2Ab, 
and Mutant Cry2Ab-ERTD) using a range of concentration is presented graphically in 
152 
 
 
 
Figure 4.2.64 for better comparison while those found to be non-active were excluded 
as their LC50 values could not be established.  
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Figure 4.2.64 Quantitative bioassay for hybrid/mutant Cry2A toxins active against Aedes aegypti. The percentage mortality values on the graph represent a pool value for three replicates per 
toxin, and then presented as a mean of three-repeated experiments. Deionised water represented by zero (0) in the concentration range was used as the negative control for the experiment. 
Error bars represent Standard error of mean (SEM).  
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The values for the concentrations and percentage mortalities in Figure 4.2.64 above 
were used to calculate the LC50 values for all the hybrid/mutant Cry2A toxins as shown 
in Table 4.2-15 below. 
 
 
Toxin 
 
LC50(mg/l) 
 
95% Confidence limits (mg/l) 
 
Cry2Aa2 
 
0.800 
 
 (0.300-16.000) 
Cry2AaAbAb           1.000 (0.700-2.100) 
Cry2AaNT+2Ab 1.600 (1.300-2.300) 
Cry2Ac 1.900 (1.500-2.700) 
Cry2AcAbAb 4.300 (2.700-9.200) 
Cry2AcNT+2Ab           2.600 (2.000-4.100) 
Mutant 2Ab-ERTD           1.500               (1.200-1.900) 
Table 4.2-15 LC50 values of Cry2A Hybrids and mutant toxins active against Aedes aegypti. 
 
Table 4.2-15 above for the LC50 values of all the hybrid/ mutant toxins active against 
Aedes aegypti showed that generally all the confidence limits overlaps suggesting that 
there is no significant difference among the mutants as all of them appeared to be toxic 
with Cry2AcAbAb perhaps a little less toxic. There is a wide difference between the 
lower and upper confidence limits for Cry2Aa; this is perhaps due the fact that there is 
no difference in the percentage mortality values at concentrations of 1mg/l and 0.5 mg/l 
of the toxin (Figure 4.2.64).   
Structural analysis of mutant Cry2Aa and Cry2Ab toxins 
Structural models for the mutated toxins were produced using Phyre2 v2.0 (Kelley et al., 
2015) using intensive modelling mode. Phyre2 uses the powerful Dunbrack rotamer 
library (Shapovalov and Dunbrack, 2011) to model mutations as best it can. The mutated 
and wild type toxins structural models produced were structurally compared in light of 
the results of bioassay obtained for both toxins, in an attempt to unravel the structural 
mechanism of action of Cry2A group of toxins.  
Rotamers can be defined as isomers of a molecule (e.g. an amino acid) that differ in the 
rotations of its internal bonds. To gain more assurance that mutations were modelled 
properly in Phyre2, we used the rotamer function in Chimera v1.11.2 (Pettersen et al., 
2004) on the original crystal structure of Cry2Aa (Morse et al., 2001) and followed the 
criteria for picking the most likely rotamer from the UCSF Chimera tutorial page. In the 
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absence of the density map of the protein, this consists in choosing the rotamers with 
the lowest clash score (least amount of overlaps with surrounding Van der Waals radii), 
then from that list, picking the rotamers with the highest number of hydrogen bonds. If 
there is still more than one choice left, the rotamer with the highest probability 
according to the literature was chosen. As an example, I have shown in Figure 4.2.65 the 
rotamer chosen for Cry2Aa-E27Q and its resultant structure. We did not find any 
differences with the models provided by Phyre2 in this way. 
 
 
Glu27 and Gln27 
Both the Phyre2 model and the original crystal structure modified using the Dunbrack 
rotamer library revealed a clear change in structural conformation when Glu27 was 
substituted with a Gln27 (Figure 4.2.66). Figure 4.2.67 demonstrates how in Cry2Aa, 
Glu27 grants an opening to the cavity that is present behind the N-terminus, whereas 
the substitution to Gln27 sterically hinders the opening to the cavity. 
 
 
Figure 4.2.65. Image of Dunbrack rotamer library choice in Chimera for replacing Glu27 by Gln27 in Cry2Aa. 
Highlighted in blue is the optimal rotamer choice in this case.  
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Figure 4.2.66 Visual representation of superimposed Cry2Aa with Glu27 (tan) and Cry2Ab with Gln27 (cyan) 
using Chimera. PDB ID of Cry2Aa: 1i5p. Model for Cry2Ab produced using Phyre2. Red tips at the end of the 
residues represent oxygen atoms. The blue tip at the end of Gln27 represents a nitrogen atom. 
 
Figure 4.2.67 Visual representation of the hydrophobic surfaces of Cry2Aa with Glu27 (left) and Cry2Ab 
with Gln27 (right) using Chimera. PDB ID of Cry2Aa: 1i5p. Both Glu27 and Gln27 are shown in yellow. Red 
surfaces indicate the Van der Waals (VdW) radii of hydrophobic residues. Blue surfaces represent the VdW 
radii of hydrophilic residues. White surfaces represent neither hydrophobic nor hydrophilic residue VdW 
radii. 
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Therefore, the results of the structural analysis (Figure 4.2.66 and 4.2.67) of creating 
mutants by changing the amino acid glutamine (Q) at position 27 from a non-toxic 
Cry2Ab to glutamic acid (E), led to the formation of a hydrophobic pore (opening). 
Likewise, changing glutamic acid (E) at the same position from the toxic Cry2Aa to 
glutamine (Q) led to the closure of the opening and a consequent loss of activity. 
Therefore, a model to explain these results is that a cavity around the E/Q amino acid 
within the N-terminal region needs to be opened to allow docking with a receptor and 
hence activity against Aedes aegypti. 
RTD and KNN 
Although the residues in both RTD and KNN have similar-to-identical biochemical 
properties only differing in that Asparagine (N) 45 is neutral and Aspartic acid (D) 45 is 
acidic- their conformations are different. As is shown in Figure 4.2.68, the 44th and 45th 
residues share roughly the same shape and conformation. Despite this similarity, the 
43rd residues, Arginine (R) 43 in Cry2Aa and Lysine (K) 43 in Cry2Ab appeared to be 
almost facing away from each other, which leads to a substantial conformational shift. 
Nonetheless, both single and double mutants created within the ‘KNN’ triad of Cry2Ab-
E (Figure 4.2.58 and 4.2.63) do not have activity against Aedes aegypti showing the 
absolute requirement for these three amino acids (RTD) along with the pore opening 
glutamic acid(E) depicted in Figure 4.2.67 for activity against this insect as shown with 
the mutant Cry2Ab-ERTD in Figure 4.2.44. 
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Figure 4.2.68 Visual representation of superimposed Cry2Aa with RTD (tan) and Cry2Ab with KNN (cyan). PDB ID 
of Cry2Aa: 1i5p. Red tips at the end of the residues represent oxygen atoms. The blue tip at the end of residues 
represent a nitrogen atom. 
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Therefore, it was obvious that all the four amino acids are required for activity against 
Aedes aegypti larvae as can be seen summarised structurally in Figure 4.2.69 below. 
 
 
 
 
 
 
 Figure 4.2.69 Structural analysis of ERTD tetrad for activity against Aedes aegypti. The rectangles represent Cry 
protein domains. The red colour represents Cry2Aa while green represents Cry2Ab. The letters ‘T’ stands for toxic 
against Aedes aegypti while ‘NT’ stands for non-toxic against Aedes aegypti. 
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From Figure 4.2.69 above, in Cry2Ab, which was non-toxic to Aedes aegypti and which 
has Q at position 27; the hole is closed, whereas in Cry2Aa, which was toxic against 
Aedes mosquito and has the amino acid E, at position 27 the cavity is open. However, 
changing the amino acid at position 27 to Q in the active Cry2Aa led to the closure of 
the cavity and a resultant loss in activity. In the same vein, changing Q to E in Cry2Ab-
RTD led to the opening of the hole and a consequent gain of activity in Cry2Ab. This, 
therefore, led us to propose some roles for these four amino acids, that the cavity 
formed by the amino acid E is the cavity required for receptor docking whereas the other 
three amino acids (RTD) are thought to be directly involved in binding to the receptor, 
as is depicted in Figure 4.2.70 below. 
 
 
Figure 4.2.70 Structure showing the positions of the tetrad ’ERTD’ in Cry2A toxins and their proposed roles. The 
arrows point at their locations on Cry2Aa toxin structure. The areas shaded indicate the positions of the amino 
acids ‘E’ and ‘RTD’ respectively in Cry2Aa structure. 
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Early hybrid created by Widner and Whiteley (1990) in which part of domain II of Cry2Ab 
was exchanged with Cry2Aa showed some little activity despite having Cry2Ab in domain 
I. Modelling showed that the cavity had opened in this hybrid as shown in Figure 4.2.71. 
This might indicate that domain II also played some significant role in specificity 
determination perhaps through its interaction with the N-terminal loop, which folds 
back in to this domain. 
 
 
 
 
 
Figure 4.2.71 Model structure for hybrid 513 created by Widner and Whiteley (1990). The rectangle indicates the 
different domains, with part of domain II of Cry2Ab exchanged with Cry2Aa coloured red while the remaining part 
of Cry2Ab is coloured green. Q is placed directly at the position of the opening on the structure, which indicated by 
a red colour. 
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4.3 Discussion 
The results obtained from the bioassay of the available Cry2A toxins carried out 
previously (Figure 3.2.11) to find the functional domain/domains among the Cry2A 
toxins were used to create hybrids/mutants towards the mosquito Aedes aegypti, 
combined with bioinformatic analyses to define regions that determine or influence 
activity towards this insect. I analysed the domains of the various Cry2A toxins, which 
were previously tested against Aedes aegypti and found to be toxic and / or non-toxic 
(Widner and Whiteley, 1990, Liang and Dean, 1994). Furthermore, it was discovered 
after the analyses that some naturally occurring hybrid Cry2A toxins, which we 
bioassayed and found to be active against this insect, have their domains I sequence 
similar to wild type Cry2Aa toxins, which were toxic against Aedes aegypti. Whereas, 
those found to be non-toxic have their domains I sequences similar to those of wild type 
Cry2Ab toxins, which were non-toxic against Aedes aegypti (Figure 4.2.1).  
Therefore, based on the above findings, we created hybrid toxins containing domain I 
from a toxic wild type Cry2A toxins, and domains II and III from a non-toxic wild type 
Cry2A toxins namely: Cry2AaAbAb and Cry2AcAbAb, which were found to be toxic. In 
the contrary, those hybrids containing sequences in their domain I from those of non-
toxic Cry2A toxins, while their domains II and III from toxic ones (Cry2AbAaAa and 
Cry2AbAcAc) appeared to be non-toxic against Aedes aegypti, results which further 
confirmed the involvement of domain I in specificity determination (Figure 4.2.16 and 
graphically in Figure 4.2.64). However, previous findings have implicated some amino 
residues in the middle of domain II (D-block) to be responsible for the specificity of Cry2A 
toxins (Widner and Whiteley, 1990, Liang and Dean, 1994). We, therefore, tried to find 
a connection between domain I and II, which based on the hypothesis we postulated 
that ‘it is the N-terminal region comprising of the first 49 amino acids, depicted in Figure 
1.7.1, that folds back and becomes a functional part of domain II and thus influencing 
toxin’s binding and specificity’. Based on this, and results from some previous researches 
(Hu et al., 2014, Mandal et al., 2007, Morse et al., 2001), we strongly believe that the N-
terminal loop comprising the first 49-amino acids presented in Figure 1.7.1 of this thesis 
might play a role in the specificity and hence toxicity of this group of toxins. 
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Therefore, we created three hybrids involving the N-terminal sequence from toxic Cry2A 
toxins (Cry2Ac and Cry2Aa2) and the other one having an N-terminal sequence from a 
non-toxic wild type Cry2A toxin (Cry2Ab) as depicted in Figure 4.2.20. The bioassay 
results obtained from these hybrids was shown in (Figure 4.2.28), which suggested that 
the N-terminal loop which folds back in to domain II is involved in specificity and hence 
toxicity of this important group of toxins against Aedes aegypti. This agreed with other 
findings, though carried out on different insects, which also showed that domain 
swapping between a toxic Cry toxin known to possess pore forming activity  and a non-
toxic Cry toxin not known with such property, brought pore forming activity and hence 
toxicity to the non-toxic Cry toxin (Hu et al., 2014). In addition, that some amino acids 
deletions and substitutions along the N-terminal sequence of the domain I of Cry2A 
sequence led to the formation of mutants with 4.1 to 6.6--fold increase in toxicity 
relative to the wild type tested (Mandal et al., 2007). 
It is worthy of note to mention the findings of Widner and Whiteley (1990) who located 
the dipteran specificity region in a lepidopteran-dipteran crystal protein from Bt 
(Cry2Aa) by creating hybrids between this toxin and a toxin that is only lepidopteran 
specific (Cry2Ab) depicted in Figure 1.9.1. They discovered a short segment of Cry2Aa 
corresponding to residues 307-382, differing only by 18 amino acid residues from 
Cry2Ab, to be responsible for dipteran specificity. This is because when this region of 
Cry2Aa was swapped to Cry2Ab (Hybrid 513) the latter gained toxicity against dipteran 
insect (Aedes aegypti mosquito) and it remained toxic to lepidopteran insect (Manduca 
sexta) as well.  
Their findings did contradict ours somehow, as our findings showed that the N-terminal 
region is responsible for specificity in Cry2A toxins, whereas in their case specificity is 
because of some few residues within domain II as mentioned above. This discrepancy 
could be explained by the fact that most of the hybrids we created showed lower 
activities compared to their respective wild type counterparts (Cry2Aa and Cry2Ac), 
which means that in the absence of structural stability data on these hybrid toxins, the 
lowered toxicities could relate to the absence of another specificity determining factor. 
This factor, may be the region in domain II of Cry2Aa that appears to confer A. aegypti 
specificity to Cry2Ab when swapped around(Widner and Whiteley, 1990). 
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Another area of discordance between our findings and theirs was the involvement of 
the C-terminus in specificity determination against Aedes aegypti even though with 
lower activity (Figure 1.9.1), which they did mention and which appeared not to be very 
relevant in our findings. Hence it could be explained that the interactions between 
domain I and domain II caused by the N-terminal loop triggered some structural 
alterations that affect domain III and hence the likely involvement of the C-terminus 
reported by them, but the C-terminus has no direct involvement in specificity 
determination based on our findings. 
The findings of Liang and Dean (1994) was that the specificity region of Cry2Aa against 
the mosquito larvae was located in regions 1 and 2 (amino acids 278-412), and was not 
related to region 3 (amino acids 413 to 487). This is very similar to the findings of Widner 
and Whiteley (1990) in that the specified dipteran activity conferring residues(D-block) 
falls in domain II of Cry2Aa, hence same explanation. Since the domain I and N-terminus 
hybrids, as well as the mutant Cry2Ab-ERTD, created in this study are much closer to 
their wild type counterparts than Hyb513, which was 20-fold less toxic than Cry2Aa, and 
DL116. It suggests that the importance of the D-block has been overestimated relative 
to the role of the N-terminus in determining specificity to Aedes aegypti. 
  
Also, it was speculated by Morse et al. (2001) that some residues, nine in total, within 
the putative receptor binding epitope (which constitutes residues 307-382) of Cry2Aa, 
could play a crucial role for the specificity of the toxin to dipteran insects. Thus, 
hypothesising that the cleavage of the 49 N-terminal amino acids of Cry2Aa exposes this 
binding motif (Figure 1.7.1). The findings by Morse et al. (2001) compared to our recent 
findings, which showed that: 
i. Deletion of the first 45 amino acids from the N-terminal of Cry2Aa toxins 
abolished its activity against Aedes aegypti (Figure 4.2.33).  
ii. Four amino acids substitutions within the N-terminal loop of a non-toxic Cry2Ab, 
at positions Q27E, KNN (43,44, and 45) to RTD; as in Cry2Aa, transformed the 
non-toxic Cry2Ab to a mutant Cry2Ab toxin, with activity against Aedes aegypti 
mosquito (Figure 4.2.44).  
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iii. That none of the triad (RTD) in combination with Cry2Ab-E mutant could result 
in activity against Aedes aegypti (Figure 4.2.58 and 4.2.63). 
iv. Substitution of the amino acid Q to E led to opening of a cavity within the N-
terminal region of Cry2Ab (Figure 4.2.67), which we earlier hypothesised that it 
has to be opened to allow docking with the receptor. In addition, that the other 
three amino acids, RTD, could be directly involved in binding to the receptor. 
Based on the above results, unlike what was speculated by Morse et al. (2001) that the 
cleavage of the N-terminal residue exposed the binding motif.  We propose that the N-
terminal is actually the binding motif, since all the four amino acids, E/RTD, within the 
N-terminal have to be present for activity against Aedes aegypti. Our findings compared 
to that speculated by Morse et al. (2001) could mean that these four amino acid changes 
within the N-terminus sequence might have resulted in some structural interactions that 
favoured the opening of the cavity and subsequent binding to the receptor. Thus, 
implying that structural interactions involving these four amino acids played a crucial 
role in specificity determination. 
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5. Studying the nature of interactions between the Aedes 
aegypti mid gut juice and Cry2A toxins. 
5.1 Introduction 
This chapter studied the nature of interactions between Aedes aegypti mid gut juice and 
the Cry2A toxins using a known protease (chymotrypsin) as a reference, to be able to 
answer some of the questions that arose from the results obtained in the previous 
chapter. We established that the N-terminal region is required for specificity 
determination in Cry2A toxins. This was arrived at through hybrid formation between a 
Cry2A toxin known to be toxic against Aedes aegypti (Cry2Aa) and another one known 
to be non-active (Cry2Ab), where we specifically discovered that the N-terminal 49-
amino acids from Cry2Aa were enough to confer activity on Cry2Ab (Figure 4.2.64). 
Therefore, we wanted to investigate how the N-terminus could influence specificity.  
Previous reports have shown that chymotrypsin and gut extracts from some insects (B. 
mori, L. dispar) cleave Cry2Aa toxin after the N-terminal 49th amino acid (Ohsawa et al., 
2012, Audtho et al., 1999) whereas others (P. xylostella) do not (Xu et al., 2016).It is not 
known if and where A. aegypti gut enzymes cleave Cry2Aa. A complication is that since 
it is known that some gut enzymes cleave the N-terminal region this would act against 
the role of this in binding, unless the fragment stays attached after cleavage. The aim of 
this chapter was to establish what happens when Cry2A toxin is exposed to Aedes 
aegypti gut extract. Thus, answering the question “if Cry2A is cleaved by Aedes aegypti 
mid gut enzymes, how is it still toxic?”. 
Morse hypothesised that for Cry2Aa, removal of the 49 amino acid N-terminal through 
cleavage reveals a putative binding region (Morse et al., 2001). We believe that for 
toxicity against Aedes aegypti, Morse’ hypothesis may not be true. This is because we 
believe based on our findings that the N-terminal 49-amino acid region of Cry2A is 
actually a putative binding region. 
We hypothesised that the N-terminus sequence of Cry2A, after exposure to the protease 
in the mid-gut of Aedes aegypti larvae, must remain attached to the rest of the toxin for 
activity to be seen, or is not cleaved.                 
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5.2 Results 
5.2.1 In vitro activation of Cry2A toxins using chymotrypsin 
To confirm previous reports’ test conditions, Cry2A toxin was digested with 
chymotrypsin, since digestion with this protease mimicked the effect in various insect 
guts (Ohsawa et al., 2012, Audtho et al., 1999, Xu et al., 2016).  We decided to carry out 
an in vitro activation of Cry2A toxins using chymotrypsin. The toxin used as 
representatives of this group of toxins was Cry2Aa; in that it was found to be active 
against Aedes aegypti, as such, it was a good reference toxin for use in activation and 
subsequent interaction studies involving both chymotrypsin and Aedes aegypti mid gut 
juice. The samples of Cry2Aa toxin employed in this initial study was expressed using 
E.coli expression system. Before activation, the proteins were solubilised using suitable 
buffers, 2 µl of each of the various concentrations of chymotrypsin shown in Figure 5.2.1 
was added to 8 µl of Cry2Aa, giving a final chymotrypsin concentration of 2 mg/ml, 0.2 
mg/ml and 0.02 mg/ml. Many optimisations were done through adjusting the pH and 
incubation periods of the crude samples before arriving at suitable conditions for 
solubilising the crude samples of Cry2Aa toxin expressed in E.coli following the 
procedure outlined in the materials and methods. The protein gel showing the activation 
of Cry2Aa toxin using chymotrypsin is depicted in Figure 5.2.1. 
 
                                                                                                             
 
 
 
 
 
 
 
 
 
Figure 5.2.1 Protein SDS-gel showing in vitro activation of Cry2Aa by chymotrypsin 
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From the above gel (Figure 5.2.1), it was observed that full digestion of Cry2Aa2 toxin 
having an approximate molecular weight of 71KDa by chymotrypsin (lane 2), showed 
the formation of an approximately 50KDa band. However, partial digestion (lane 3 and 
4) resulted in the formation of approximately 58KDa and 50KDa bands. The band 
indicated by an asterisk is probably from E.coli as it is also present in the solubilised 
sample. Though the incubation periods in this research differ from those of other 
researchers but the sizes of the bands resulting from both complete and partial digestion 
with chymotrypsin were consistent with those described in previous literature (Xu et al., 
2016, Ohsawa et al., 2012, Audtho et al., 1999).  
5.2.2 In vitro activation of Cry2A toxins using Aedes mid gut juice (AMJ) 
On full digestion, a 50KDa protein was obtained because of the N-terminal cleavage of 
Cry2A toxin by chymotrypsin, which was reported by Xu et al. (2016) to occur around 
the 144th amino acid. In addition, the results of our bioassay showed that this 50KDa 
protein was not toxic against Aedes aegypti. Therefore, we want to find out what is 
happening in the case of Aedes mid gut juice activated Cry2A toxin, as cleavage after the 
region containing the amino acids E/RTD similar to what was obtained in the case of 
chymotrypsin would act against the role of the N-terminus in binding, unless the 
fragments stayed attached after cleavage.  
This was achieved by carrying out an in vitro activation of Cry2A toxin with Aedes aegypti 
mid gut juice. The mid gut juice of Aedes aegypti was prepared following the protocol 
outlined in the method section (Chapter 2). The E. coli expressed Cry2A toxin gave 
unclear results, so I decided to use a Bt expressed Cry2Aa toxin. I was able to arrive at a 
concentration for both the Cry2Aa and Aedes mid gut protease that worked well after 
several trials by changing their amounts and incubation periods. Different dilutions of 
the Aedes mid gut juice was used for digestion as indicated in Figure 5.2.2 by adding 5 
parts of each dilution to 1 part of the Cry2Aa toxin. They were activated by incubating 
them for a period of 1 hour at 370C. The chymotrypsin-activated Cry2A toxin on this 
same gel (lane 2-5) were incubated for 5 minutes only. The gel showing the complete 
and partial activation of Cry2Aa by Aedes aegypti mid gut juice, run along with 
chymotrypsin for comparison, is shown in Figure 5.2.2. 
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The result above (Figure 5.2.2), showed that unlike chymotrypsin which digested the 
Cry2Aa to a 50KDa fragment on complete digestion, and 58KDa and 50KDa proteins on 
partial digestion, the Aedes mid gut juice digested Cry2Aa toxin to an approximately 
58KDa band (lane 6). Partial digestion by Aedes mid gut juice (lanes 7 and 8), unlike 
chymotrypsin, does not result in the formation of two distinct bands. Thus, indicating 
that Aedes aegypti mid gut protease cut the toxin at only one location. The faint protein 
bands indicated by an asterisk, appeared to come from the expression host as this is also 
present in the solubilised (un-activated Cry2Aa toxin). 
These results were consistent with  chymotrypsin cleaving Cry2Aa toxin at around 144th 
amino acid position on complete digestion as speculated by Xu et al. (2016), whereas 
the first protein band arising from the partial digestion with chymotrypsin, 
approximately 58KDa, corresponding to its first cleavage site appeared to correspond to 
the Aedes aegypti mid gut protease cleavage site (Figure 5.2.2). Thus, this may signify 
that chymotrypsin and Aedes mid gut juice might share a cleavage site. 
5.2.2 Protein SDS-gel showing the complete and partial activation of Cry2Aa by Aedes mid gut juice. 
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5.2.3 Bioassay results of Cry2Aa toxins digested using chymotrypsin and Aedes mid 
gut juice compared to the solubilised Cry2Aa. 
 
Following the activation of Cry2A toxin with chymotrypsin, we discovered the formation 
of a 50kDa band, and this cleavage by chymotrypsin which has been shown to occur at 
the N-terminal portion of Cry2Aa was reported to occur around the 144th amino acid (Xu 
et al., 2016). Whereas, activation using Aedes mid gut juice resulted in the formation of 
an approximately 58kDa protein. We decided to test these on Aedes aegypti, since the 
49 N-terminal region is known to play a significant role in the activity of Cry2A toxins 
against Aedes aegypti. This was achieved by carrying out bioassay experiment of 
solubilised Cry2A toxin, chymotrypsin activated Cry2Aa and Aedes mid gut juice 
activated Cry2Aa toxin against Aedes aegypti. 
Bioassay was carried out using both the solubilised Cry2A, chymotrypsin activated and 
Aedes mid gut juice activated Cry2Aa at a concentration of 2 mg/ml following the 
general bioassay procedure reported in the Methods section (Chapter 2). In addition, 
the bioassay consisted of crude Cry2Aa crystals as positive control and deionised water 
as negative control, plus equal volumes of the two buffers (50 mM Na2C03 and 1XPBS 
Buffer) used for preparing the toxin to be sure the buffers do not have any activity 
against Aedes aegypti. This was to be able to see if chymotrypsin cleaved Cry2Aa is still 
active against Aedes aegypti or not, which will shed more light on the requirement of 
the N-terminal region for activity against Aedes aegypti. More also, to see if the Aedes 
mid gut juice activated Cry2Aa protein is active against Aedes aegypti in which case it 
may suggest that the N-terminal portion remained attached to the rest of the toxin after 
cleavage. The graph of the bioassay experiment is shown in Figure 5.2.3. 
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From the results of the bioassay in Figure 5.2.3, it is clear that the crude, solubilised 
Cry2Aa and Aedes mid gut juice activated Cry2Aa toxin were active against Aedes 
aegypti. On the contrary, Cry2Aa activated by chymotrypsin showed no activity towards 
this insect. In addition, the buffers used have no effect on Aedes aegypti, as the negative 
control with deionised water and the two buffers showed no activity. Therefore, we 
speculated that the lack of activity seen in the chymotrypsin activated Cry2Aa toxin was 
due to loss of the N-terminus following cleavage, and that the activity seen in the Aedes 
mid gut juice activated Cry2Aa might indicate that the N-terminal portion remained 
attached to the rest of the toxin after cleavage by the Aedes mid gut juice. 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
M
or
ta
lit
y a
t 7
2 
ho
ur
s (
%
)
Activity of Aedes mid gut juice digested Cry2Aa and 
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Figure 5.2.3 Activity of chymotrypsin activated, Aedes mid gut juice activated and solubilised Cry2A toxin against 
Aedes aegypti. The percentage mortality values on the graph represent a pool value for three replicates per toxin, 
and then presented as a mean of three-repeated experiments. Error bars represent standard error of mean (SEM). 
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5.2.4 Proposed mechanism of action of Aedes mid gut juice on Cry2A toxins. 
Based on the results of the activation of Cry2A toxins using both chymotrypsin and Aedes 
mid gut juice along with the bioassay experiment performed we decided to critically 
analyse these results here so we could come up with a suitable model to describe the 
mechanism of action of Aedes mid gut juice activated toxin against Aedes aegypti. 
The results showed that Cry2Aa on complete activation using chymotrypsin yielded a 
50KDa band (Figure 5.2.1). However, on partial digestion with chymotrypsin, it yielded 
two bands of 58KDa and 50KDa respectively (Figure 5.2.1), which may correspond to 
cuts at Y49 and L144 respectively indicated by previous research (Audtho et al., 1999). 
However, complete digestion by the Aedes mid gut juice yielded only one band of 
approximately 58KDa (Figure 5.2.2). Our results also showed that the 50kDa Cry2Aa 
peptide from chymotrypsin digestion was non-toxic to Aedes aegypti while the 58kDa 
Cry2Aa peptide from digestion with Aedes mid gut juice was active against Aedes aegypti 
(Figure 5.2.3). This was instrumental in the formulation of our model as we earlier 
speculated that the lack of activity of this 50KDa protein from chymotrypsin digestion 
was due to the loss of the first 49 amino acids, comprising the region containing the 
amino acids E/RTD, from Cry2Aa essential for killing Aedes aegypti. 
On activation of Cry2Aa with Aedes gut extracts we observed that Cry2Aa was cleaved 
to form approximately a 58kDa toxin, and this was found to be active against Aedes 
aegypti, which could suggest that the region containing the amino acids E/RTD essential 
for activity against Aedes aegypti remained attached to the rest of the toxin after 
cleavage. Therefore, based on our results, the first 49 amino acids are essential for killing 
Aedes aegypti. We therefore considered two possible models for the activation of 
Cry2Aa. The first one is that cleavage with Aedes mid gut juice might occur before the 
four specificity-conferring amino acids (E/RTD) found within the N-terminus, in which 
case the toxin remains active to bind to the insect’s receptors and elicit toxicity. The 
second is that even after cleavage; the cleaved portion of the N-terminus might remain 
attached to the rest of the toxin due to hydrogen bonding or other forces of attractions. 
These forces might still hold the toxin intact. From our results for activation of Cry2A 
toxin with Aedes aegypti mid gut juice (Figure 5.2.2), the enzyme cuts at only one site 
(lane 6) giving an approximately 58KDa protein. This reduction in size and data from 
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previous studies (Xu et al., 2016, Ohsawa et al., 2012, Audtho et al., 1999) indicate that 
the 58KDa band arises from a cleavage around amino acid 49 (Y49), and all suggesting 
that the region containing E/RTD is upstream of the cleavage site. Therefore, the 
hypothesis suggesting that cleavage by Aedes aegypti mid gut juice might occur before 
the E/RTD amino acids within the N-terminal of Cry2A toxins could not stand. Hence, we 
considered the second model proposing that the fragment generated after cleavage of 
the N-terminal region still stays attached to the rest of the toxin, binds to the receptors, 
and elicits activity, a model we referred to as the “intact N-terminal model”. This is 
depicted diagrammatically in Figure 5.2.4. 
 
The intact N-terminal model for the mechanism of action of Cry2A against Aedes aegypti 
(Figure 5.2.4) suggested that after cleavage of the toxin by Aedes mid gut juice, the 
cleaved portion containing the amino acids E/RTD remained attached to the rest of the 
toxin by some forces of interaction. Thus, keeping the toxin intact, and maintaining its 
Figure 5.2.4 Intact N-terminal model for Cry2Aa activation by Aedes mid gut juice. 
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receptor binding property, hence binds to the receptors in the insect’s mid gut to exert 
its toxicity, hence the reason why this was found to be active against Aedes aegypti. On 
the other hand, the model proposes that on activation of Cry2Aa toxin with 
chymotrypsin (Figure 5.2.1) it resulted in two protein fragments of approximately 58KDa 
and 50KDa. However, after cleavage, the cleaved portion that contained the amino acids 
E/RTD is unable to remain attached to the rest of the toxin and thus detached from it. 
We speculate that the force holding the amino acids 1-144 to the rest of the toxin is 
weaker compared to the bond holding amino acids 1-49 to the rest of the toxin, hence 
the reason why it detached from the rest of the toxin as shown in Figure 5.2.4. Therefore, 
this result in the inability of the toxin to bind to the insect’s receptor and hence 
consequent loss of activity as evident in our results in Figure 5.2.3. 
5.2.5 Experiment to support the “intact N-terminal model” of Cry2A activity against 
Aedes aegypti.  
Based on the intact N-terminal model for the activity of Cry2A toxin against Aedes 
aegypti, we proposed that the N-terminal portion might remain attached to the rest of 
the toxin after cleavage, which bind to the receptors and elicit activity. Therefore, we 
attempted to demonstrate the workability of this model experimentally.  
We ran a native gel, which would hopefully maintain the 3D structure of the Cry2A as it 
is free of any denaturing conditions. The procedure used involved treating the 
solubilised Cry2Aa toxin each with the Aedes mid gut juice and chymotrypsin following 
the usual activation procedure described in the methods section (Chapter 2). The 
reaction was stopped after the specified durations by treatment with a protease 
inhibitor. The samples were not treated with SDS or boiled; instead, they were run on a 
native gel.  This might enable us demonstrate if Cry2Aa cleaved by Aedes aegypti mid 
gut juice and/ or chymotrypsin remains attached to the rest of the toxin or not after 
cleavage. If the N-terminal fragment remains attached to the rest of the toxin after 
cleavage, as suggested by our model, it would give a similar band pattern to the 
solubilised Cry2Aa, which served as a control in this case.  
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From the above gel (Figure 5.2.5), it could be deduced that the Aedes aegypti mid gut 
juice activated Cry2Aa toxin has a similar band pattern to the solubilised (un-activated 
Cry2A toxin (S)). This might indicate that after cleavage by Aedes mid gut juice; the two 
fragments generated i.e. from the N-terminal fragment, and the rest of the toxin, remain 
attached to each other as proposed by our model.  
The chymotrypsin activated Cry2Aa toxin (Figure 5.2.5, lane C) ran lower on the gel 
compared to the other two (the solubilised and the AMJ activated toxin). Thus, this 
might indicate that after cleavage by chymotrypsin, the resulting two fragments 
probably do not remain attached to each other, and that the smaller fragment 
generated from the N-terminus might have detached from the rest of the toxin after 
cleavage. Hence, the reason for the differential migration of the protein compared to 
the both the solubilised and the Aedes mid gut activated toxin. Therefore, the above 
experiment does not unequivocally support our “intact N-terminal model” for the 
activity of Cry2A toxins against Aedes aegypti for the fact that the technique used (native 
gel) separates proteins based on charge and not molecular weight, we could not 
establish if Cry2Aa activated by the Aedes mid gut juice and the solubilised Cry2Aa are 
Figure 5.2.5 Native SDS-Page gel for Aedes mid gut juice and chymotrypsin activated Cry2Aa toxin. 
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of the same molecular weight even though they migrated at equal distance on the native 
gel depicted in figure 5.2.5. 
5.3 Discussion 
The mode of interaction of Cry2Aa and the Aedes mid gut was studied in this chapter. 
This was in an attempt to answer the question whether the whole or part of the 49-
amino acids comprising the N-terminal of the Cry2A toxin is being cleaved by the 
protease in the Aedes aegypti mid gut or not, and if the cleaved portion remains 
attached to the rest of the toxin after cleavage. We discovered that Aedes mid gut juice 
digested Cry2Aa of approximately 68KDa in to an approximately 58KDa protein on 
complete digestion (Figure 5.2.3). This cleavage almost certainly occurred after the 
E/RTD region of the N-terminus, which we speculated to be responsible for receptor 
docking / binding. Hence, suggestive of the fact that the cleaved portion has to remain 
attached to the rest of the toxin for activity. 
However, digestion of Cry2Aa by chymotrypsin yielded approximately a 58KDa band and 
50KDa on partial digestion whereas complete digestion resulted in the formation of only 
the 50Da band protein, which is not further digested with increased concentration of 
chymotrypsin (Figure 5.2.3). Though the incubation periods differ but the position of the 
bands resulting from both complete and partial activation with chymotrypsin were 
consistent with previous literatures. For instance, Ohsawa et al. (2012) demonstrated 
that Cry2Aa3 was hydrolysed with chymotrypsin to yield two peptides 58KDa and 50KDa 
by cleaving the linkages 49Y/V50 and 144L/S145 respectively in the protoxin. In addition, 
the larger fragment of 58KDa disappeared after a long incubation period and/or 
treatment with increased concentration of chymotrypsin while the smaller fragment of 
50KDa did not. Xu et al. (2016) studied the role of proteolysis in the activation and 
toxicity of Cry2Ab against Plutella xylostella. They discovered that both trypsin and 
chymotrypsin cleaved Cry2Aab at R139 and L144 respectively, resulting in the 
production of an activated toxin of 50KDa in each case, similar to what they obtained 
when activated by the mid gut juice of Plutella xylostella. Comparing our findings with 
theirs, it is likely that the two bands obtained (58KDa and 50KDa) from partial digestion 
with chymotrypsin (Figure 5.2.1), may likely correspond to the cuts at Y49 and L144 
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though this is yet to be proven. Whereas the single band obtained (50KDa) on complete 
digestion (Figure 5.2.1) might likely resulted from the cut at L144. 
The results for the bioassay for chymotrypsin activated Cry2Aa, Aedes mid gut juice 
activated Cry2Aa and the solubilised Cry2Aa toxin depicted in Figure 5.2.3 showed that 
the solubilised Cry2Aa and Aedes mid gut juice activated Cry2Aa toxin were active 
towards Aedes aegypti whereas the chymotrypsin activated Cry2Aa toxin showed no 
activity. These bioassay results led to the speculation that the lack of activity of the 
chymotrypsin activated toxin was due to the loss of the N-terminal portion, which we 
had demonstrated to be essential for the activity of Cry2A toxins towards Aedes. More 
also, that the activity seen in the Aedes mid gut juice activated Cry2Aa might be as a 
result of the N-terminal portion remaining attached to the rest of the toxin after 
cleavage. These results are in line with the intact N-terminal model, which we proposed 
depicted in Figure 5.2.4 showing that after cleavage of Cry2Aa by chymotrypsin the N-
terminus portion of the Cry2Aa detaches from the rest of the toxin thereby losing its 
ability to bind to the receptor. 
The results in Figure 5.2.2 demonstrating the effect of digesting Cry2A toxin with Aedes 
aegypti mid gut juice showed that both Aedes aegypti mid gut juice and chymotrypsin 
might share a similar cleavage site around Y49. Audtho et al. (1999) showed that 
cleavage of Cry2Aa1 by the mid gut juice of gypsy moth (Lymantria dispar) fourth instar 
larvae resulted in the formation of two major fragments after one minute; a 58KDa 
fragment and a 49KDa fragment. N-terminal sequencing revealed that the protease 
cleavage sites are at the C terminal of Y49 and L144. These results are similar to ours in 
terms of digestion with chymotrypsin but differ in terms of digestion with the Aedes mid 
gut juice, which yielded only one band on full digestion. Our results showed that the 
Aedes aegypti mid gut juice and chymotrypsin might share a cleavage site around (Y49) 
for Cry2Aa.  
We supported our “intact N-terminal model” for the mechanism of action of Cry2A toxin, 
which we proposed as opposed the partial cleavage of the N-terminal portion before 
the E/Q region, by running both Aedes mid gut juice and chymotrypsin activated Cry2Aa 
on a native gel (which maintained the 3D structure of the toxin intact) depicted in Figure 
5.2.5. It was discovered that the Aedes aegypti mid gut activated Cry2Aa had the same 
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band position with the solubilised (non-activated) toxin. However, the chymotrypsin 
activated toxin resulted in a protein at a different band position compared to the other 
two, probably due to the loss of the detached part of the N-terminus. This, therefore, 
supports our model that the portion of the N-terminal region of Cry2Aa cleaved by the 
Aedes aegypti mid gut juice stays attached to the rest of the toxin, binds to the receptors 
and elicit toxicity. In addition, contrary to the speculation by Morse et al. (2001) that the 
entire N-terminus portion has to be cleaved in order to expose the receptor binding 
motif for the activation of Cry2Aa toxin and hence activity to occur.  Our results, 
therefore, supports the idea that the N-terminal region is actually the receptor-binding 
motif and therefore required to remain attached to the rest of the toxin for the activity 
of Cry2A toxins against Aedes aegypti.  
We considered the possibility of H-bonds holding the cleaved fragments of the N-
terminal to the rest of the toxins by observing the H-bonds within the structure of 
Cry2Aa since it has already been resolved through X-ray crystallography (Morse et al., 
2001). The structure, which is depicted in Figure 5.3.1, revealed that there is likely one 
H-bond found between L5 and L369, which connects the first 49 amino acids (coloured 
orange) to the rest of the toxin. There are no H-bonds between the α-helix from the first 
49 amino acids and those from amino acids 50-144 (coloured red), which we could have 
considered to be holding the two helices together even after cleavage. In addition, we 
found only one H-between G66 and L264 connecting amino acids 50-144 and the rest of 
the toxin. Therefore, with only 2 H-bonds between amino acids 1-144 and the rest of 
the toxins, this could explain why the region containing amino acids 1-144 could detach 
after cuts at amino acids 49 and 144 by chymotrypsin.  However, it cannot be explained 
how the region containing amino acids 1-49 remains attached. We could only presume 
that there are other forces such as Van der Waals or hydrophobic interactions involved.  
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These results indicate the significance of the N-terminus region in the activity of Cry2A 
toxins suggesting that the region containing the amino acids E/RTD, after being cleaved, 
must remain attached to the rest of the toxin for activity to occur. 
This requirement for the N-terminal region for activity in Cry proteins was also observed 
by a previous work on Cry4D protein, which showed that while the full-length protein 
was highly toxic to mosquito larvae, the truncated protein with a 9.6kDa deletion at the 
N-terminus was non-toxic to mosquitoes (Pang et al., 1992).  
 
 
 
Figure 5.3.1 Structure of Cry2Aa showing the first 49 amino acids coloured orange, amino acids 50-144 coloured 
red, and the rest of the toxins coloured gold and potential H-bonds between the molecules coloured blue. 
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6. General discussion  
This study sought to understand the mechanism for the mosquitocidal activity of Cry2A 
toxins against Aedes aegypti. It involved confirmation of some of the  available Cry2A 
toxins used in this study by sequencing the genes and comparing the results of the gene 
sequencing obtained to those of the sequences of known Cry2A toxins from the Bt 
nomenclature database (Crickmore et al., 1998). The toxins were further characterised 
by expressing and harvesting the crystal toxin protein and assaying them against Aedes.  
The results of the bioassay for the wild type toxins indicated that all the Cry2Aa toxins 
with the exception of Cry2Aa17 and mCry2Aa17 were toxic against Aedes aegypti 
mosquito whereas all the Cry2Ab were nontoxic against this insect. These results agreed 
with those of previous researches where these two toxins were tested against Aedes 
aegypti (Widner and Whiteley, 1990, Liang and Dean, 1994). The toxicity profile of 
Cry2Aa17 against three order of insects was reported to be like those of Cry2Ab toxins 
thus implicating domain I as a specificity-determining region (Shu et al., 2017). 
We discovered that the domain I of Cry2A toxins is responsible for specificity 
determination against Aedes aegypti after creating hybrids through domain I swaps. 
However, these results contradict those of previous researchers who alluded specificity 
determination in Cry2A toxins against Aedes aegypti to amino acid residues in the 
middle of domain II (D-block) of Cry2A toxins (Widner and Whiteley, 1990, Liang and 
Dean, 1994). But, it was discovered that the activities of our domain I hybrids were much 
closer to their wild type counterparts compared to their hybrids, which they created 
through some amino acids swaps within the D-block located in domain II. For instance, 
Hyb513 was 20-fold less toxic than Cry2Aa. This suggests that the role of the D-block 
located in domain II was overestimated relative to that of domain I in determining 
specificity to Aedes aegypti. 
We got some reports implicating the N-terminus region as playing a crucial role in 
specificity, as well as toxicity determination in Cry toxins. A conclusion arrived at after 
the researchers discovered that N-terminal swaps between an active Cry toxins known 
to possess a pore forming activity  and a non-active Cry toxin not known with such 
property brought pore forming activity and hence toxicity to the non-active Cry toxin 
(Hu et al., 2014). In addition, another researcher reported that some amino acids 
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deletions and substitutions along the N-terminal portion of domain I of Cry2A sequence 
led to the formation of a mutant with more toxicity relative to the wild type (Mandal et 
al., 2007). 
Following the findings of (Hu et al., 2014, Mandal et al., 2007), along with Widner and 
Whiteley (1990), and Liang and Dean (1994) mentioned above. We created hybrids 
through N-terminal 49 amino acid swaps among the Cry2A toxins to find the connection 
between domain I and II, which based on the hypothesis we postulated was that it “folds 
back and becomes a functional part of domain II, and thus influencing toxin’s binding 
and specificity”. Hybrids were also created through the deletion of the N-terminal region 
of Cry2Aa in trying to achieve this goal. These results showed that the N-terminal 49 
amino acid residues were required for the activity of Cry2A toxins against Aedes aegypti.   
These results contradict the speculation made by Morse et al. (2001) that the cleavage 
of the N-terminal region of Cry2Aa toxin exposes the binding epitope, as our findings 
indicated that the N-terminal region, actually, constitutes the binding motif. 
The results of mutagenesis carried out within the N-terminal region of Cry2Aa showed 
that four amino acids E, R, T and D at positions 27, 43, 44 and 45 of Cry2Aa might be 
responsible for the specificity of Cry2Aa toxin against Aedes aegypti.  
Results from modelling suggested that the amino acid E27 is associated with the opening 
of a cavity within Cry2A toxins as changing the amino acid glutamine (Q) at position 27 
from a non-toxic Cry2Ab to glutamic acid (E), led to the formation of a hydrophobic pore 
(opening). Likewise, changing glutamic acid (E) at the same position from the toxic 
Cry2Aa to glutamine (Q) led to the closure of the opening and a consequent loss of 
activity. In addition, the results showed that even if this hole is open by the presence of 
the amino acid E at position 27 and any of the triad (RTD) is changed, there is consequent 
loss of activity. Thus, it clearly showed that all these four amino acids (ERTD) have to be 
present for activity to occur in Cry2A toxins. This, therefore, made us to propose some 
roles for these four amino acids; that the hole formed by the amino acid E is the cavity 
required for receptor docking whereas the other three amino acids (RTD) are thought 
to be directly involved in binding to the receptor. These results contradict that of Widner 
and Whiteley (1990) in which part of domain II of Cry2Ab was swapped with Cry2Aa and 
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showed some activity despite having Cry2Ab in domain I, a hybrid they referred to as 
hybrid 513. However, modelling showed that the cavity had opened in this hybrid.  
Previous reports have shown that chymotrypsin and gut extracts from some insects (B. 
mori, L. dispar) cleave Cry2Aa toxin at both the N-terminal 49th and 144th amino acids 
(Ohsawa et al., 2012, Audtho et al., 1999). Whereas others (P. xylostella) do not cleave 
Cry2Aa, but was reported by Xu et al. (2016) to cleave Cry2Ab at the 144th amino acid 
position only. It was not known if and where Aedes aegypti gut enzymes cleave Cry2Aa. 
The implication of which is since it is known that some gut enzymes cleaved the N-
terminal region in which case it would act against the role of the N-terminus in binding, 
unless the fragment stays attached after cleavage. 
Therefore, we attempted to answer the question whether the 49-amino acids 
comprising the N-terminal region of Cry2A toxin is being cleaved by the protease in the 
Aedes aegypti mid gut or not, and if it stays attached to the rest of the toxins after the 
cleavage to elicit toxicity. This was achieved through studying the mechanism of 
interaction of Cry2Aa toxin with Aedes mid gut juice (AMJ), and chymotrypsin as a 
reference protease. The results showed that on full digestion of Cry2Aa with AMJ an 
approximately 58KDa protein was produced, which may indicate a cut after the amino 
acid E/RTD that we earlier speculated to play a role in receptor docking/binding. On the 
other hand, chymotrypsin produced a band at approximately 50KDa position on 
complete digestion, and two bands of approximately 58KDa and 50KDa on partial 
digestion; similar to what was obtained by previous studies (Audtho et al., 1999, Xu et 
al., 2016). These researchers speculated that the cleavage site for the complete 
digestion with chymotrypsin was L144 when they sequenced the protein. However, we 
are yet to establish the exact location where AMJ cleaved Cry2Aa toxin. It is likely that 
Aedes mid gut juice and chymotrypsin might share a cleavage site (the one yielding a 
58KDa peptide), which may be Y49, the higher band formed on partial digestion with 
chymotrypsin (Audtho et al., 1999) . In addition, that the region containing the amino 
acids E/RTD is perhaps completely digested by chymotrypsin, but rather cleaved in the 
case Aedes mid gut juice, hence explaining why it may still get attached to the rest of 
the toxin. The 50KDa protein produced by chymotrypsin digestion was found to be 
nontoxic against Aedes aegypti, which we speculated was perhaps because of the loss 
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of the N-terminal containing E/RTD. Leading us to propose a model, we referred to as 
the “intact N-terminal model” which proposed that after cleavage of the toxin by Aedes 
mid gut juice, the cleaved portion of the N-terminal remained attached to the rest of 
the toxin by some forces of interaction. Thus, keeping the toxin intact, and maintaining 
its receptor binding property. On the other hand, the model proposes that the two 
fragments resulting from chymotrypsin cleavage are unable to remain attached to the 
rest of the toxin and thus detach from it. Therefore, this results in the inability of the 
toxin to bind to the Aedes receptor and hence consequent loss of activity.  
We tested this model experimentally by running a native gel, which retained the 3D 
structure of the toxin intact after activation by the respective proteases. Using this we 
found that the protein from the solubilised toxin migrated the same distance with that 
of the AMJ activated as the two bands from these proteins occurred on similar location 
on the gel. In addition, both of them differ from the chymotrypsin-activated toxin, which 
differed probably because of the loss of the N-terminal portion of the toxin. However, 
we could not establish if the Cry2Aa toxin activated by the Aedes mid gut juice and the 
solubilised Cry2Aa are of the same molecular weight using this technique as proteins are 
being separated based on charge and not molecular weight, though they migrated the 
same distance on the gel (Figure 5.2.5). 
The proposal by Morse et al. (2001) that the cleavage of the N-terminal region of Cry2Aa 
toxin exposes the binding epitope of the toxin, which enable binding of the toxin to the 
insect receptors could work for targets other than Aedes.  
Cry2Aa toxin has a broad spectrum of activity against various insects; the same approach 
used in this current study could be applied towards understanding the nature of the 
specificity of other related Cry toxins against other insects. This will help in designing a 
recipe for generating a more potent and broad-spectrum biological insecticides that 
could withstand insect resistance through mutagenesis, genetic engineering and 
bioassay studies. 
Future studies might focus on excising the bands resulting from the Cry2Aa activated by 
Aedes mid gut juice and the solubilised Cry2Aa obtained from the native gel or separate 
the two proteins using size exclusion chromatography and obtain their amino acids 
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sequences to see if they are of the same molecular weight for the intact N-terminal 
model to be fully demonstrated experimentally. More also, PISA software could be used 
to understand the forces of attraction and/ or bonds that might be helping the cleaved 
portion of the N-terminal to remain attached to the rest of the toxin after cleavage. 
Future studies might seek to understand the cleavage sites of both Aedes mid gut juice 
and chymotrypsin activated Cry2Aa toxins through excising the bands, purifying them, 
and sequencing the protein, which will give an idea of the specific amino acids found 
within these cleavage sites and hence much more insight in to the type of bonds and /or 
interactions therein. In addition, it will be very interesting to study the activity of other 
Cry toxins, different from Cry2A, against Aedes aegypti via N-terminal modifications.  
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8. Appendix 
Multiple sequence alignment for the N-terminal sequence of Cry2A toxins 
